<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1101210402
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Parinso
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LACOSAMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        203.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MSN LABORATORIES PRIVATE LIMITED " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MSN LABORATORIES PRIVATE LIMITED 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2272]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AX18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lacosamide SPC Tablets 50 mg/ 100 mg/ 150 mg/ 200 mg contains Lacosamide as Active Ingredient. This belongs to a group of medicines called &ldquo;antiepileptic medicines&rdquo;. These medicines are used to treat epilepsy.</p><p>&bull;&nbsp;&nbsp;&nbsp; You have been given this medicine to lower the number of fits (seizures) you have.</p><p>&nbsp;</p><p><strong>What Lacosamide SPC Tablets is used for</strong></p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lacosamide SPC Tablets is used in adults, adolescents and children aged 4 years and older.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is used to treat a certain type of epilepsy characterised by the occurrence of partial-onset seizure with or without secondary generalisation.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In this type of epilepsy, fits first affect only one side of your brain. However, these may then spread to larger areas on both sides of your brain.</p><p>Lacosamide SPC Tablets may be used on its own or with other antiepileptic medicines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to Lacosamide SPC, or any of the other ingredients of this medicine (listed in section 6). If you are not sure whether you are allergic, please discuss with your doctor.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a certain type of heart beat problem called second- or third-degree AV block.</p><p>&nbsp;</p><p>Do not take Lacosamide SPC Tablets if any of the above applies to you. If you are not sure, talk to your doctor or pharmacist before taking this medicine.</p><p>&nbsp;</p><p>&nbsp;</p><p>Warnings and precautions</p><p>&nbsp;</p><p>Talk to your doctor before taking Lacosamide SPC Tablets if:</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have thoughts of harming or killing yourself. A small number of people being treated with antiepileptic medicinal products such as Lacosamide SPC have had thoughts of harming or killing themselves. If you have any of these thoughts at any time, tell your doctor straight away.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have a heart problem that affects the beat of your heart and you often have a particularly slow, fast or irregular heart beat (such as AV block, atrial fibrillation and atrial flutter).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have severe heart disease such as heart failure or have had a heart attack.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are often dizzy or fall over. Lacosamide SPC Tablets may make you dizzy - this could increase the risk of accidental injury or a fall. This means that you should take care until you are used to the effects of this medicine.</p><p>&nbsp;</p><p>&nbsp;</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Lacosamide SPC Tablets.</p><p>If you are taking Lacosamide SPC Tablets and you are experiencing symptoms of abnormal heartbeat (such as slow, rapid or irregular heartbeat, palpitations, shortness of breath, feeling lightheaded, fainting), seek medical advice immediately (see section 4).</p><p>&nbsp;</p><p>&nbsp;</p><p>Children under 4 years</p><p>&nbsp;</p><p>Lacosamide SPC Tablets is not recommended for children aged under 4 years. This is because we do not yet know whether it will work and whether it is safe for children in this age group.</p><p>Other medicines and Lacosamide SPC Tablets</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>In particular, tell your doctor or pharmacist if you are taking any of the following medicines that affect your heart - this is because Lacosamide SPC Tablets can also affect your heart:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat heart problems;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines&nbsp; which&nbsp; can&nbsp; increase&nbsp; the&nbsp; &ldquo;PR&nbsp; interval&rdquo;&nbsp; on&nbsp; a&nbsp; scan&nbsp; of&nbsp; the&nbsp; heart&nbsp; (ECG&nbsp; or electrocardiogram) such as medicines for epilepsy or pain called carbamazepine, lamotrigine or pregabalin;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat certain types of irregular heart beat or heart failure.</p><p>&nbsp;</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Lacosamide SPC Tablets.</p><p>Also tell your doctor or pharmacist if you are taking any of the following medicines - this is because they may increase or decrease the effect of Lacosamide SPC Tablets on your body:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for fungal infections called fluconazole, itraconazole or ketoconazole;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a medicine for HIV called ritonavir;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat bacterial infections called clarithromycin or rifampicin;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a herbal medicine used to treat mild anxiety and depression called St. John&rsquo;s wort.</p><p>&nbsp;</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Lacosamide SPC Tablets.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Lacosamide SPC Tablets with alcohol</strong></p><p>&nbsp;</p><p>As a safety precaution do not take Lacosamide SPC Tablets with alcohol.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>It is not recommended to take Lacosamide SPC Tablets if you are pregnant or breast-feeding, as the effects of Lacosamide SPC Tablets on pregnancy and the unborn baby or the new-born child are not known. Also, it is not known whether Lacosamide SPC Tablets passes into breast milk. Seek advice immediately from your doctor if you get pregnant or are planning to become pregnant.</p><p>They will help you decide if you should take Lacosamide SPC Tablets or not.</p><p>Do not stop treatment without talking to your doctor first as this could increase your fits (seizures).</p><p>A worsening of your disease can also harm your baby.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>&nbsp;</p><p>Do not drive, cycle or use any tools or machines until you know how this medicine affects you. This is because Lacosamide SPC Tablets may make you feel dizzy or cause blurred vision.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>Taking Lacosamide SPC Tablets</strong></p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take Lacosamide SPC Tablets twice each day - once in the morning and once in the evening.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Try to take it at about the same time each day.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the Lacosamide SPC Tablets tablet with a glass of water.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may take Lacosamide SPC Tablets with or without food.</p><p>&nbsp;</p><p>You will usually start by taking a low dose each day and your doctor will slowly increase this over a number of weeks. When you reach the dose that works for you, this is called the &ldquo;maintenance dose&rdquo;,&nbsp; you&nbsp; then&nbsp; take the same amount each&nbsp; day.&nbsp; Lacosamide SPC Tablets&nbsp; is used&nbsp; as a long&nbsp; term treatment. You should continue to take Lacosamide SPC Tablets until your doctor tells you to stop.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>How much to take</strong></p><p>&nbsp;</p><p>Listed below are the normal recommended doses of Lacosamide SPC Tablets for different age groups and weights.</p><p>Your doctor may prescribe a different dose if you have problems with your kidneys or with your liver.</p><p>&nbsp;</p><p><strong>Adolescents and children weighing 50 kg or more and adults</strong></p><p>&nbsp;</p><p><u>When&nbsp; you&nbsp; take Lacosamide SPC Tablets&nbsp; On&nbsp; its own</u>&nbsp;&nbsp;</p><p>&nbsp;</p><p>The usual starting dose of Lacosamide SPC Tablets is 50 mg twice a day.</p><p>&nbsp;</p><p>Your doctor may also prescribe a starting dose of 100 mg of Lacosamide SPC Tablets twice a day.</p><p>Your doctor may increase your twice daily dose every week by 50 mg. This will be until you reach a maintenance dose between 100 mg and 300 mg twice a day.</p><p>&nbsp;</p><p>&nbsp;</p><p>When you&nbsp;take&nbsp;Lacosamide SPC Tablets with other antiepileptic medicines</p><p>&nbsp;</p><p>The usual starting dose of Lacosamide SPC Tablets is 50 mg twice a day.</p><p>&nbsp;</p><p>Your doctor may increase your twice daily dose every week by 50 mg. This will be until you reach a maintenance dose between 100 mg and 200 mg twice a day.</p><p>If you weigh 50 kg or more, your doctor may decide to start Lacosamide SPC Tablets treatment with a single &ldquo;loading&rdquo; dose of 200 mg. You would then start your ongoing maintenance dose 12 hours later.</p><p><strong>Children and adolescent weighing less than 50 kg</strong></p><p>&nbsp;</p><p>The dose depends on their body weight. They usually start treatment with the syrup and only change to tablets if they are able to take tablets and get the correct dose with the different tablet strengths. The doctor will prescribe the formulation that is best suited to them.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>If you take more Lacosamide SPC Tablets than you should</strong></p><p>&nbsp;</p><p>If you have taken more Lacosamide SPC Tablets than you should, contact your doctor immediately.</p><p>Do not try to drive.</p><p>You may experience:</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea) or being sick (vomiting);</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fits (seizures), heart beat problems such a slow, fast or irregular heart beat, coma or a fall in blood pressure with rapid heartbeat and sweating.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>If you forget to take Lacosamide SPC Tablets</strong></p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have missed a dose within the first 6 hours of the scheduled dose, take it as soon as you remember.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have missed a dose beyond the first 6 hours of the scheduled dose, do not take the missed tablet anymore. Instead take Lacosamide SPC Tablets at the next time that you would normally take it.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop taking Lacosamide SPC Tablets</strong></p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not stop taking Lacosamide SPC Tablets without talking to your doctor, as your epilepsy may come back again or become worse.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your doctor decides to stop your treatment with Lacosamide SPC Tablets, they will tell you how to decrease the dose step by step.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Nervous system side effects such as dizziness may be higher after a single &ldquo;loading&rdquo; dose.&nbsp;</p><p>&nbsp;</p><p><strong>Talk to your doctor or pharmacist if you get any of the following:</strong></p><p><strong>Very common: </strong>may affect more than 1 in 10 people</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling dizzy or sick (nausea);</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Double vision (diplopia).</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Common: </strong>may affect up to 1 in 10 people</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems&nbsp;in&nbsp;keeping&nbsp; your&nbsp; balance,&nbsp; shaking&nbsp; (tremor),&nbsp; tingling&nbsp; (paresthesia)&nbsp; or&nbsp; muscle spasms, falling easily and getting bruises;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Troubles with your memory, thinking or finding words, confusion;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rapid and uncontrollable movements of the eyes (nystagmus), blurred vision;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A spinning sensation (vertigo), feeling drunk;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Being sick (vomiting), dry mouth, constipation, indigestion, excessive gas in the stomach or bowel, diarrhoea;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased feeling or sensitivity, difficulty in articulating words, disturbance in attention;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Noise in the ear such as buzzing, ringing or whistling;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irritability, trouble sleeping, depression;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleepiness, tiredness or weakness (asthenia);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching, rash.</p><p>&nbsp;</p><p><strong>Uncommon: </strong>may affect up to 1 in 100 people</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slow heart rate, palpitations, irregular pulse or other changes in the electrical activity of your heart (conduction disorder);</p><p>&nbsp;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exaggerated feeling of wellbeing, seeing and/or hearing things which are not there;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reaction to medicine intake, hives;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood tests may show abnormal liver function, liver injury;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thoughts of harming or killing yourself or attempting suicide: tell your doctor straight away;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling angry or agitated;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal thinking or losing touch with reality;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious allergic reaction which causes swelling of the face, throat, hands, feet, ankles, or lower legs;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fainting;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulties in coordinating your movements or walking.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Not known: </strong>frequency cannot be estimated from available data</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal rapid heartbeat (ventricular tachyarrhythmia);</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A sore throat, high temperature and getting more infections than usual. Blood tests may show a severe decrease in a specific class of white blood cells (agranulocytosis);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A serious skin reaction which may include a high temperature and other flu-like symptoms, a rash on the face, extended rash, swollen glands (enlarged lymph nodes). Blood tests may show increased levels of liver enzymes and a type of white blood cell (eosinophilia);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens&ndash;Johnson syndrome), and a more severe form causing skin peeling in more than 30 % of the body surface (toxic epidermal necrolysis);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Convulsion.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Additional side effects in children</strong></p><p>&nbsp;</p><p><strong>Common: </strong>may affect up to 1 in 10 children</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Runny nose (nasopharyngitis);</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever (pyrexia);</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sore throat (pharyngitis);</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eating less than usual.</p><p>&nbsp;</p><p><strong>Uncommon: </strong>may affect up to 1 in 100 children</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sleepy or lacking in energy (lethargy).</p><p><strong>Not known: </strong>frequency cannot be estimated from available data</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in behaviour, not acting like themselves.</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p><p>By reporting side effects you can help provide more information on the safety of this medicine. You can also report side effects directly via: submitting completed forms to: npc.drug@sfda.gov.sa.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do Not Store above 30&deg; C .</p><p>Protect from light and moisture.</p><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and blister after EXP.</p><p>The expiry date refers to the last day of that month.</p><p>This medicine does not require any special storage conditions.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Lacosamide SPC Tablets contains</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is Lacosamide SPC.</p><p>Each film coated tablet contains</p><p>Lacosamide SPC Tablets --------- 50 mg/ 100 mg/ 150 mg/ 200 mg</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: <u>Tablet core:</u></p><p>Microcrystalline Cellulose PH 101,&nbsp; Low substituted Hydroxy propyl cellulose,&nbsp; Hydroxypropyl cellulose, Crospovidone, Colloidal silicon dioxide, Magnesium Stearate, Purified water.</p><p><u>Tablet coat:</u></p><p>50 mg: Opadry II Purple 85G500001</p><p>100 mg: Opadry II yellow 85G52072</p><p>150 mg: Opadry II Tan 85G27190</p><p>200 mg: Opadry II Blue 85G20458</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Lacosamide SPC  Tablets  50  mg: 
Light pink colored, oval shaped, biconvex, film coated tablets debossed with "11" on one side and plain on the other side. 

Lacosamide SPC  Tablets  100 mg: 
Yellow colored, oval shaped, biconvex, film coated tablets debossed with "12" on one side and plain on the other side. 

Lacosamide SPC  Tablet s  150 mg: 
Tan colored, oval shaped, biconvex, film coated tablets debossed with "13" on one side and plain on the other side. 

Lacosamide SPC  Tablets  200 mg: 
Blue colored, oval shaped, biconvex, film coated tablets debossed with "14" on one side and plain on the other side. 


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Sudair Pharma Company (SPC)</p><p>King Fahad road, Building 911- The First Round</p><p>Riyadh, Saudi Arabia</p><p>Tel: +966-11-920001432</p><p>Fax: +966-11-4668195</p><p>Email: info@sudairpharma.com Mailing: P.O. Box 19047 Riyadh, Saudi Arabia</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>MSN LABORATORIES PRIVATE LIMITED Formulations Division, Unit-II, Survey</p><p>Nos. 1277, 1319 to 1324, Nandigama (Village &amp; Mandal), Rangareddy District, Telangana</p><p>509228, India.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                January 2020 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="rtl"><strong>1. ما هو لاكوساميد اس بي سي أقراص؟ وما هي دواعي استعماله؟</strong></p><p dir="rtl"><strong>&nbsp;ما هو لاكوساميد اس بي سي أقراص</strong></p><p dir="rtl">&nbsp;يحتوي لاكوساميد اس بي سي 50 مجم/100 مجم/150 مجم/200 مجم أقراص على لاكوساميد اس بي سي كمادة فعالة. ينتمي لاكوساميد اس بي سي إلى مجموعة من الأدوية تسمى &quot;مضادات الصرع&quot;. تستخدم هذه الأدوية لعلاج مرض الصرع.</p><ul dir="rtl"><li>لقد تم وصف هذا الدواء لتقليل عدد النوبات (النوبات التشنجية) التي تعاني منها.</li></ul><p dir="rtl">&nbsp;</p><p dir="rtl"><strong>ما هي دواعي استعمال لاكوساميداس بي سي أقراص.</strong></p><ul dir="rtl"><li>يستخدم لاكوساميد اس بي سي أقراص في المرضى من البالغين والمراهقين والأطفال الذين تتراوح&nbsp;أعمارهم 4 سنوات فأكثر.&nbsp;</li><li>&nbsp;يستخدم هذا الدواء لعلاج أحد أنواع الصرع الذي يصحبة الإصابة بنوبات تشنجية جزئية مع أو بدون التعميم الثانوي.</li><li>&nbsp;في هذا النوع من الصرع، تؤثر نوبات التشنج أولا على جانب واحد فقط من الدماغ. ومع ذلك، قد يمتد تأثير هذه النوبات فيما بعد، ليشتمل على كل من جانبي الدماغ.</li><li>&nbsp;يمكن استخدام لاكوساميداس بي سي أقراص بمفرده أو مع غيره من الأدوية المضادة للصرع.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>يحظر عليك تناول لاكوساميد اس بي سي أقراص في الحالات التالية:</strong></p><p dir="rtl">&nbsp;إذا كنت تعاني من حساسية تجاه لاكوساميد اس بي سي أو تجاه أي مكون من المكونات الأخرى الداخلة في</p><p dir="rtl">تركيب هذا التواء (المدرجة في القسم رقم 6). إذا لم تكن متأكدا ما إذا كنت تعاني من حساسية تجاه أي من</p><p dir="rtl">الأدوية، يرجى التحدث إلى الطبيب المعالج لك.</p><p dir="rtl">&nbsp;إذا كنت تعاني من نوع معين من أمراض القلب يعرف باسم إحصار أذيني بطيني من الدرجة الثانية أو الثالثة (&quot;وهو عبارة عن اضطراب في تنظيم معدل نبضات القلب&quot;).</p><p>&nbsp;</p><p dir="rtl">يحظر عليك تناول لاكوساميد اس بي سي أقراص، إذا انطبقت عليك أي حالة من الحالات المذكورة أعلاه. إذا لم تكن متأكدا من هذه الأمور، يرجى التحدث إلى الطبيب المعالج لك أو الصيدلي الخاص بك قبل تناول هذا الدواء.</p><p>&nbsp;</p><p dir="rtl"><strong>تحذيرات واحتياطات&nbsp;</strong></p><p><strong>ت</strong>حدث إلى الطبيب المعالج لك قبل تناول لاكوساميد اس بي سي أقراص في الحالات الآتية:&nbsp;</p><ul dir="rtl"><li>&nbsp;إذا كانت لديك أفكار تحثك على إيذاء نفسك أو الانتحار. فقد تم الكشف عن وجود عدد قليل من المرضى الذين يتم علاجهم باستخدام أدوية مضادة للصرع مثل &quot;لاكوساميد &nbsp;اس بي سي&quot;، والذين تراودهم أفكار&nbsp;لإيذاء أنفسهم أو الانتحار. فإذا راودتك أي من هذه الأفكار، يرجى التحدث إلى الطبيب المعالج لك فورا.</li></ul><p>&nbsp;</p><ul dir="rtl"><li>&nbsp;إذا كنت تعاني من أمراض بالقلب تؤثر على نبضات القلب وغالبا ما تعاني من تباطؤ أو تسارع أو عدم انتظام نبضات القلب (مثل إحصار أذيني بطيني ورجفان أذيني ورفرفة أذينية &quot;وهي حالات تطلق على عدم انتظام ضربات القلب&quot;).</li><li>إذا كنت تعاني من مرض حاد بالقلب مثل فشل القلب أو كنت قد عانيت من أزمة قلبية.</li><li>&nbsp;غالبا ما تشعر بدوار أو إغماء. فقد يتسبب لاكوساميد اس بي سي أقراص في الشعور بدوخة، وقد يزيد من خطر حدوث إصابات عرضية أو إغماء. لذلك، يرجى توخي الحذر إلى أن تعتاد على الآثار الجانبية الخاصة بهذا الدواء.&nbsp;</li></ul><p>&nbsp;</p><p>&nbsp;إذا انطبق عليك أي حالة من الحالات السابقة (أو لم تكن متأكدا)، فيرجى التحدث إلى الطبيب المعالج لك أو الصيدلي الخاص بك قبل تناول لاكوساميد اس بي سي أقراص يرجى استشارة الطبيب المعالج لك فورا، إذا كنت تتناول لاكوساميد اس بي سي أقراص وتعاني من أعراض اضطراب ضربات القلب (مثل تباطؤ أو تسارع أو عدم انتظام ضربات القلب، خفقان القلب، ضيق التنفس، شعور بالدوار والإغماء) (انظر القسم رقم 4).&nbsp;</p><p>&nbsp;</p><p dir="rtl"><strong>الاستخدام في المرضى من الأطفال الذين تقل أعمارهم عن 4 سنوات</strong></p><p dir="rtl">&nbsp;لا يوصى باستخدام لاكوساميد اس بي سي أقراص في المرضى من الأطفال الذين تقل أعمارهم عن 4 سنوات. حيث أنه لم يتوافر دراسات كافية حول فعاليته، وما إذا كان أمينا للاستخدام في المرضى من الأطفال في هذه الفئة العمرية أم لا</p><p dir="rtl">&nbsp;</p><p dir="rtl">&nbsp;</p><p dir="rtl"><strong>تناول لاكوساميد اس بي سي أقراص بالتزامن مع الأدوية الأخرى&nbsp;</strong></p><p dir="rtl"><strong>ي</strong>رجى إخبار الطبيب المعالج لك أو الصيدلي الخاص بك، إذا كنت تتناول أو تناولت مؤخرا أو قد تتناول أية أدوية أخرى.</p><p dir="rtl">&nbsp;وبشكل خاص، أخبر الطبيب المعالج لك أو الصيدلي الخاص بك، إذا كنت تتناول أيا من الأدوية التالية التي تؤثر على القلب، وذلك حيث أن لاكوساميد اس بي سي أقراص يمكن أن يؤثر أيضا على القلب:</p><p dir="rtl">&nbsp;أدوية تستخدم لعلاج أمراض القلب.</p><p dir="rtl">أدوية تزيد من فترة (PR) في تخطيط كهربية القلب عند فحص القلب (مخطط كهربائية القلب ECG مثل الأدوية التي تستخدم لعلاج الصرع أو لتسكين الألم وهي كاربامازيبين أو لاموتر جين أو بريجابالين؛</p><p dir="rtl">&nbsp;أدوية تستخدم لعلاج أمراض معينة مثل عدم انتظام ضربات القلب أو فشل القلب.</p><p dir="rtl">&nbsp;</p><p dir="rtl">إذا كان ينطبق عليك أي حالة من الحالات السابقة (أو إذا لم تكن متأكدا)، يرجى التحدث إلى الطبيب المعالج لك أو الصيدلي الخاص بك قبل تناول لاكوساميد اس بي سي أقراص.</p><p dir="rtl">&nbsp;أخبر أيضا الطبيب المعالج لك أو الصيدلي الخاص بك، إذا كنت تتناول أيا من الأدوية التالية، حيث أن هذه الأدوية قد تزيد أو تقلل من تأثير المادة الفعالة في لاكوساميد اس بي سي أقراص في الجسم:</p><ul dir="rtl"><li>أدوية تستخدم لعلاج العدوى الفطرية و هي فلوكونازول أو إيتراكونازول أو كيتوكونازول؛</li><li>أدوية تستخدم لعلاج فيروس نقص المناعة البشرية و هو ريتونافير؛</li><li>أدوية ستخدم لعلاج العدوى البكتيرية وهي كلاريثروميسين أو ريفامبيسين؛</li><li>أدوية عشبية تستخدم لعلاج الغضب والاكتئاب المتوسط وهي نبتة سانت جون.</li></ul><p dir="rtl">&nbsp;</p><p dir="rtl">إذا انطبق عليك أي حالة من الحالات السابقة (أو إذا لم تكن متأكدا)، يرجى التحدث إلى الطبيب المعالج لك أو الصيدلي الخاص بك قبل تناول لاكوساميد اس بي سي أقراص.</p><p dir="rtl"><strong>تناول لاكوساميد أس بي سي أقراص مع الكحوليات</strong></p><p dir="rtl">يحظر عليك، كتدبير وقائي، تناول لاكوساميد اس بي سي أقراص مع الكحوليات.<strong> </strong></p><p dir="rtl"><strong>استخدام الدواء أثناء فترة الحمل والرضاعة الطبيعية</strong></p><p dir="rtl">إذا كنت حاملا أو تمارسين الرضاعة الطبيعية أو تعتقدين أنك قد تكونين حاملا أو تخططين لذلك، فاستشيري الطبيب المعالج لك أو الصيدلي الخاص بك قبل تناول هذا التواء. لا يوصي بتناول لاكوساميد اس بي سي أقراص إذا كنت حاملا أو تمارسين الرضاعة الطبيعية حيث أن تأثير لاكوساميد اس بي سي أقراص على الحمل والجنين أو الطفل حديث الولادة غير معروف. من غير المعروف أيضا ما إذا كان لاكوساميد اس بي سي أقراص يفرز في لبن الأم أم لا. استشيري الطبيب المعالج لك فورا إذا كنت حاملا أو تخططين للحمل من أجل الحصول على النصيحة. حيث سيساعد في تحديد ما إذا كان يجب عليك تناول لاكوساميد اس بي سي أقراص أم لا.</p><p dir="rtl">لا تتوقف عن تناول العلاج دون استشارة الطبيب المعالج لك أو لا، لأن ذلك قد يزيد من حدة النوبات التي تعاني منها (النوبات التشنجية). وقد يؤدي تفاقم المرض لديك إلى إلحاق الضرر بطفلك</p><p dir="rtl">&nbsp;</p><p dir="rtl"><strong>القيادة واستخدام الآلات</strong></p><p dir="rtl">&nbsp;يحظر عليك قيادة السيارة أو ركوب الدراجات أو تشغيل أي أدوات أو آلات حتى تتأكد من تأثير هذا الدواء عليك. حيث قد يتسبب لاكوساميد اس بي سي أقراص في الشعور بدوار أو يتسبب في عدم وضوح الرؤية</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>. كيفية تناول لاكوساميد اس بي سي أقراص:&nbsp;</strong></p><p dir="rtl">ينبغي عليك دائما تناول هذا الدواء تماما كما وصفه الطبيب المعالج لك أو الصيدلي الخاص بك. ويجب عليك المتابعة مع الطبيب المعالج لك أو الصيدلي الخاص بك إذا لم تكن متأكدا من كيفية التناول.</p><p dir="rtl"><strong>تناول لاكوساميد اس بي سي أقراص:</strong></p><ul dir="rtl"><li>&nbsp; تناول لاكوساميد اس بي سي أقراص مرتين يوميا، مرة صباحا ومرة مساء.&nbsp;</li><li>&nbsp;حاول تناول هذا الدواء في نفس الوقت تقريبا من كل يوم.</li><li>&nbsp;&nbsp;ابتلع لاكوساميد اس بي سي أقراص بكوب من الماء.&nbsp;</li><li>&nbsp;تناول لاكوساميد اس بي سي أقراص مع الطعام أو بدونه.</li></ul><p dir="rtl">ستبدأ عادة بتناول جرعة قليلة يوميا وبعد ذلك سيقوم الطبيب المعالج لك بزيادة الجرعة تدريجيا في غضون عدة أسابيع. وعندما تصل إلى الجرعة المناسبة لك والتي تسمى &quot;بجرعة المداومة والاستمرار&quot;، سوف تستمر في المواظبة على تناول هذه الجرعة يوميا. يستخدم لاكوساميد اس بي سي أقراص كعلاج طويل الأمد. يوصي بالاستمرار في تناول لاكوساميد اس بي سي أقراص ما لم يخبرك الطبيب المعالج لك بإيقافه.&nbsp;</p><p>&nbsp;</p><p dir="rtl"><strong>مقدار الجرعة التي ينبغي تناولها&nbsp;</strong></p><p dir="rtl">يوضح فيما يلي الجرعات المعتادة والموصى بها من لاكوساميد اس بي سي أقراص لمختلف الفئات العمرية والأوزان.</p><p dir="rtl">&nbsp;قد يصف لك الطبيب المعالج لك جرعة مختلفة إذا كنت تعاني من مشاكل في الكلى أو الكبد.</p><p>&nbsp;</p><p dir="rtl"><strong>الاستخدام في المرضى من المراهقين والأطفال الذين تبلغ أوزانهم 50 كجم أو أكثر والمرضى من البالغين</strong></p><p dir="rtl">&nbsp;عند تناول لاكوساميد اس بي سي أقراص بمفرده جرعة البدء المعتادة من لاكوساميد اس بي سي أقراص هي 50 مجم مرتين يوميا قد يصف الطبيب المعالج لك أيضا جرعة بدء تصل إلى 100 مجم من لاكوساميد اس بي سي أقراص مرتين يوميا.</p><p dir="rtl">قد يزيد الطبيب المعالج لك الجرعة لتصبح مرتين يوميا في كل أسبوع بمقدار 50 مجم. وستستمر في المواظبة على هذه الجرعة حتى تصل إلى جرعة المداومة التي تتراوح بين 100 مجم و300 مجم مرتين يوميا.</p><p dir="rtl">&nbsp;</p><p dir="rtl"><u><strong>عند تناول لاكوساميد &nbsp;اس بي سي أقراص مع غيره من الأدوية المضادة للصرع&nbsp;</strong></u></p><p dir="rtl">جرعة البدء المعتادة من الاكو ساید اس بي سي أقراص هي 50 مجم مرتين يوميا.</p><p dir="rtl">&nbsp;</p><p dir="rtl">قد يزيد الطبيب المعالج لك الجرعة لتصبح مرتين يوميا في كل أسبوع بمقدار 50 مجم. وسوف تستمر في المواظبة على هذه الجرعة حتى تصل إلى جرعة المداومة التي تتراوح بين 100 مجم و 200 مجم مرتين يوميا. قد يقرر الطبيب المعالج لك البدء في تناول جرعة أولية &quot;جرعة البدء&quot; فردية من لاكوساميد اس بي سي أقراص، والتي تبلغ 200 مجم إذا كان وزنك يبلغ 50 كجم أو أكثر. ثم تبدأ بتناول جرعة المداومة بعد 12 ساعة من تناول الجرعة السابقة</p><p>&nbsp;</p><p dir="rtl"><strong>الاستخدام في المرضى من الأطفال والمراهقين الذين تقل أوزانهم عن 50 كجم&nbsp;</strong></p><p dir="rtl">تعتمد مقدار الجرعة التي يتم تناولها على وزن الجسم. عادة ما يبدأ الأطباء العلاج بالدواء الشراب ثم يتم تغييره بعد ذلك إلى أقراص فقط إذا كان المرضى لديهم القدرة على تناول الأقراص وتناول الجرعة المناسبة بتركيزات مختلفة من الأقراص. وسوف يقوم الطبيب المعالج بوصف تركيز الدواء المناسب لهم</p><p dir="rtl"><strong>&nbsp;</strong></p><p dir="rtl"><strong>ما الذي ينبغي عليك فعله إذا تناولت كمية أكثر مما يجب من لاكوساميد اس بي سي أقراص</strong></p><p>&nbsp;اتصل بالطبيب المعالج لك فورا، إذا تناولت كمية كبيرة من الأقراص أكثر مما يجب. ولا تحاول القيادة. فقد تعاني من الحالات التالية:&nbsp;</p><ul dir="rtl"><li>&nbsp;دوخة.</li><li>&nbsp;شعور بإعياء (غثيان) أو تعب (قيء).&nbsp;</li><li>نوبات (نوبات تشنجية)، مشاكل في ضربات القلب مثل تباطؤ أو تسارع أو عدم انتظام ضربات القلب أو غيبوبة أو انخفاض ضغط الدم مع تسارع ضربات القلب وزيادة إفراز العرق.</li></ul><p>&nbsp;</p><p dir="rtl"><strong>ما الذي ينبغي عليك فعله إذا نسيت تناول لاكوساميد اس بي سي أقراص:&nbsp;</strong></p><ul dir="rtl"><li>إذا نسيت تناول جرعة في خلال أول 6 ساعات من موعد تناول الجرعة المحددة، فتناولها بمجرد تذكرك لها</li><li>&nbsp;إذا نسيت تناول جرعة بعد مرور أول 6 ساعات من موعد تناول الجرعة المحددة، فيحظر عليك تناول الجرعة التي أغفلتها. وبدلا من ذلك، يمكنك تناول الجرعة التالية من لاكوساميد اس بي سي أقراص في موعدها المحدد.&nbsp;</li><li>&nbsp;لا تتناول جرعة مضاعفة لتعويض جرعة أغفلتها</li></ul><p>&nbsp;</p><p dir="rtl"><strong>إذا توقف عن تناول لاكوساميد </strong><strong>اس بي سي أقراص</strong></p><ul dir="rtl"><li>يحظر عليك التوقف عن تناول لاكوساميد اس بي سي أقراص من تلقاء نفسك دون استشارة الطبيب المعالج لك حيث قد يؤدي ذلك إلى التعرض للإصابة بمرض الصرع مرة أخرى أو تفاقم المرض لديك.</li><li>إذا قرر الطبيب المعالج لك إيقاف العلاج لاكوساميد اس بي سي أقراص، فسيخبرك الطبيب المعالج بكيفية تقليل الجرعة تدريجيا</li></ul><p>&nbsp;</p><p dir="rtl"><strong>إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدواء، فاستشر الطبيب المعالج لك أو الصيدلي الخاص بك.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl">قد يسبب هذا الدواء، مثله مثل كافة الأدوية، أثارا جانبية على الرغم من عدم حدوثها لجميع المرضى. وتتمثل الآثار الجانبية للجهاز العصبي في الشعور بدوخة قد تكون شديدة عقب تناول الجرعة الفردية الأولية &quot;جرعة البدء &quot;</p><p dir="rtl">&nbsp;</p><p dir="rtl"><strong>تحدث إلى الطبيب المعالج لك أو الصيدلي الخاص بك، إذا عانيت من أي حالة من الحالات التالية:</strong></p><ul dir="rtl"><li>آثار جانبية شائعة جدا: قد تؤثر على أكثر من مريض واحد من بين كل 10 مرضى</li><li>&nbsp;شعور بصداع،</li><li>&nbsp;شعور بدوخة أو إعياء (غثيان).</li><li>&nbsp;ازدواج الرؤية (عدم وضوح الرؤية).</li></ul><p>&nbsp;</p><p dir="rtl"><strong>&nbsp;آثار جانبية شائعة: </strong>قد تؤثر على ما يصل إلى مريض واحد من بين كل 10 مرضى</p><ul dir="rtl"><li>فقدان التوازن أو هزة (رعشة) أو وخز (تنميل أو تشنج بالعضلات أو الإغماء والإصابة بكدمات بسهولة؛</li><li>اضطرابات في الذاكرة أو التفكير أو تلعثم أو ارتباك؛&nbsp;</li><li>حركات سريعة لا إرادية للعين (هزة بالعين)، عدم وضوح الرؤية؛</li><li>&nbsp;شعور بدوار (دوخة)، شعور بحالة سكر.</li><li>&nbsp;إعياء (قيء)، جفاف الفم، إمساك، عسر الهضم، فرط الغازات بالمعدة أو بالأمعاء، إسهال؛</li><li>ضعف الشعور والإحساس، صعوبة في النطق تلعثم، اضطراب في الانتباه.</li><li>ضجيج في الأذن مثل: طنين أو رنين أو صفير.&nbsp;</li><li>&nbsp;تهيج، اضطرابات في النوم، اكتئاب.</li><li>&nbsp;نعاس أو تعب أو ضعف (وهن)؛</li><li>&nbsp;حكة، طفح جلدي.</li></ul><p>&nbsp;</p><p dir="rtl"><strong>&nbsp;آثار جانبية غير شائعة:</strong> قد تؤثر على ما يصل إلى مريض واحد من بين كل 100 مريض</p><ul dir="rtl"><li>&nbsp;تباطؤ معدل ضربات القلب أو خفقان أو عد انتظام ضربات القلب أو تغييرات أخرى في نشاط كهربائية القلب (اضطراب السلوك).</li><li>&nbsp;شعور مفرط بالسعادة و/أو رؤية و/أو سماع أشياء غير موجودة.</li><li>&nbsp;تفاعلات حساسية تجاه تناول الدواء، شری (ارتكاريا).</li><li>&nbsp;قد تظهر اختبارات الدم اضطراب بوظائف الكبد أو وجود إصابة بالكبد.</li><li>&nbsp;قد تراودك أفكار تحتك على إيذاء نفسك أو محاولة الانتحار : فينبغي عليك أخبار الطبيب المعالج لك فورا؛</li><li>شعور بغضب أو ارتباك.&nbsp;</li><li>اضطراب التفكير أو فقدان التواصل مع الأمور الواقعية.</li><li>&nbsp;تفاعلات حساسية خطيرة سبب تورم في الوجه أو الحلق أو اليدين أو القدمين أو الكاحلين أو الجزء السفلي من الساقين.&nbsp;</li><li>&nbsp;إغماء.</li><li>مشاكل في تنسيق وتنظيم الحركة أو المشي.&nbsp;</li></ul><p dir="rtl">&nbsp;</p><p dir="rtl">آ<strong>ثار جانبية غير معروف معدل تكرارها:</strong>&nbsp; لا يمكن تقدیر معدل التكرار من واقع البيانات المتاحة</p><ul dir="rtl"><li>اضطراب و سرعة ضربات القلب (عدم انتظام ضربات القلب البطيني)؛&nbsp;</li><li>التهاب الحلق وارتفاع درجة الحرارة والإصابة بحالات عدوى أكثر من المعتاد. قد تظهر اختبارات الدم انخفاض حاد في نوع معين من خلايا الدم البيضاء (ندرة المحببات)؛</li><li>&nbsp;تفاعلات جلدية خطيرة، قد تشمل ارتفاع درجة الحرارة وأعراضا شبيهة بأعراض الإنفلونزا، طفح جلدي على الوجه، طفح جلدي منتشر في مناطق عديدة، تورم الغدد (تضخم العقد الليمفاوية). قد تظهر اختبارات الدم زيادة في مستويات أنزيمات الكبد وفي أحد أنواع خلايا الدم البيضاء (فرط الحمضيات) (&quot;وهو عبارة عن زيادة غير طبيعية في مستوى الحمضيات&quot;)؛</li><li>&nbsp;طفح جلدي منتشر في جميع أجزاء الجسم مع بثور وتقشر الجلد ولا سيما حول الفم والأنف والعينين والأعضاء التناسلية (متلازمة ستيفن جونسون) و أكثر الأعراض حدة تلك التي تسبب تقشير الجلد في أكثر من 30% من سطح الجسم (تقشر الأنسجة المؤثرة البشروية الممي) (&quot; وهي عبارة عن عوارض جلدية نادرة ومهددة للحياة، تظهر نتيجة لتناول الدواء&quot;).&nbsp;</li><li>تشنجات</li></ul><p>&nbsp;</p><p dir="rtl"><strong>آثار جانبية إضافية في المرضى من الأطفال</strong></p><p dir="rtl"><strong>&nbsp;آثار جانبية شائعة:</strong> قد تؤثر على ما يصل إلى مريض واحد من بين كل ۱۰ مرضى</p><ul dir="rtl"><li>سيلان الأنف (التهاب البلعوم الأنفي)؛</li><li>حمى (ارتفاع درجة حرارة الجسم).&nbsp;</li><li>التهاب الحلق (التهاب البلعوم).&nbsp;</li><li>تناول الطعام أقل من المعتاد.</li></ul><p dir="rtl"><strong>&nbsp;آثار جانبية غير شائعة:</strong> قد تؤثر على ما يصل إلى مريض واحد من بين كل ۱۰۰ مريض&nbsp;</p><ul dir="rtl"><li>&nbsp;شعور بنعاس أو نقص الطاقة (خمول).</li></ul><p>&nbsp;</p><p dir="rtl"><strong>آثار جانبية غير معروف معدل تكرارها:</strong> لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة&nbsp;</p><ul dir="rtl"><li>&nbsp;اضطرابات في السلوك، تصرف مغايرة لطبيعة الأطفال.</li></ul><p>&nbsp;</p><p dir="rtl"><strong>&nbsp;الإبلاغ عن الآثار الجانبية:</strong></p><p dir="rtl">&nbsp;إذا تعرضت للإصابة بأية آثار جانبية، فيرجى التحدث إلى الطبيب المعالج لك أو الصيدلي الخاص بك. ويشمل ذلك أية آثار جانبية محتملة غير مدرجة في هذه النشرة يمكنك المساعدة في توفير معلومات إضافية حول أمان استخدام هذا الدواء من خلال إبلاغك عن الآثار الجانبية يمكنك أيضا الإبلاغ عن الآثار الجانبية بشكل مباشر عن طريق إرسال نماذج مكتملة من الحالات المرضية إلى البريد الإلكتروني التالي: npc.drug@sfda.gov.sa</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ هذا الدواء في درجة حرارة لا تتجاوز 30 درجة مئوية&nbsp;</p><p dir="rtl">يحفظ بعيدا عن الضوء والرطوبة&nbsp;</p><p dir="rtl">يحفظ هذا الدواء بعيدا عن رؤية وتناول الأطفال.</p><p dir="rtl">&nbsp;لا تستعمل هذا الدواء بعد انتهاء تاريخ الصلاحية المدون على العبوة و الشريط بعد كلمة &quot;EXP&quot;.</p><p dir="rtl">&nbsp;يشير تاريخ انتهاء الصلاحية إلى أخر يوم من ذلك الشهر</p><p dir="rtl">&nbsp;لا يتطلب هذا الدواء أية شروط خاصة للحفظ</p><p>&nbsp;</p><p>ينبغي عدم التخلص من الأدوية عن طريق إلقائها في مياه الصرف الصحي أو مع النفايات المنزلية استشر الصيدلي الخاص بك عن كيفية التخلص من الأدوية التي لم تعد بحاجة إلى استخدامها. سوف تساعد هذه الإجراءات في الحفاظ على البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl">ماهي محتويات لاكوساميد اس بي سي أقراص</p><ul dir="rtl"><li>المادة الفعالة هي لاكوساميد اس بي سي.</li></ul><p>&nbsp;</p><p dir="rtl">يحتوي كل قرص مغلف على ما يلي:&nbsp;</p><p dir="rtl">لاكوساميد اس بي سي أقراص ---------------- 50 مجم/100 مجم 150 مجم/200 مجم</p><p>&nbsp;</p><ul dir="rtl"><li>المكونات الأخرى لهذا الدواء هي:&nbsp;</li></ul><p dir="rtl"><u><strong>المحتوى الداخلى للقرص:</strong></u></p><p dir="rtl">&nbsp;سليلوز دقيق التبلور 101 PH، هيدروكسي بروبيل سليلوز منخفض الاستبدال، هيدروكسي بروبيل السليلوز، كروسبوفيدون، ثاني أكسيد السيليكون الغروي، ستبرات المغنيسيوم، ماء نقي</p><p>&nbsp;</p><p><u><strong>الغلاف الخارجي للقرص:</strong></u></p><p dir="rtl">50 مجم: أوبادري من النوع الثاني أرجواني 85G500001</p><p dir="rtl">&nbsp;100 مجم: أوبادري من النوع الثاني أصفر 85G52072</p><p dir="rtl">&nbsp;150 مجم: أوبادري من النوع الثاني ذهبي 85G27190</p><p dir="rtl">&nbsp;200 مجم: أوبادري من النوع الثاني أزرق 85G20458</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><u>لاكوساميد اس بي سي 50 مجم أقراص:</u></p><p>أقراص مغلفة لونها وردي فاتح، بيضاوية الشكل، ثنائية التحدب، محفور على أحد جانبيها رقم &quot;11&quot; وملساء من الجانب الأخر</p><p>&nbsp;</p><p dir="rtl"><u>لاكوساميد اس بي&nbsp;سي&nbsp;100 مجم أقراص</u></p><p dir="rtl">&nbsp;أقراص مغلفة لونها أصفر، بيضاوية الشكل، ثنائية التحدب، محفور على أحد جانبيها رقم &quot;12&quot; وملساء من الجانب الأخر.</p><p>&nbsp;</p><p dir="rtl"><u>لاكوساميد اس بي سي 150 مجم أقراص</u></p><p dir="rtl">&nbsp;أقراص مغلفة لونها ذهبي، بيضاوية الشكل، ثنائية التحدب، محفور على أحد جانبيها رقم &quot;13&quot; وملساء من الجانب الأخر</p><p>&nbsp;</p><p dir="rtl"><u>لاكوساميد اس بي&nbsp;سي&nbsp;200 مجم أقراص</u></p><p dir="rtl">أقراص مغلفة لونها أزرق، بيضاوية الشكل، ثنائية التحدب، محفور على أحد جانبيها رقم &quot;14&quot; وملساء من الجانب الأخر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>مالك حق التسويق شركة سدير فارما (SPC)</strong></p><p dir="rtl">&nbsp;طريق الملك فهد، مبنى رقم 911 - الدوار الأول</p><p dir="rtl">&nbsp;الرياض - المملكة العربية السعودية</p><p dir="rtl">هاتف: 920001432-11-966+</p><p dir="rtl">&nbsp;فاكس: 4668195-11-966+&nbsp;</p><p dir="rtl">البريد الإلكتروني: info@sudairpharma.com</p><p dir="rtl">صندوق بريد رقم: 19047، الرياض - المملكة العربية السعودية</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p dir="rtl"><strong>الشركة المصنعة&nbsp;</strong></p><p dir="rtl">شرطة مختبرات إم. إس. إن. الخاصة المحدودة،&nbsp;</p><p dir="rtl">قسم المستحضرات الصيدلانية، الوحدة الثانية</p><p dir="rtl">&nbsp;تقسيم رقم 1277، 1319 حتى 1324،</p><p dir="rtl">&nbsp;نانديجاما، (فاليدج و ماندال)،&nbsp;</p><p dir="rtl">منطقة رانجاريدي،</p><p dir="rtl">&nbsp;تيلانجانا 509228، الهند.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يناير 2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lacosamide SPC Tablets 50 mg/ 100 mg/ 150 mg/ 200 mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film coated tablet contains
Lacosamide SPC --- 50 mg/ 100 mg/ 150 mg/ 200 mg
For the full list of excipients, see section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet 

Lacosamide SPC Tablets 50 mg
Light pink colored, oval shaped, biconvex, film coated tablets debossed with "11" on one side and plain on the other side.

Lacosamide SPC SPC Tablets 100 mg
Yellow colored, oval shaped, biconvex, film coated tablets debossed with "12" on one side and plain on the other side.

Lacosamide SPC SPC Tablets 150 mg
Tan colored, oval shaped, biconvex, film coated tablets debossed with "113" on one side and plain on the other side.


Lacosamide SPC Tablets 200 mg
Blue colored, oval shaped, biconvex, film coated tablets debossed with "114" on one side and plain on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lacosamide SPC is indicated as monotherapy and adjunctive therapy in the treatment of partialonset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong></p><p>Lacosamide SPC must be taken twice a day (usually once in the morning and once in the evening). Lacosamide SPC may be taken with or without food.</p><p>If a dose is missed, the patient should be instructed to take the missed dose immediately, and then to take the next dose of Lacosamide SPC at the regularly scheduled time. If the patient notices the missed dose within 6 hours of the next one, he/she should be instructed to wait to take the next dose of Lacosamide SPC at the regularly scheduled time. Patients should not take a double dose.</p><p><em>Adolescents and children weighing 50 kg or more, and adults</em><em> </em></p><p>The following table summarises the recommended posology for adolescents and children weighing 50 kg or more, and for adults. More details are provided in the table below.</p><p><img alt="" width="600" height="195" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p><strong>Monotherapy</strong></p><p>The recommended starting dose is 50 mg twice a day which should be increased to an initial therapeutic dose of 100 mg twice a day after one week.</p><p>Lacosamide SPC can also be initiated at the dose of 100 mg twice a day based on the physician&#39;s assessment of required seizure reduction versus potential side effects.</p><p>Depending on response and tolerability, the maintenance dose can be further increased at weekly intervals by 50 mg twice a day (100 mg/day), up to a maximum recommended daily dose of 300 mg twice a day (600 mg/day).</p><p>In patients having reached a dose greater than 400 mg/day and who need an additional antiepileptic medicinal product, the posology that is recommended for adjunctive therapy below should be followed.</p><p>&nbsp;</p><p>Adjunctive therapy</p><p>The recommended starting dose is 50 mg twice a day which should be increased to an initial therapeutic dose of 100 mg twice a day after one week.</p><p>Depending on response and tolerability, the maintenance dose can be further increased at weekly intervals by 50 mg twice a day (100 mg/day), up to a maximum recommended daily dose of 400 mg (200 mg twice a day).</p><p>Initiation of Lacosamide SPC treatment with a loading dose</p><p>Lacosamide SPC treatment may also be initiated with a single loading dose of 200 mg, followed approximately 12 hours later by a 100 mg twice a day (200 mg/day) maintenance dose regimen. Subsequent dose adjustments should be performed according to individual response and tolerability as described above. A loading dose may be initiated in patients in situations when the physician determines that rapid attainment of Lacosamide SPC steady state plasma concentration and therapeutic effect is warranted. It should be administered under medical supervision with consideration of the potential for increased incidence of serious cardiac arrhythmia and central nervous system adverse reactions (see section 4.8). Administration of a loading dose has not been studied in acute conditions such as status epilepticus.</p><p>&nbsp;</p><p>Discontinuation</p><p>In accordance with current clinical practice, if Lacosamide SPC has to be discontinued, it is recommended this be done gradually (e.g. taper the daily dose by 200 mg/week).</p><p>In patients who develop serious cardiac arrhythmia, clinical benefit/risk assessment should be performed and if needed Lacosamide SPC should be discontinued.</p><p>&nbsp;</p><p><strong>Special populations</strong></p><p><em>Elderly (over 65 years of age) </em></p><p>No dose reduction is necessary in elderly patients. Age associated decreased renal clearance with an increase in AUC levels should be considered in elderly patients (see following paragraph &#39;renal impairment&#39; and section 5.2). There is limited clinical data in the elderly patients with epilepsy, particularly at doses greater than 400 mg/day (see sections 4.4, 4.8, and 5.1).</p><p><em>Renal impairment </em></p><p>No dose adjustment is necessary in mildly and moderately renally impaired adult and paediatric patients (CL<sub>CR </sub>&gt; 30 ml/min). In paediatric patients weighing 50 kg or more and in adult patients with mild or moderate renal impairment a loading dose of 200 mg may be considered, but further dose titration (&gt; 200 mg daily) should be performed with caution. In paediatric patients weighing 50 kg or more and in adult patients with severe renal impairment (CL<sub>CR</sub> &le; 30 ml/min) or with end-stage renal disease, a maximum dose of 250 mg/day is recommended and the dose titration should be performed with caution. If a loading dose is indicated, an initial dose of 100 mg followed by a 50 mg twice daily regimen for the first week should be used. In paediatric patients weighing less than 50 kg with severe renal impairment (CL<sub>CR </sub>&le; 30 ml/min) and in those with end-stage renal disease, a reduction of 25 % of the maximum dose is recommended. For all patients requiring haemodialysis a supplement of up to 50 % of the divided daily dose directly after the end of haemodialysis is recommended. Treatment of patients with end-stage renal disease should be made with caution as there is little clinical experience and accumulation of a metabolite (with no known pharmacological activity).</p><p>&nbsp;</p><p><strong>Hepatic impairment</strong></p><p>A maximum dose of 300 mg/day is recommended for paediatric patients weighing 50 kg or more and for adult patients with mild to moderate hepatic impairment.</p><p>The dose titration in these patients should be performed with caution considering co-existing renal impairment. In adolescents and adults weighing 50 kg or more, a loading dose of 200 mg may be considered, but further dose titration (&gt; 200 mg daily) should be performed with caution. Based on data in adults, in paediatric patients weighing less than 50 kg with mild to moderate hepatic impairment, a reduction of 25 % of the maximum dose should be applied. The pharmacokinetics of Lacosamide SPC has not been evaluated in severely hepatic impaired patients (see section 5.2). Lacosamide SPC should be administered to adult and paediatric patients with severe hepatic impairment only when the expected therapeutic benefits are anticipated to outweigh the possible risks. The dose may need to be adjusted while carefully observing disease activity and potential side effects in the patient.</p><p>&nbsp;</p><p><strong>Paediatric population</strong></p><p>The physician should prescribe the most appropriate formulation and strength according to weight and dose.</p><p>&nbsp;</p><p><em><u>Adolescents and children weighing 50 kg or more</u> </em></p><p>Dosage in adolescents and children weighing 50 kg or more is the same as in adults (see above).</p><p><em>Children (from 4 years of age) and adolescents weighing less than 50 kg</em><em> </em></p><p>The dose is determined based on body weight. It is therefore recommended to initiate treatment with the syrup and switch to tablets, if desired.</p><p>Monotherapy</p><p>The recommended starting dose is 2 mg/kg/day which should be increased to an initial therapeutic dose of 4 mg/kg/day after one week.</p><p>Depending on response and tolerability, the maintenance dose can be further increased by 2 mg/kg/day every week. The dose should be gradually increased until the optimum response is obtained. In children weighing less than 40 kg, a maximum dose of up to 12 mg/kg/day is recommended. In children weighing from 40 to under 50 kg, a maximum dose of 10 mg/kg/day is recommended.</p><p>The following table summarises the recommended posology in monotherapy for children and adolescents weighing less than 50 kg.</p><p><img alt="" width="600" height="168" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>Adjunctive therapy</p><p>The recommended starting dose is 2 mg/kg/day which should be increased to an initial therapeutic dose of 4 mg/kg/day after one week.</p><p>Depending on response and tolerability, the maintenance dose can be further increased by 2 mg/kg/day every week. The dose should be gradually adjusted until the optimum response is obtained. In children weighing less than 20 kg, due to an increased clearance compared to adults, a maximum dose of up to 12 mg/kg/day is recommended. In children weighing from 20 to under 30 kg, a maximum dose of 10 mg/kg/day is recommended and in children weighing from 30 to under 50 kg, a maximum dose of 8 mg/kg/day is recommended, although in open-label studies (see sections 4.8 and 5.2), a dose up to 12 mg/kg/day has been used by a small number of these children. The following table summarises the recommended posology in adjunctive therapy for children and adolescents weighing less than 50 kg.</p><p><img alt="" width="600" height="151" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>Loading dose</p><p>Administration of a loading dose has not been studied in children. Use of a loading dose is not recommended in adolescents and children weighing less than 50 kg.</p><p><em>Children less than 4 years</em><em> </em></p><p>The safety and efficacy of Lacosamide SPC in children aged below 4 years have not yet been established. No data are available.</p><p>Method of administration</p><p>Lacosamide SPC film-coated tablets are for oral use. Lacosamide SPC may be taken with or without food.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
Known second- or third-degree atrioventricular (AV) block. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Suicidal ideation and behaviour</u></p><p>Suicidal ideation and behaviour have been reported in patients treated with antiepileptic medicinal products in several indications. A meta-analysis of randomised placebo-controlled trials of antiepileptic medicinal products has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for Lacosamide SPC.</p><p>Therefore, patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge (see section 4.8).</p><p><u>Cardiac rhythm and conduction</u></p><p>Dose-related prolongations in PR interval with Lacosamide SPC have been observed in clinical studies. Lacosamide SPC should be used with caution in patients with underlying proarrhythmic conditions such as patients with known cardiac conduction problems or severe cardiac disease (e.g. Myocardial ischaemia/infarction, heart failure, structural heart disease or cardiac sodium channelopathies) or patients treated with medicinal products affecting cardiac conduction, including antiarrhythmics and sodium channel blocking antiepileptic medicinal products (see section 4.5), as well as in elderly patients.</p><p>In these patients it should be considered to perform an ECG before a Lacosamide SPC dose increase above 400 mg/day and after Lacosamide SPC is titrated to steady-state.</p><p>In the placebo-controlled trials of Lacosamide SPC in epilepsy patients, atrial fibrillation or flutter were not reported; however, both have been reported in open-label epilepsy trials and in postmarketing experience.</p><p>In post-marketing experience, AV block (including second degree or higher AV block) has been reported. In patients with proarrhythmic conditions, ventricular tachyarrhythmia has been reported. In rare cases, these events have led to asystole, cardiac arrest and death in patients with underlying proarrhythmic conditions.</p><p>Patients should be made aware of the symptoms of cardiac arrhythmia (e.g. slow, rapid or irregular pulse, palpitations, shortness of breath, feeling lightheaded, fainting). Patients should be counselled to seek immediate medical advice if these symptoms occur.</p><p><u>Dizziness</u></p><p>Treatment with Lacosamide SPC has been associated with dizziness which could increase the occurrence of accidental injury or falls. Therefore, patients should be advised to exercise caution until they are familiar with the potential effects of the medicine (see section 4.8).</p><p><u>Potential for electro-clinical worsening in specific paediatric epilepsy syndromes</u></p><p>The safety and efficacy of Lacosamide SPC in paediatric patients with epilepsy syndromes in which focal and generalised seizures may coexist have not been determined.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lacosamide SPC should be used with caution in patients treated with medicinal products known to be associated with PR prolongation (including sodium channel blocking antiepileptic medicinal products) and in patients treated with antiarrhythmics. However, subgroup analysis in clinical trials did not identify an increased magnitude of PR prolongation in patients with concomitant administration of carbamazepine or lamotrigine.</p><p><u>In vitro </u><u>data</u></p><p>Data generally suggest that Lacosamide SPC has a low interaction potential. In vitro studies indicate that the enzymes CYP1A2, CYP2B6, and CYP2C9 are not induced and that CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6, and CYP2E1 are not inhibited by Lacosamide SPC at plasma concentrations observed in clinical trials. An in vitro study indicated that Lacosamide SPC is not transported by P-glycoprotein in the intestine. In vitro data show that CYP2C9, CYP2C19 and CYP3A4 are capable of catalysing the formation of the O-desmethyl metabolite.</p><p><u>In vivo </u><u>data</u></p><p>Lacosamide SPC does not inhibit or induce CYP2C19 and CYP3A4 to a clinically relevant extent. Lacosamide SPC did not affect the AUC of midazolam (metabolised by CYP3A4, Lacosamide SPC given 200 mg twice a day), but C<sub>max </sub>of midazolam was slightly increased (30 %). Lacosamide SPC did not affect the pharmacokinetics of omeprazole (metabolised by CYP2C19 and CYP3A4, Lacosamide SPC given 300 mg twice a day).</p><p>The CYP2C19 inhibitor omeprazole (40 mg once daily) did not give rise to a clinically significant change in Lacosamide SPC exposure. Thus, moderate inhibitors of CYP2C19 are unlikely to affect systemic Lacosamide SPC exposure to a clinically relevant extent.</p><p>Caution is recommended in concomitant treatment with strong inhibitors of CYP2C9 (e.g. fluconazole) and CYP3A4 (e.g. itraconazole, ketoconazole, ritonavir, clarithromycin), which may lead to increased systemic exposure of Lacosamide SPC.</p><p>Such interactions have not been established in vivo, but are possible based on in vitro data. Strong enzyme inducers such as rifampicin or St John&#39;s wort (Hypericum perforatum) may moderately reduce the systemic exposure of Lacosamide SPC. Therefore, starting or ending treatment with these enzyme inducers should be done with caution.</p><p><u>Antiepileptic medicinal products</u></p><p>In interaction trials Lacosamide SPC did not significantly affect the plasma concentrations of carbamazepine and valproic acid. Lacosamide SPC plasma concentrations were not affected by carbamazepine and by valproic acid. Population pharmacokinetic analyses in different age groups estimated that concomitant treatment with other antiepileptic medicinal products known to be enzyme inducers (carbamazepine, phenytoin, phenobarbital, in various doses) decreased the overall systemic exposure of Lacosamide SPC by 25 % in adults and 17 % in paediatric patients.</p><p><u>Oral contraceptives</u></p><p>In an interaction trial there was no clinically relevant interaction between Lacosamide SPC and the oral contraceptives ethinylestradiol and levonorgestrel. Progesterone concentrations were not affected when the medicinal products were coadministered.</p><p><u>Others</u></p><p>Interaction trials showed that Lacosamide SPC had no effect on the pharmacokinetics of digoxin.</p><p>There was no clinically relevant interaction between Lacosamide SPC and metformin.</p><p>Co-administration of warfarin with Lacosamide SPC does not result in a clinically relevant change in the pharmacokinetics and pharmacodynamics of warfarin.</p><p>Although no pharmacokinetic data on the interaction of Lacosamide SPC with alcohol are available, a pharmacodynamic effect cannot be excluded.</p><p>Lacosamide SPC has a low protein binding of less than 15 %. Therefore, clinically relevant interactions with other medicinal products through competition for protein binding sites are considered unlikely.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Pregnancy</strong></u></p><p>Risk related to epilepsy and antiepileptic medicinal products in general</p><p>For all antiepileptic medicinal products, it has been shown that in the offspring of treated women with epilepsy, the prevalence of malformations is two to three times greater than the rate of approximately 3 % in the general population. In the treated population, an increase in malformations has been noted with polytherapy, however, the extent to which the treatment and/or the illness is responsible has not been elucidated.</p><p>Moreover, effective antiepileptic therapy must not be interrupted, since the aggravation of the illness is detrimental to both the mother and the foetus.</p><p>Risk related to Lacosamide SPC</p><p>There are no adequate data from the use of Lacosamide SPC in pregnant women. Studies in animals did not indicate any teratogenic effects in rats or rabbits, but embryotoxicity was observed in rats and rabbits at maternal toxic doses (see section 5.3). The potential risk for humans is unknown.</p><p>Lacosamide SPC should not be used during pregnancy unless clearly necessary (if the benefit to the mother clearly outweighs the potential risk to the foetus). If women decide to become pregnant, the use of this product should be carefully re-evaluated.</p><p><u><strong>Breast-feeding</strong></u></p><p>It is unknown whether Lacosamide SPC is excreted in human breast milk. A risk to the newborns/infants cannot be excluded. Animal studies have shown excretion of Lacosamide SPC in breast milk. For precautionary measures, breast-feeding should be discontinued during treatment with Lacosamide SPC.</p><p><u><strong>Fertility</strong></u></p><p>No adverse reactions on male or female fertility or reproduction were observed in rats at doses producing plasma exposures (AUC) up to approximately 2 times the plasma AUC in humans at the maximum recommended human dose (MRHD).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lacosamide SPC has minor to moderate influence on the ability to drive and use machines. Lacosamide SPC treatment has been associated with dizziness or blurred vision.</p><p>Accordingly, patients should be advised not to drive or to operate other potentially hazardous machinery until they are familiar with the effects of Lacosamide SPC on their ability to perform such activities.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Summary of the safety profile</strong></u></p><p>Based on the analysis of pooled placebo-controlled clinical trials in adjunctive therapy in 1,308 patients with partial-onset seizures, a total of 61.9 % of patients randomised to Lacosamide SPC and 35.2</p><p>% of patients randomised to placebo reported at least 1 adverse reaction. The most frequently reported adverse reactions (&ge; 10 %) with Lacosamide SPC treatment were dizziness, headache, nausea and diplopia. They were usually mild to moderate in intensity. Some were dose-related and could be alleviated by reducing the dose. Incidence and severity of central nervous system (CNS) and gastrointestinal (GI) adverse reactions usually decreased over time.</p><p>In all of these controlled studies, the discontinuation rate due to adverse reactions was 12.2 % for patients randomised to Lacosamide SPC and 1.6 % for patients randomised to placebo. The most common adverse reaction resulting in discontinuation of Lacosamide SPC therapy was dizziness.</p><p>Incidence of CNS adverse reactions such as dizziness may be higher after a loading dose.</p><p>&nbsp;</p><p>Based on the analysis of data from a non-inferiority monotherapy clinical trial comparing Lacosamide SPC to carbamazepine controlled release (CR), the most frequently reported adverse reactions (&ge; 10 %) for Lacosamide SPC were headache and dizziness. The discontinuation rate due to adverse reactions was 10.6 % for patients treated with Lacosamide SPC and 15.6 % for patients treated with carbamazepine CR.</p><p><u>Tabulated list of adverse reactions</u></p><p>The table below shows the frequencies of adverse reactions which have been reported in clinical trials and postmarketing experience. The frequencies are defined as follows: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100) and not known (frequency cannot be estimated from available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p><img alt="" width="600" height="504" src="data:image/png;base64,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" /></p><p><img alt="" width="600" height="593" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAArIAAAKqCAYAAADG/L12AAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAAEnQAABJ0Ad5mH3gAAPVVSURBVHhe7P3Pi9zIuu+N1l9xIMc5rZl5B6dHOcpJncGeeHA9yEFNalBwGwwnIQcNHjT4giBhcQzNLkgoDA3FKgQFzeKa5IjmLvy+Ju9OFpvXmCLvNnsbk+RiYdYyRbIwpkieG88T8UihH/lD5ZKqVP5+GkW7lFIopPhGxFehUGiPAAAAAAAAaCBiZPf29rBgwYIFCxYsWLBgacySMrIA1Ak01xyQV4CBDkDVQGOgDKoXCSEeUDfQXHNAXgEGOgBVA42BMqheJIR4QN1Ac80BeQUY6ABUDTQGyqB6kRDiAXUDzTUH5BVgoANQNdAYKIPqRUKIB9QNNNcckFeAgQ5A1UBjoAyqFwkhHlA30FxzQF4BBjoAVQONgTKoXiSEeEDdQHPNAXkFGOgAVA00BsqgepHw4YnnimbRiPqdfeqFH926DKsFTS9OzDZdCqZLt3IDyxlFoz519o4oXFy7lbfJRwp7bWoHU7px7HxOYUC9Vme3c7pDUGE1h/uVV9e0CI9orx3QtIpiCNaCMguqBhoDZVC9SJgWjzVUvG79cr+N0vU0oLaks73GyLrGcOdz+URR/5Hbvioje0OuIvppyOb3C81Gj0uc093C6QTNIJ1XS5oGHaczXdJ6S8qfXb7p5ozL3k+/wLTeAzgvAagSaAyUQfUiYZF4VrMRdQsboc+mITu690bJNqbrjCyjZnZX06cN+H0ysta8JnlU9pzuDlRYzaGwfliMadBp0V5rQNHVyq1VVrScDqnT6tFwsjB/3Ryph9D7ei9AmQVVA42BMqheJCwUzyKknln/bb0pd8fDN7LGLFyeUq/l5xGMLLh9ivPqK83DY2rtPabR7Itbp6zoKhpQux/RlVtzI5ZvadTbxzCCewLKLKgaaAyUQfUiYaF4djWyPC7zlMeOukeJcS+MMVqz3+k86FGr/YzCV8/MNi3qBBNjCbN8pcX0JfW5h0fi2afe8DUtpCuHfwspMA1aOxjTu3DgjtWlQTRPentS6ejS0/4T08iWNLJrz4VRI/uEgpDH39q0tnovaLL4Gl8vm36z9EJa8G7xek7L/02z6Myey/NzejXomvUH5vgfkvXueq8WUwrl2j2n6F3ojmeu32BsrktiYuPjyXl8Ts4pmlDY5/jNb51nFHEa7xGcLtAM1ubVVUT9VlGZ5qE4RxmDy/XBK9G4aNKUrWA8s/vx+PNzO7b7eXhue3r3/g/qdNJDnNrmOJ/jOsU3t1c0Gw/j8hCXSZ94jLuLr9On0+m39RZ/b/B1A6BKoDFQBtWLhIXiKTKyqzlFA2NK4x5J2/PSEjP22TQWEwq4EeJG5suUgrY2Qvt0eP5nGhvj1joMaZ5tPVINIg9dODD7WIOpQxwkHjWWq0sadc1xuiOaSVxuHzVs2pNTyshuOBc5XTWyXeqHl+YvY7AnL6Tx1HOKH7emGll+/H9IvdFb+uyPHWwd0/nkN7P9I+r9z+O4gZXrrecn69TU6xhYrwcsl0d6TtyYn9Ll8to+4jUGuDu6vFeNNqcRNIP1eeU0abQczhPjKGU2LpuW1Tykw7aWX65H9CbuoytXVv+tw19pMjY3vRLnf9jx+lqe/HIRlzE3jEFvbOO4/fL0gcLDfVcmTKLi+sGVdbATfD0BqBJoDJRB9SJhoXiyPYzx4j9ad48X43FyzuzFjYx7caxwHF2CNHKtR9SPPsnfdliA11OaM2zpx/zW7Cb7c+NmTWkZI7vtXNLHtGTNpR7XSws3vgc/JefvzqWVfeyaO0d37TxTnBsusdbIetfu2t5Q5I53xxRqDtxLNuWVLXt+ryzfVP5L5sbJlhNfg3qDatepbv0yzOTLQH6dK5deHZOtD/L1g1kndY6pzzKGG6wHZRZUDTQGyqB6kbBQPDmTZJCejacFY0T58f+f7CM/s0/OyKYaovXw4/QLecTIhnlXI/vFNYLpsas3HyO77lyKjKwaVy8O15OrjTY3oge+iSy6rkzFRjYe6nBPQIXVHDbnlZvRQ40kP11pp3toYy2beHKL6HJdWdzFyGqvsHeznCoXa+LW3t0d6yaAMguqBxoDZVC9SFgonnWGK8Nq8ZqGPX5sF9B5NKUo1Yu5o5FdLWgyNMaRx82d/07vouclemSX+UfuhpsY2c3nsqORTfXSfjb/Pkr3Mq27rrn1MLLgfrA5r7QM8PCVf6eP4XHBS15Wy+vrkm8xsiYF0ru6L8N3eMiPfQlNe2C1PO4SN9gEyiyoGmgMlEH1ImGheDYZWe6ZPfqZoqu/2d6Y+PGcM3tx47BLY6ENYWJErWHzGp6NRvar23+fDsMP8ePM8kbW9SytPZciI1vQG2SwDatp2E/O6MQfVsDAyAqosJrD1rzS3s3WD9T54YfM8ADGla3OkKY8RjXmKy1mH0zJ+jYjG98Im3RyWlMvksX1S2bYgkvzfRtyc59BmQVVA42BMqheJCwSj45hyxku12jYXhfXqMhLVl+St5LV2O30+E4bMfeyxnJGY3msnx3j5qfFNYxqfvXFrPhlMP+Fj3UvOmlPjR5ny7nE22df9kobaIumLz82dd111fXx9rlr5/d8ufNxRrbVH9N8+iuNpn/N9z7Ji3TmOtyzsYCosJrD9rzSssEmMn1Tp+jNXaf/kqYyowDPYnBBw3Bm/rWl15TjnE9oNJrSMjbNehzXA7vpRi1+2UtnMzBlN9IXyvwhEGATKLOgaqAxUAbVi4Rp8bjGgxultYuaPzVzvI7frh9TdMINkmmwfuwlU93wssHM6iN93o4bmzfRCzF1e50BnY2eUvorQWd0lkqf7SH149hrHdIvJ2Y/7pkJp24aLx/tXdU4uJfzP9afSz+kGfck8fRc8glYt9/aKXz0Tep0L5DtUdVjJmY2u37vcY968YwPZmn/TOEZm31d53plY8PO6f0Thc/9czKmIByJ0Y3X3aNeWU4PaAY75ZWbeWT97Bg89tyfYs/cEJ5OTNnMlkXfzDrDadaLCf342psJhRcu+/+Mt0nW2yWepYCJb5D1tyGNZ+iLLQNfNwCqBBoDZVC9SAjxVIC89FLcOwWguSZxv/OKbxr/QL3cXLZXdDk6psO1Q4tAWVBmQdVAY6AMqhcJIZ7bhocB/ETdXOMKFGiuOdzrvJJhRcfeuHWFy+BzGvjjYsE3gTILqgYaA2VQvUgI8dwyMibvMDWLAkgDzTWH+5xXdmy5P/aWsUOeDo8KPr4CbgzKLKgaaAyUQfUiIcRzG3gvvODzl1uB5prD/c4rHntrP2EtZY+XtWPjwbeAMguqBhoDZVC9SAjxgLqB5poD8gow0AGoGmgMlEH1IiHEA+oGmmsOyCvAQAegaqAxUAbVi4QQD6gbaK45IK8AAx2AqoHGQBlULxJCPKBuoLnmgLwCDHQAqgYaA2VQvUi4XTxXNItG1O/se598dV/k2vjVrtuGvwYU0ajfvXefXAXlQIXVHL4tr6qqJ+6i/vm+QZkFVQONgTKoXiTcJp7ky1Ped/7vgutp8mUfGNlGgwqrOeTyyn0aWcrh2iX7udmauIrop2Hms9rgVuB8BaBKoDFQBtWLhLuIx5rZOzayjJpZGNlGgwqrOWTziuuCfe/zr7m6YXlJYf9J6vPM9WCnwNNPP4PbBWUWVA00BsqgepFwF/HAyILbBBVWc8jm1fX0F/rJM6lFdcNq9pIGtdYVK+OfT6nX2oORrQiUWVA10Bgog+pFwkLxrBY0Pe1Tx/y2t9elp/0n1IobKx6r+judBz1qxWPUeF1I/U7LbL9PvWBEwdGLZPzackbRSOMzS+qjATwG90wmNW8/P6dXg67Z5oCC6WfzG094/tLF26LO06fSWKWMrIl7zGmRuPnYr2jGvUV8zPPAbN+h5+E5DTiOzpCmy3/QLBzYtPDk6WcBHeFxZK2gwmoO2/Jq/U1uUT2RfMCgHYzpnZZDU8cMornUB6vFlELZ5zlF77ROMWV/MHYfOcjGm5hYqVtyy5H9hK0/JCKuP0zdg7pgJ/i6AVAl0Bgog+pFwrx4PtM0ODCm7xlF/NnH5VsayZdzXGO1uqRRlxsXU/lrAyXrHtFh+MGaU/5M67EzsvLJ1n1q6ePIOD5rVm1D6BqY1jGdT34zppPj+k+6mg5NI6ON3BVdjg6tYdWGSOLuUG/42jRyppGMnpntTaNnGsko6Ng4zdI6/JUmY/Obif+P4/9FXfP/cG4/abmah3SMxqtW8poD95VtebXWyBbUE/aTslrWezScmJtZ3a47otm1tw/flEq51q/mPbaffS6qfxhnVJMe2U8U9R+Z7ZyRZa4i6ns3wpIe1AU7sU0HAHwr0Bgog+pFwqx4bGPzyBvjZixkNPB6ZJmPFPbaSUMij/xNwzN6S9lXPPLx2QbjkBsUbrzY+bpGqNWPjF11uAYrta6wIRpQdCX2Od5nT9YZY8tvNmeOLQ1v65BGl3GsoGZQYTWHbXm1vkeWydQTTM5wLs2NM990quHM75M/xk3iNWSGJqEu2B2UWVA10Bgog+pFwrR43LQ2fuVv2N6QuF5cExcPGxhd6LfONb7MW8xqOHX/XCNkkHWZBjLVEGnc5u/cwun/Unzs5YQCfVzZP6GLeIgDqAvOI9AMtuVVk40s6oLdQZkFVQONgTKoXiRMiyfzGM+xU0PijXXlOO141H+6+LLT8WT2LzCytie3Rd3RZdK4FBnZVBp81phoJh4/y6aXhyJMcj3JoDpQYTWHbXnVaCPLoC7YCZRZUDXQGCiD6kXCtHh0GMF+Mt7VsJuRVXSsKm//Xy6+9OP93LCBAiOrwwhahyHNk4R4DZGmVV8MS1gt3tP7pQ4t2DCn5WpOkbxc5jV2oHJQYTWHbXl1f42s3pRvMbIK6oKNoMyCqoHGQBlULxLmxKOP2+KXMbSCtz0W0kOaGotqXKZpIIbHajhXtJSXtJx5jV/2ekETfnlMja7/koX0vmaMbDxcQV/6UIPM6TCLvBxi407NgsDzWA4vaBa/JJI2stfTF3Qcm3R3DH+cLagcVFjNYXNefaV5eGxuJjNPTpRsPcGrcmVdX8rKvMwVm1S9YfWOURCvGtlWf0zz6a80mv49fVO+WtBkqLObWDP7EXXBzqDMgqqBxkAZVC8SFolntXhNQx0i0DqkX06eUpunpwmntPjqejX4N1mOKPz4hoZHAZ3HU2x1qR9eJo/oUlNkmcamN6TxzL5gYXtbkvhSZjbV+BhD+8sL6vNLZUFIUzHFvMmETvmztbINj3V7aX77u+vl0XgTM8tG9ih4aT91y791BhS6tIB64OsOmsHavNLezbiMmcXvIc39fkRn4c+Zsn5GZ9yz6q1LLe2fKTzzx8G3qXd2lq9/uAc1vuHWG1+ThniGFLMdl/N3Y7OvqZtGv0n9gbpgd/j6AFAl0Bgog+pFQogH1A001xyQV4CBDkDVQGOgDKoXCSEeUDfQXHNAXgEGOgBVA42BMqheJIR4QN1Ac80BeQUY6ABUDTQGyqB6kRDiAXUDzTUH5BVgoANQNdAYKIPqRUKIB9QNNNcckFeAgQ5A1UBjoAyqFwkhHlA30FxzQF4BBjoAVQONgTKoXiSEeEDdQHPNAXkFGOgAVA00BsqgepGQ/8CCBQsWLFiwYMGCpSlLysgCUCfQXHNAXgEGOgBVA42BMqheJIR4QN1Ac80BeQUY6ABUDTQGyqB6kRDiAXUDzTUH5BVgoANQNdAYKIPqRUKIB9QNNNcckFeAgQ5A1UBjoAyqFwkhHlA30FxzQF4BBjoAVQONgTKoXiSEeEDdQHPNAXkFGOgAZFktxjQ4GNL0Y0i9vTb1wo/uF+YzTYMDo5t96o3e0ufpCzoavqbFyv1cADQGyqB6kRDiAXUDzTUH5BVgoAOQYvWBwqMfaXR5Zf64pkX4Y9rILv5Ew/ADXc9DOmwdUTj/QNHgMR2adeu8LDQGyqB6kRDiAXUDzTUH5BVgtuvgE0X9R7TXHdFsQ6/bepY0DTq01wtp4dbcO66nFLSzPY8lWc5oHPSo9a3nuVrQ9LRPnXZA02u3LmZlDvOKgt4PlaV1NRvRQT8itrGFRjbmI4WHzyi6MqK4iqh/sF4fqGtAGVQvEt4L8ZgCE41Modwzd24LLZWmAPTa1A6mpphUDRf8iEb9broiXfAjkw4F06VbUQOF1+JhgQqrOSCvALNVB2xSWjxJ+WMazb64lR7LCQX9i/trUrkNmL6g/rcYv604s26u5bcZdjaORzaeIiMrhpvz4ltM96a0Zo3reiO7mv1KP2kv7OqSRgc/WVNbAOoaUAbVi4TrxXNFs+jM3NXtWzHz0unTKLqkefScBtEnt9234hWYuzJvccEvKrR1cg+uRQ3w+YFmgLwCzGYdrIyPNW3C+UtjZlvUHV1a4xLjxkvead26BTbanf1v68HcCddz/c3XwpnZwh5Zg9xYfGPvsetMKjayx14+FxvZ1SKi4TCixdV7ms6uYGTBraJ6kbBQPKs5RYOu+a1L/VFEs6UV3moxpZAfNXzTnV4RauDu0Lypmb3zyvYeXIuKQYXVHJBXgNmoAxkv+bMxKH8rGF5wRZejQ9NmuI4Crtdm7+wj684T6nVasu6P//ZG2pb9+AkcPyULqS+/m/06fTqdLmjldzq4OvJ6GlCb/3ambrV4TUPtgGkdunGcVzQbD6nXekLBOf/f+235lkZ+h03vX+l/y7Yd6vW4Lub27j9oMQ0p6P1L8oROH+/LfsYE88tMc36Kx3/bJ3lx2uL63NXv2s4sLynkJ4GyTYs6g7F9IUof63vXKN0eqJF9Sie/uOvbGZhrax/22/bMb6fN+YcDl1ZznP5Lmi6+ut++mnMzNyHuWrd6L2giv/lGNt3Jcv76JBlaIE8u3Tl+fGOO+5j+9X9f0EDzTnvpMbQA3CKqFwnz4kneNiwemM2/P4aRrQwYWXB/QF4BZpMOkvGS3DM7MKYqO7zAN2+eIeoMaSqdJMk6HUq2kpeEujSI5rTSjpXWMYXzr8Y/jo1J8ntPef8jYxw/m39yz+qB3U/bstaAXo2fO0Np36Jfcu9gt0UtNWOe8UvM54GNM/6d1+lQs680D4+N0eRzuKbldGhMov2Nr0c33k6vSZGRdb+Z9EVXX2x8cu0+FVyjLM7IZs24bp8ysprWZxQZg2qvnzn3w5DmZlN7rd25yvVruXxIjOx8MaHT/pG7rga+eTl8nPytGHM/+cMLujD5lELyEC97gdtD9SJhTjw61kkKV7HkVvML+unUPVZI3ZXyfj0aTriI8h3173TOd5XtZxS+ema2MXeCwcQUZd6NC4a7E+0cU1/uiLWwJ8MakjGy6bvG+A44TqIOcNc76y71w0s5VjF+fCZdT5/au3Q1sjxW9TyQu/L4Dty/qzXnGZwFdDT0exDcOFs5vn/X+y3XgtHeBI6X75iHNJY77w3xenf6rV5AZ0GfhvF53C2cJtAMkFeAWa+DLzQbHVFfh5pJ+5EdXuCbN6bo8br/TgTH+Tjds5uKl39/Etef8sj66FS2TUyov3AdfrXBUBpSxi9rPh3+OxNihNcMRci8W2HTtOa4Pqn9tg1ByA8tSBlo/3wkrW0vT/wbjs/2WhcexxlZ7hXuHrme7QTp+T56UTy0IcM1pt8Ct4zqRcK0eFTgxvzEbyRuQrdP381J4fqid7C87NPh+Z9pbO6q5S7wirdru8coxoxdnjqTZgu7LZB239jIuorMVl7aa5xUFvau0t1tx78/SirYFOaYcgft7vjNmcaPv6RAu4pU0uAdg9PlegXkb3PMY2dk08f3zonvkD+b873htdC76bZ73KN305vjfUnjf30c33HbOJ7ByILSIK8As1YHrmfT1kHekhpekDVvRWbON7Ludz8O1yOq7YGti21ny2p2Skdi0py5yxpQx0ZDmTKy2W0dvtHMbJ+irJHlTpPwxHWq6H5F18gnb2TXpk/+nb65sGnibf+64TjOyP7QoY5p2zb1pt4GazUGQAGqFwnT4tGKwDOQG3GPLOLeW1f44sLlCkKqd9eZxNQ6d/fpVxxSKLOPmhJjmhRELvT5qV+s4fuh2MhmHysx2hMdF2i9FpkKKR5z5VN0Tu7a7GkFcsNrIWn1z0NNtl6LonhtPrR6p3RZ+FjqbkGF1RyQV4BZp4PERCp+b58OL8iasiKT5hvZgnoxaxzjevGj2fan+Fi2XSjuwNhoKMsa2Vwvp8fORlY7Lty7KLNzb7+ia+STN7Kp4/jnU9DeJdsu7bVO3Xgorm3p/UoTaeeL2r7bA3UNKIPqRcK0eBIju1uPrMKP6f9kH3GbfXNG1r9rjAuHX0BdofUrjoyRVfiFswt55M93/n6lYu5m1xb6DBJ35m5aCv5mIxv3OMuwgRO64JcP5Iei8zTJcj3L9hxueC3cdeA8SS+a/qJ4tceZt+NK8jdvYP/dw+kHzQB5BZhCHci4TGNustNt6dMzfXHJM2XzxVv6y2Kef2yeMVu240LjMO1L9Iw6BZ0ArSc9euK/QKR1tBsPynXhVXRCp7N/OoOtbUym8yM2fu9p8Zd/p8uxv63F1udqktVse+bu6s80ujB1sj8Mwn+ZS+poV1/Lcd11kX+7c4zbmx2HFqTGyD5KhltIu6GdKNqpkh5zHF9rOS99msiYY49emeN67ZOMifXG4FYA6hpQBtWLhFnxqPkqvkPLo2+I8jjM82hKERfM2FQVmCw1nan4dzCyPIh8aIwyj009/53eRTx4/2ZG1p5j+lHLTkaWicfOskl0Qx30+CkzaUidww2vhcSRSUOKIiPLGDOr42c5P/0XF+4YVFjNAXkFmJwOtL6UusU3fK4+kvVmkXpJTRq/1/AnCp9z/WZ/t3Wj1nn+OrPP5IWrZ83iv5HvSBtLhes9b7YDvpE/ndDHCfdAurjafQp+To5njZq+UNaj/9fzHv23eFtXr6bOV9sd1ya5bZMnYMlQNZ4B4HX4jPZN+xhOZzRJneeEPutQMn635NWInpp/8zsQJ/3/7m3n2sAsRbMm8OG3ppU7YsJ4NiLpiPKvtZjjeSZPInoT/72pPbo5HDcAu6J6kTAnHr3z4jGXa8bEyPxwo6mpfrKP9F2FFJuqIpPl9vHGmm43svnHVfbRiBaoojg34IYRJGNIDbsaWSWeoozT/Fd3fL/HwGySqmhveC1SY4M9Vn+j2Xuu2NcZ2YR4XO2ORr9qUGE1B+QVYKADUDUbNeb8AG9jl7xXyK2vAvEJmae5ZdGp1e5Je9xUVC8SFoknNj65x9L27fnDQ73zdCZKHuN8MfnjZg1QQ1fYU5k89tb56pLjsRCtWdWeYfv4Q02lezSiQohNoh9nMi40MdxZkinG7F2s9hi4wiDGPDsWlTX8go5jc59M7cLnGr/spXfF+vhGzfKNr8VV/FiIexbsozqePeGEQjb1hfEaMzx8lphj97it3HCR6ijSHLifIK8AAx2AqtmqMR02kukwYsQv7NqRtRZu03+u1gjHHVWmfYeR/SZULxKuFQ8/tgj1Ebpb+LF+OHVmivEfSbCJG1N0wuavRZ0fe4kx5CVltNKPMuyjlB/M//nxy4K+Sm+rt6/J8Lk3yTWbvjfRCzsEIn7kZOJMTc/lG78CUo9aTNp/eUH9tvl/EBrj/vdEbLLYOzCZQiR4mUyxlXrcxY+0/Om/OK5X9vFN6lGPWUpcC0l+6hGSWQonBzdLHC8b2T4F5/ombPZR0t3CaQXNAHkFGOgAVM12jRW9SGjJv3RYFu1UqrhHV3BPYmFkvwnVi4SooEDdQHPNAXkFGOgAVM1OGiscasc9qf2UuS33dbd/eNNe8sIdV/+323bz191Sc8DzOOfJR5rL02Pzt3QsFfXAunX6942/7vZ9w9dL/u//AUBdQHPNAXkFGOgAVM1uGksP6RPY3OZmrij/dTd/+jL7b952w9fd5H0inSnCHUfMqxuWGD8hzfbA+kbW9TLL+ZT9utv3jepFQlRQoG6gueaAvAIMdFAG+87FQXBGZ/wOSfYRcjzW080OMOy7r2F+3+yqMfv+jL6MzkbwJzrwhhUkJtRf2Hxu/rqbb2R5qEF6W4c3i5BNR1EvqXunxx/q5/fA5v72SM1ShCEIm1C9SLireAC4LaC55oC8Agx0sDv84u+RvhDNxiRlRIzJuTihcL60vW/mtzm/4Nv98RtfVGo+O2ssNW0lm70jb1iBvhheZDCzZnWTkc3/LXhGs/B34QZG9kZfd/u+Ub1IiAoK1A001xyQV4DJ6yAzX2y88IulI4oyc77eCG7cR33q3ElDzi/vRjTq/0sy1dJOUy/xY+WjZG7bnJH1ML8dymPtfK/i90heY+tIXvo6Gb+ko0F6Nh5rMLPzC1tu08jaHtn8i2dmzxJG1ujsxl93+75RvUi4u3gAuB2gueaAvAJMsQ6yYwGNxdCXbL55XJ9Of2jM8V005Nrrl/0C5FbY4P+YmJ+1Rtac3+kw7oVlU3RwT6ZHvCtK1TVuLnh/esyYG37dLTau84/0l7/M6R8FQwuseXXH1DG28ZSffJxf6cIcU432yBzT/0BH6uNIclxnVuXfdkjK7l93+75RvUhYSjwA3ALQXHNAXgGmWAfZnidLYU/WjbjjHqkbTX7PJqWX9NIVGlk2LL/QMPpIV7N/l2kRYWTL1jUFL33FcG96+a+7yRAPs49+jS3Z1uk7Nd2l65X1Z0fQl8g4CfLJYF5v1snX7P6lcGrPb/6623cMXxf5v/8HAHUBzTUH5BVginWQN7LxdETaI1s4hdDfaRYOvHmxteeM4Y+9uN9apvF/YsyAMRkfxRy77cUYOpMb/52eR1w/MJOKj5f4WDoVkz+9kjGs3lRIrSc9etJSI8vx+1Mv5c2SfUveH1qgwy9sHGLwu/+L/vc4+/EdDC1g+HoAsCuqFwkhHlA30FxzQF4BplgH+mKNM2XxouMGPbPpDzWQx8L28az9ImKLumLi3KT0bt7P9Ke13VjCdvL1Jnmp6sh+OdHG46ZKco+WpRdrzbGSj+540yu5Xj77qPiLe8zrjGx26iX32FembtLPurtH1HKcrm/OLdx794fhn5LPojvkPPGyl+gEgF1RvUgI8YC6geaaA/IKMMU6yPbIci+lfqZcDee2cX6219I+OuVtf3CmlskOLfB/93s+3XjatcdQ/GPpC0PeEAgxvd7LO9mhBd6LPmmy1+GrfK3xaLjL42Bzjph+S0BdA8qgepEQ4gF1A801B+QVYIp1UDxG1r4Qo+P61o1zvaJZFMaf+5Ztc2NS8/tK3Dwu8vM7Gh385MZHrjuGUnAss3brW+pbjSwb998p5JkVTLzZ6wDKgboGlEH1IiHEA+oGmmsOyCvAFOtgs5G1X0wqMJnyIswjN03X26SXNPOlpUKDKts8ol7/mLrxdq5H1j3aT7HuWOanrHFNvZHObDSyV3Q5OqRWp0+j6B3NCq4DKAfqGlAG1YuEEA+oG2iuOSCvAFOsA2cgPQOXvMWtY0/zQwusgbSP8HUcrDWX+iY6f7N+Qdc6RtYcO9lfhwT4Y1vVhHpvjfNxR6/cS2JFxyoYWuDG1toXxZZujCyPi7VmNmV0xeS6sb2rOUWDLozsN4K6BpRB9SIhxAPqBpprDsgrwOR1oG/ks9HLLNJLOTOG0vWouvXaE5qemuicRk+N0XUvePmzBux1BhT0O9Tpv6Sp/+JU9tv6gh2XKtMY8b5xfMXH+uXkqTG4btvYgPozEbSo8/Nz6rft1E2Lr2xc3fbSKzu3PbLm71bvD/Rq9KP5t2+kQVn42gKwK6oXCSEeUDfQXHNAXgHmPulgNTulo/iFMPBQQF0DyqB6kRDiAXUDzTUH5BVg7o0OZKqrw2RmAfBgqF5jOnewN5ykFnQ2jx+8Fxlvwm3FY8m93FgK9wTk0A35WS1oenFC/U7XexnyI4X9n+h0Ws2MHKoXCdFQgbqB5poD8gowd64D/SSpGz+L3tiHx3aNGSM3fUH9G5o4a9x4aEjNRlbGU/Nx/Rk5dsU752+K5zYxJpbHj8cfF/Hnk87O6sFDdQ7cx0JuF9WLhGioQN1Ac80BeQUY6ABUzVaNyct4+99g4gpe8KsLuRG7gQHNnvNN47lF5IMf3odJYgrnWTZmVj5kUvQp4W9D9SIhKihQN9Bcc0BeAQY6aCgyo8KhMRfv7Mt52bl23UwN8nLc2zENj/TTvvWzUWPxS3vc62cWPg//xUB+OW8wpoXzSvGnkvk3rxff9sqacx2f2BcD3UuBSW+ti9t/UXHTsXKfYDbx/e/fKOAp33pP7KwXvL9O5Ta6SF4+5BcD415WXqzBTqXFHMv+3yyb4uGT1rT0TijSzzLzF/UWJu9d2u1X60zCeShAGFBvX190XPcp5yx2ppJkijyPtR8MyX7o5HbgdMr//T8AqAtorjkgrwADHTSRrzQP+3SoRoeNhpg05ZoWFycUzpdmu2Njcn6lf4ueUffQfva3brZqTE2c9Ea63lX+OMbVF5t+/TSyjKM2RjKYmPN2U7q5mSmsSXTmLzVvsfYcFn0Ced2xPiVmVz/BHBtTY3bl+A633hrJf9pp6yQ+s4+Y9A4dhh+s0eP0H/VtOlLnbFgbj/s3p0Wnr5NPMvO2fHPyxX7+2RnN2CzrjB3S01v02egMcs3W9IqvNbJu6EHRPM/fgOpFQlRQoG6gueaAvALMdh24+WJv3Fht+zqXsv6FnXRPVmbRBts3BtwrddqnTpn5X1PGgscA+i/fZP8uQdaw3AZsOuKvnxlyRtbD/HYoho7z8ehOXqbjfNrIpmvkmSg732/x8AGrEf0tqzm/59D/BHKGlGFzuveva9Hj/0za0+lwRtmVHU7/gfZ4Zs95YzyZtDijHk97l0p38cdMLP6nnDOk4siw4bd0Om8H1YuEW8UDwC0DzTUH5BVgtupAX8bSXrEs/Ai7f7HFpG4nMatrGkVp6L05axnpoXua2d57QaWMkfVxx4pfvsn+vRHuKfz5Vhv2HGwsfIOV/TvGmLbToeuJ3GDgKmarxrKmjlnOKAr5bXl+BG9N1CbTlP4tf/MkJjj3CWRHwbGK4ihMZ2ZdLo1iOn8w1/1j+vpn49oYTzYtGUO61cgWf8o5BYwsABZorjkgrwCzWQfco/ScBucvjZkteiTpHu8WmqiybHlhRxr6NY1wjk29UjuS7X3b6WWclXvMe7sNew42Fn4PeaGR5TfQf6GhMVBXs3+nmTyuboKRdUMBWl3qjyKazc5jE2V7ZItvqLYZ2eJPIK8/1q0ZWR172ntKT7uegc7GtTGebzCyGz7lnAJGFgALNNcckFeA2agDGdP3s2l8/1YwvOAq/gIWxyE9qbN3mRdkjuiP//aGQrNuXxvPDS/ybGwUpaH3jCwbk4H2BBvTNg0p6P1LpjF/Sie/uDR2BiZ9bF90mID/0s6v9G+p/TmKTUaj6AWaL84UuXXSe/sfmXQx/r7m/OOvmyXDF54Ep+5zwN4LPz6poQX6JTY+3jtjeLrmhuPfaR5/htcskm9NGFrwnhZ/+T8pfG5Mm6TZTQelJso9Uo9fbDLX7Cr6lS7M9UvfBLlH8Sm96o2S/wlkZxCLjrXr0ILUOj1GxmzLNkVja/Wc39LiH5viyZyPuw5aFlKfWHbGWcfp2jJl40l/yjmDxFk8RtbGX2RkXTlLXedvR/Ui4VbxAHDLQHPNAXkFmE06SMb0rWmgUz1F7t8mvvgFGW+dbTxdPLmXa2ycuxhZiV8XNRnxb9rYugY2+zlbTtfnidvWMxa5/XWdZ1r8v8WYFL9AkzqHXLz8kpY5Z/fmuBqLFr+E9VW3XfPiUAqO50fqejcBFmPGJiMaXriXi2KsSbu3L3vJDAzm5kZeZprTld4Q8N+vRvRUXmyy5nW1eO1MPl8ra/Q/yzW3126v3afgZ6dDs6RMG+db6hPI2iObPdaQTvr/PR1HnJe8uPzMrPs56Hvp8J8GFNxE+Of8OqTna+NJn89e72dzs6OfkDZ6PDvbnIbPxZ9ylnKRwvUcx73VFqtnjd8rDwKfF2YtAA8MaK45IK8As14HmTGVrlcp3WhlH3kW9GKVeMGkVI9sdmzupserhlSvUqoXzZF9fOob16K/Y9LnlzsHP17p9Wp71zBzg5BJ18brsVrQZNinoaZ3Eybt93b6rRq5s08gc74fnd5qr2UVrJ1Hdg1lt98V1YuEaKhA3UBzzQF5BZi1OnCPL/n31JJ6jJg1stm/mQIjW/hyzRbjljWyWbYY2dTvRaa0tJEtfoFmo5GVONI3A3b74nRtvB4Ngq/PnXNnn0C2vecHd2GgS+OGV8TDcNbBw2DwZS/wQIHmmgPyCjDrdJDvvSoaXlDWyG56uWaLcROTd3Mjm4o7Z0oNZYzshhdoNhpZd3PgP77dlC4Y2VtAernNDZibg7U+M+meTsgj/deZISD3GWNmpy+pv3EmElOmD48qu56qFwnRUIG6geaaA/IKMIU6EKNW0HvlhhckL2glxnW+eEt/WczzQwtS5s1tX/hyjTOfuXG4DmdkC788ZEi/8FI0RlYn0jcUDC1I728QA+r1nnp/fxWDadOZfYEmNp/zj/SXvyzoOhWvGyO717U9WW6cZHxOqXStG5fcPFDXgDKoXiSEeEDdQHPNAXkFmJwOnGHk9ek5XW3Pql1vFuntVDPKvU5/sm+bu9+tsXPGNV43oc9rXuR5Gz03BtCP2x3WYM2h+63g93SatffTfRRB1nm9YkXbZte9iTb/Hf2fa1+giV/g4q8ufXxdmK7JsGcMKq/jWQtCmqW+HGW3Tb200/BeWT4HAHZF9SIhxAPqBpprDsgrwEAHoGqgMVAG1YuEEA+oG2iuOSCvAAMdgKqBxkAZVC8SQjygbqC55oC8Agx0AKoGGgNlUL1ICPGAuoHmmgPyCjDQAagaaAyUQfUiIcQD6gaaaw7IK8BAB6BqoDFQBtWLhBAPqBtorjkgrwADHdwuMmvBwZCmH3m6rvQUXzyl1nI6lJkU5JOrnyd3+sWtuoDGQBlULxJCPKBuoLnmgLwCzHYduIndU1/0KkPRRxKKuKLZeEi9Vn6qqdz0W/4iU3Hxl4ZeUdD7IWMca4a/HnX0o/uOPc9l+2MmPR/pYvgbza/5K1Oc1v+Q6cu6hyHNb3RtmwHnEwC7onqREOIBdQPNNQfkFWC26kC/jLRuYv7lhIKNXwHajcSsrpkz1c2zmvqyl3x29CmFH9+4OVizPaDr4J7RF9SPt/1szPbP3zxXK39U4SD+YEORkVX4t777SALfKBw1/qMHm0BdA8qgepEQ4gF1A801B+QVYDbrgL8u9ZwG5y/li17xV65i2AAe7NDbugv6JasSRtan4Gtda2Hz3dl32+rj/m/96EDWuG4wsqtLOv3pwvXCfqHZ6Cj5otgDBHUNKIPqRUKIB9QNNNcckFeA2agDeVT+M0VXfysYXnBFl6ND94Uq15M6e0fjoEetzhPqdVqy7o//9oZCs25fDejyksJ+1+3jf+6Wvar7vOsuRpY/fTvweoLldzay/2kMJH/q1sQvww68r4ux4ZbP1fJXuTTdZpEeZ16cEU59fcsY3tFbWrLhleELj6jTe2K/GJYy8Gxcjz2zv8bI8mdph79QtPhEs+l7Ey+MLAA+qhcJIR5QN9Bcc0BeAWaTDpJH5eu++++Pf/UMY2dIU/7sqrfOGlAXT2tgzPEXmhvj58e5i5GV+HXxjWRsZNk4sjl87H3K1o3z1e1T22aPy73M/+IMtvbWPqL+q9/c8Y35DibmzPKkhhYs+GUv3p7j5Ti71P3XVzQeJCbeml4MLQDAR/UiIcQD6gaaaw7IK8Cs10Gmp1Ae3WeHF2Rf5MoYRuEjhb128ZAAMXsdCqbWFpbqkc2OzU2ZU+4NPfKMbCadm4ysOw5fF3+R424bviBjdh/TIJp714j5SovJiIYXH/Lr8bIXAClULxJCPKBuoLnmgLwCzFod8KP7Lg8PyJi61PCCrJHN/s0UGNnljKLwhPoy/OCGRjbLbRlZMddrzGpmvyJWi9cypZY97hZMfJh+C4A0qhcJIR5QN9Bcc0BeAWadDlazUzpK9b4WDS8oa2RXtLw8pV6rS/1RRLPZ+c17ZLPclpF1x2nFsw94ZPYDu4G6BpRB9SIhxAPqBpprDsgrwBTqQF6IOsyP23TDC5IXtBKDOF+8pb8s5vmhBa5n1xpDt7306trH6p3YyDrzuW6ar00Gk5GeVB364Jvuf9JyFrreX2eEY0P6nhZ/eUsfJ87Izj/SX/7yjiY8E8NeNxkicPU7DU9NvGVmRgAxqGtAGVQvEkI8oG6gueaAvAJMTgfOMPL69JyutmfVrjeL9HaqGd2n3vBPFD43JtX9bntOnXGN103os/TImr9bPRq+GtFT82/+ytXb6Lkxk37c7rAG22Pqfiv4PZ1mZ4zj2Qk0bf9CvSCkKT/G55kD+KUrTsNkQdf8NS5jdFs995g/O7NC/yVNP77OHwPsBF8zAHZF9SIhxAPqBpprDsgrwEAHoGqgMVAG1YuEEA+oG2iuOSCvAAMdgKqBxkAZVC8SQjygbqC55oC8Agx0AKoGGgNlUL1ICPGAuoHmmgPyCjDQAagaaAyUQfUiIcQD6gaaaw7IK8BAB6BqoDFQBtWLhBAPqBtorjkgrwADHYCqgcZAGVQvEkI8oG6gueaAvAIMdACqBhoDZVC9SMh/YMGCBQsWLFiwYMHSlCVlZAGoE2iuOSCvAAMdgKqBxkAZVC8SQjygbqC55oC8Agx0AKoGGgNlUL1ICPGAuoHmmgPyCjDQAagaaAyUQfUiIcQD6gaaaw7IK8BAB6BqoDFQBtWLhBAPqBtorjkgrwADHYCqgcZAGVQvEkI8oG6gueaAvAIMdACqBhoDZVC9SAjxgLqB5poD8gow0AGoGmgMlEH1IuHDEc81LcIj2msHNL12q+6c20/TajGli1GfOvfqPMuBCqs53O+82rV8faSw16Z2MDV7gJuAMguqBhoDZVC9SLhePF9pMf2NRv2ubGOXLvVHEc3mv9Po4qPb7hu5iuin4V02MJ8o+umXWzKFtxlXEbZBlrx4KEb2ekpBO5ngeK/zjKLFV/cj452zLG3qhbekPbCVVF7RkqZBx8sLXjoUTJfud87OgNre7/Wbx5WpUoY09NIEvh3OSwCqBBoDZVC9SFgontWcogEb2H3qBSFN1VisFjQ97VPn1hqoLzQbPb7TnpLVbETdWzKFtxnXepyxe3A9solhbR2GNF+51Q65tq0BRVeZH0ClFOXVajGmQadFe4X5saLldEidVo+Gk4X5q2ZWlzTqdlPmGnw7xWUWgNsDGgNlUL1ImBfPFV2ODqnFJnb0lvLNwVeah8e0/83m0zR4l6fUa91Fr41j+ZZGvf3bMYW3GddGHrKRPaBej3v8WtQJJmntLULqNficm0pxXtk6oLX3mEazL26dwj2iA2r3I1OT1I3WXeleYvDtwGSAqoHGQBlULxJmxbOah3RozGVxb4tjOaFh8HvcUK0WEzr1hiC0ei9oEj8evqJZOJBe3L1Wj4KzgI6GE/rsTKzuI48ooylF54FZ36Hn4bnt9ekMabo06VjOKOKxobp9p0+nU+3xMaZ49judBz1qqdnh3uPQxhVEEwo1ffroWo1nfHw11BzXKwr0N07zeOZMFf8WUp/TJb3VIwqOXtD0c1Fc5hyzaZLhGqHE3Q7G9E6vy16XBtHcncu26/mQjeyPFM7fU3jI13KfDsMP8TXJGVnv6YBcp7gH0H/8fUThwuzA++p2vZAWvP/yMtZEqxfQWdD3HkcbzY6HsT5bvSGNZ6p2zsOXTgP8u9HB8DUt1hSVpsPnWMhVRP1WwQ0HD6/pH2UMLpebyBumZPbrv0w/6YnL6pTGXGZ4u86AwtknWkxeuLww+w3G7lpny7yaWJtnsrj1s+jMlTl7w8zjzEPZ7zlF77Q8+3Ez+XrgTnqY7wlrdQDALQGNgTKoXiRMi8e9PGHWtXbuUeGG65EznNf2saLZP2405JHwsTEottFio3ysY2KdwbDbpsfftQ5/pcn4GXV4348zMTet3ildiqlV43hAwfSziZQfJzpjIY2XHbIQx+WMoKTFNFjd0aVrkPKmUIx82zVa8RAL/ziPEoO1+kDhsTGysm8mrlyazCo5vk1T3DDqdt0RzSTSzdfzwRtZYzzjR9d63ZmUkbW9fi393dxYBbx9/Lu7hmpkGTFe5rqLkbX6SIYwcA/jM2dkbW9jWzWjadEbqpSB+2w0e2CO83B7AIvzinFlzCvbjGg81rLF3hzrEx5jEPUmVq6puTFwdQ4vcVl1N9StzqG5qb00+2kv8CPqR58Ky1dSfyX54Zc5KUP+fvFNiNYXXg+zaKrtzK1JY2TqIhdPk8veTeHzBqBKoDFQBtWLhGnxJGYyMU5KYnKTxRgF14MWG1/38o7uLy9/tA5pdFlgi1NGltFjuMbKYRujzDrtOY4bzazByzdq8YtF2iuX28cZHM/Ea0Mo62T/dUMuigxmwbrcOes1d6aLzfGG61l8nGaR1pzC52WNrLkIntlxPegpI+tMTfzUwF3D+PfMNWVSeW9/j2+MfMTo/OBpTU2O1Z/VXaJF+3LT92hktWz4vbJs7P/Fu1Fk1PD6T3jUlOpNZUFZVZ17pthea/9lv2xZKIrHkCtz+TKUjdv+7dU5zgDvfoP/sNikAwBuA2gMlEH1ImFaPNpo+2Yvg/Z+ZYce8OPBi1/jR3Fxo6Hbc4PXP6GLeDiAYa2R9RuiNY2T9qzEjdEOjdpWI+v+5vPPLrKP9sCZvzt9Gl1MvUeR+caxcN02I6usu56Fx2kWfD55+LzUyDJqdriXzhjO2XnBGFl+zP8n+3iZ8yT+fZuRNUbZ9XTbmTh+Sx5zu/yJ8z1e0rMlyDRoMgyGf8to8wFRnFeK6/nWuoB7q9vpHtp1etUbRKvrDUbW269OI5u/eS4+j++FzToA4NuBxkAZVC8SZsWjDUz2kWFCtkI3ZkLGsPGY0TOK3o0zPYgGHt8aN/peD85ORlbNddYsZNOxQ6O2o5FNpT1HMuaOr138yDkXF1OwbquR3XY9i47TLIorLD4v38gyeuNgNNN7kpo7d7V4TUOTBzy+9ZzHVvM1jH/fZmQZb4wl56MOU5D8yWrNw9xgTIZmHx47ff47vYueGwO0YfuGs7lx0SEe3LP67/SRh2RkeyxzN5yOVDm4f0Y2fjLieu3joQ7okQWgEqAxUAbVi4Q58bgKPP/yg5JpBNyYwfhxojMMhWYwHnPqDMZORlYby/TQgvyjvh0ata1G1h+f6p+4MZezD9Z8x+i4OW388o1j4bptRnbr9Sw6TrMorrD4vLJG1hDr0eRbNp/ix87uGsa/683PJiObEI+D5d9SY2A9Vn+j2ft/OC0mYymtAfpejaxBjWrrB+r84A/JUDK9to50j+c9NLLxDSXf5PDCN5avaJYdivKdsFUHAHwj0Bgog+pFwkLxeG/0c49XmJodwL3lq42ANBJqepO3vdVgXk9f0HH89rnrYdNGzTUwrf6Y5tNfaTT9a3Hva9w7om/vOxPp9xrHDao2mAU9uWJSTKOUHVfL+8wnNBpN6Up6Xsz5xG9V8zlf0DCc0cqYoeGxviCkj6e1Mc7HtcylyeyVeqTK6ItJzhxtuZ7582wehZqT83pSMJ2T+UmNZmw83LWW8bNfkrfL42uiNz9u5gPtRTXH5WPv9UYUDp8l2nHDX+w11iENXeqfTtyNnMmH8ITC2dIZJTfLxHLm3rDP3GQ9IArzKoU3HGmNJuOXvXR2B3dDm7xsp3F411F1njOb3k1eriyokeV4ZjQd/So3pFrmcmUojtvvWbZx2zR7N0LfOdt1AMC3AY2BMqheJFwvHn6EHma+7MULjyk8T8a6+iaB38R/M6YTbiR4u/CSPhsjexS8TOKRKXXcwzn/wwvDP1H4nHsm9TgZMxubBvt7akok7W2L9/0f1OuxOdS/TVzhSExzvE565rRXlePzTHJqeiXP0LCRPQroPJ4GzJ6jTWUmro+vM2k6orPwZ9MQJ+vawRmdsSHztgnnH9dfz7MT6mfibGJDy2lPUPPhnVeu19TcNPDLX/tqPPzeMtbOmKITNkJ8AxLaXjN/ejXWnAzRYO3yeNi/03TYp+DcXE/JZ28/hscn+1N7eVO96ZAGXs/5/CZ6YYfi+Lp+QPB5biX7FCEH3wx6U1mlejf1iYS71twrenaWLjvGcL55wyY2Wdf+OaCfC8pC8rEGOyvIVzG/3naPe9RLxf0zhWe+/myvbDJzhrctL+teXH3g8LkDUCXQGCiD6kVCiAfUDTTXHL7bvOJe+t4fMkOM3A3VYX54ykMHZRZUDTQGyqB6kRDiAXUDzTWH7zOveAjUY2+8rMdVRIOBjsv/fkCZBVUDjYEyqF4khHhA3UBzzeG7zCsdQ5v6eqAbVnLYXzOby8MGZRZUDTQGyqB6kRDiAXUDzTWH7zWv4s/YmvPna2DH9YbJfMPfGSizoGqgMVAG1YuEEA+oG2iuOSCvAAMdgKqBxkAZVC8SQjygbqC55oC8Agx0AKoGGgNlUL1ICPGAuoHmmgPyCjDQAagaaAyUQfUiIcQD6gaaaw7IK8BAB6BqoDFQBtWLhNvFwx9GGFG/s+9NR+Mmsfe+ulM9PKl6ZD+sUPCZUdAcUGE1h2bmlf3yW/L1vIqQr/BlPtzyQEGZBVUDjYEyqF4k3CYe+1lIfmvX/w75HeB/vQtGttGgwmoO6/OKbyx/p/PUm/385bSIZvNxvXOtXkX007Bi02rO9yoa0vA7MK1FoMyCqoHGQBlULxLuIh5rZu/YyDJqZmFkGw0qrOZQnFf6OWb+tO+IoviT0wuahoH9dHBtZfQLzUaPq+99lbllu99F72sRKLOgaqAxUAbVi4S7iAdGFtwmqLCaQz6vVrScDo2J3aPWYUhz/wuugvu9ljLqPhlrjHO1RvaKLkeH1PpOhhEUgTILqgYaA2VQvUhYKB7uWTntS2PFjwuf9p+YSlyNrPdIMR4jy+tC6ndaZnueOHxEwdGLZPzsckbRSOMzS+qLOTwG94yC3j61n5/Tq0HXbHNgGozP5revtJi+dPG2qPP0ab63x8Q9jh9v8rFf0Yy/j87HPOfeoQ49D89pwHF0hjRd/oNm4cCmpdWj4Cygo8ofSwIfVFjNIZ9XnyjqPzLrH1E/+uTWZVh9oPCnX2kmBZzrBje2Xcoo9+K+TD4sEPfiGpMYTSjU7TrPKIo/PmDqiFyZndBnZ2JtvLyw0Zwn9Yma27guOKSR+c3WJ8aI917QxE9HXOfZ4wwnXEepifWOw/Xe56R+SZnbTXXdTud6P+F0AlAl0Bgog+pFwrx4+DvjB0nlunxLI9MoxGNk9fONXAGrkZV1j+gw/OAqbNOQHTsjy/8+3DeNxildisHU+KxZTcbgmqV1TOeT34zp5Lj+k66k56dLg2ieblDUyErcHeoNX9Ni5T3uDMYUBR0bp1lah7/SZGx+M/H/cfy/qGv+r5+ZXM1DOoaRrZW85sB9JZdXVxH12Ty2BhRdSWnfCJevw5a5wRy9pSWbWjWfclP5TxkWEJdTZyxXsxF1TTnuji6lPpG/15VZeeEq6ZG1+9r47Do13rzOpEPqiiQdtleZx78OTN3ibqCXEwrY7MY36u7l1rhH1g5nsHF6RnZjXffXnc71vsJpBqBKoDFQBtWLhFnx2IrV723RSt4fWmDfCo4rennkr41Vmnx8Zp00bqZC745sr41rjFp97wURZ5hT67QRdUbWNnBeg6omW9YZYyuNT/rYYpy5Z+aytldRQAZUWM0hl1eurO42Y4kzfCnT+5Xm4bGpT9S8ZU2iITOEaGOZzRhZIbduaW7O+cb2iMKFbqVm9DGNZlc2TXE63fZrjWzxuu113fZzva+gzIKqgcZAGVQvEqbFoxWtX+G7hmSTkdVeXBMXP0obXUxpIe1WUQNgUMOp+69tjDLjclOVvsZt/s4tnP4vxcfW3hZ5xHlCF/EQB1AXnEegGeTySo3sTj2y2XrCYg2flvcdzN2mMntjI6s36L7x5KFMf0pmYihlZHep63Y413sKyiyoGmgMlEH1ImFaPH4vxRe3juvabUaWSca6cpzpR4eZyj27f0FjZBu7zCO3IiObaSQT1jQsTDxmzsTFjWMwyfUkg+pAhdUccnmlxixTRxSSvWFVUuV9R3O3rsze2MhqvWaPu1q8pqGpu1q9gM6jqR2aFKe7qC7JrtO6M1vf+HXdjud6D0GZBVUDjYEyqF4kTItHeyn2k/Guht2MrKJjVXn7/yro9TC4Bi4eNlDUGLlhBKk3o1OVfmZcm8dq8Z7eL3VoQbZh8VjNKZKXy9INHKgWVFjNIZ9XOjQgUzZ9uFwNX5ob2b/Z8amZ3tv0I/iS5i5bZm9sZP1hDy6dOtRJty9lZIt6eA2pug5GFoB1QGOgDKoXCXPi0cd4+tZu3HDYnhDpIdWeFm2gTGU8PNZGbeWm53EVevwChL4h7Iyu//JG6lGjosMV9AUNNcicDrNwo3Nt4069Gby8pHB4YRqk4h6S6+kLOo5NujvGTo9JwW2BCqs5FOZVXCdkH/XzDAWvKDj8MR7PGr/sJWVYVsi+iQkuKKc6Ft4Zy41l1pnWVn9M8+mvNDI3tVqfJOPr1chmXzrTnl13Yy4vuH6x58BPluJ6QQ0o12kzmo5+9Z42ecZ1a123/VzvKyizoGqgMVAG1YuEReLRx2z8217rkH45eUptnvYmnNLiq+tB4N9kOaLw4xsaHgV0Hk8706V+eGkaCMfSnyLLNDC9IY3dJOq2tzeJL2VmVwuaDL2ptX55QX1+qSwI4+l7VosJneam9vm7a7g03qTh4EbxKHiZTAfUGVCoE7qDWuDrDprB+rwyJm0aJkOJZEmXTYszt/F2vI2bIi82mLq/KafhSIxpvK4X0sdNZTY21SZeY5Y/TtL1ie3p1OPoVIL8m6mjTiduLL85l8kLN2yB4xlTdMKGk+uTUNK6WoztFH5ygz+jSSrd3tOqtXXdbud6X3tlOX0AVAk0BsqgepEQ4gF1A801h4eRV2oiMYTopqDMgqqBxkAZVC8SQjygbqC55vAw8gpG9ltBmQVVA42BMqheJIR4QN1Ac83hYeSVfhRhh5kWQCEos6BqoDFQBtWLhBAPqBtorjk0P6/ci1zmPOzivWgFdgZlFlQNNAbKoHqREOIBdQPNNQfkFWCgA1A10Bgog+pFQogH1A001xyQV4CBDkDVQGOgDKoXCSEeUDfQXHNAXgEGOgBVA42BMqheJIR4QN1Ac80BeQUY6ABUDTQGyqB6kRDiAXUDzTWHm+bVajGlC/5ASuFnrG8L/ijDb/KhhPRXAcFtgzILqgYaA2VQvUgI8YC6geaaQzqv9FOt3teocgtPcTVLZgooZWQ/UfTTL7tv7z5Py8eBka0WvsYAVAk0BsqgepEQ4gF1A801h8K8Wl3SqNvKm1T5XOyhm97KTXtVwsiuZiPqlu3BdWYWRrZaUGZB1UBjoAyqFwkhHlA30FxzKM6rXUxqSSO7fEuj3n7JHlwDjGwtoMyCqoHGQBlULxJCPKBuoLnmUJxXNzSyqwVNT/vUMXFyvHutHg0nC1qpidX1Zmn/HNDPbfd3L6RFalhDm3rhRxtnoZG9otl4SL2W3b/VG9J4dmXW85jakAJzrHYwpnfhwKWlS4NoTiu7syG9/15nQKHs71jOaBz0qCX77lMveEWzZbL3Q4SvAwBVAo2BMqheJIR4QN1Ac82hOK+yJnVFy8tT6h2y4VTy21xFA2P+DiiYfjZmcEJBxx+eUGB8ryLqs5kUI8toHJuM7Feah8fU7r2gyeKr8c5jGvBxOkOaTP+VumZbPqfYROswie6IZuJF7f6t1iGNLo151XS2BhRdmQ1WHyg87FBv+JoWK2OMo2fGDLeoE0zoIX8vDGUWVA00BsqgepEQ4gF1A801h+K8cqbT/JZaYsPJZI2pGkRnCI3tmwadzUb2ekoB98p68V5PA2pvMrJiTH+gfvRJfib6QrPRY5O+R3Zdzvi6dOwdUbgwa8Q8t6g7unQ9tM6sunTLON74HAxqhP11D5BiHQBwe0BjoAyqFwkhHlA30FxzKM6rvOlczUM63Ngjq/Dj/T/RuT6av20j6/7mdKcXt88WIytG1Y8/xaZZG5wRfqDwOQJQJdAYKIPqRUKIB9QNNNccivNqnUn1KTC7i9c07O1TqxfQeTSlqIoeWfm742ZOKOA2jOzG836YoMyCqoHGQBlULxJCPKBuoLnmUJxXNzGynyjqP/LGou4wtEAf25cxsm5oQG7M6upvNHt/tdXI6rjc1mFI89xIgcw4X4/V4j29f8AvfKHMgqqBxkAZVC8SQjygbqC55lCYV7uMC81t44xq5xlFiy+0nL2S2QNyv/Pf8wmNRlNjMZ35bR1TOOcXt2yPLqdJhwrYHlRjPPsR2XkF3FjcvS71Tye0kORd0Sw8oXD2Jd4+MbLuGPIhhy/m78/G2B6Yv/epN3rrzDCPkz2hEZtXednLpKHTp9Ppwo6jXV5SOLxwBv1hgjILqgYaA2VQvUgI8YC6geaaQzqviseIJqbQoUMC4m24t/OftJi8cFNaGZM4HFN0wi9htajTD2m2/OJmAODpsuyMA9wDKrMhyD52u3fRc2obEzm6mNLHCffOesfRntvsNF/OdH6V3txk+3ZwRmdsnuN1rld2zf7qU1eLCZ32u24fTtdLmkp6Hy58rgBUCTQGyqB6kRDiAXUDzTUH5BVgoANQNdAYKIPqRUKIB9QNNNcckFeAgQ5A1UBjoAyqFwkhHlA30FxzQF4BBjoAVQONgTKoXiSEeEDdQHPNAXkFGOgAVA00BsqgepEQ4gF1A801B+QVYKADUDXQGCiD6kVCiAfUDTTXHJBXgIEOQNVAY6AMqhcJIR5QN9Bcc0BeAQY6AFUDjYEyqF4khHhA3UBzzQF5ZT/UkJsr9zsDOgBVA42BMqheJIR4QN1Ac80hnVfFH0RIli71R+d04X08ADwMOH8BqBJoDJRB9SIhxAPqBpprDoV5dRVRn7+2pV/SYvhrWGGQfLkr/rwreAigzIKqgcZAGVQvEkI8oG6gueZQnFf2cXvKyDpWizENOi2z3wEF089uLWg6KLOgaqAxUAbVi4QQD6gbaK45FOfVeiNrrCxdRQNqmf1a/Vd0mRqK0KZe+NFs4w9ROKJw8ZWWs5D6YoD3qReMKDh6QdPrlVn/O50HPWr1TigKB9SRfcw2w9e0iMcvXNFsPHS9wea4vSGNZ1dm/Y77Ly8p7HfdvgGdBX0aTrk/2cQbnVHQ2/fGyH6lxfSlS2tRWh4mfK4AVAk0BsqgepEQ4gF1A801h+K82mRkDTr0oDWg6OoLLaJnYiBTL0ytLml0cESjS2M4+d/dR3QYfrBja1cfKDw2RvbvLh6z716rR8MJj729osvRoTHK+277rzQPj6nde0ETY4jjHuHOkKbz8Q77f6HZ6DG1DkOay8E5vmdiZFezEXV5Xz/tcm4t6gQTWtJnmgYH5vcOBWJ8Hy4os6BqoDFQBtWLhBAPqBtorjkU59UWI3s9paDNBpB7W9n+faKo/8gZW9t1ySbxoB8ZW2mQ7deMq9W4UuNx2fgas9od0eya//0D9aNP7kdrTPf2Htl12/ZfLY0Z7VCrd0qXy4Ju1UVIPXMN1Miu5iEdtlzchutpQG0YWQC+GWgMlEH1IiHEA+oGmmsOxXm1Y49sO6CpdGOuaDkdUkfNpZjNI898as+m2afTp9HFNHlUX2REfWN8+UcxmrJvanHDGLbtf3Xt0sb78KwLv9F08dVtZ8gYWWW1mNLFub7cBiMLwLcCjYEyqF4khHhA3UBzzaE4r3YdI+t6XJlsL+rBT3HvrCUZj8rHlKEB3ENaaERtL6oY5Y9sNDcYyW37q9HWsbR8bP9FtayRXS1oMjTbtXoUnP9O76Ln6JEF4BaAxkAZVC8SQjygbqC55lCcV+uN7PpZC+xY1tbeYzoJ/5AMK8jx1Y2p3dCj6kyxGOXUmFWP1d9o9t4cYdv+bpUSp1+3TxlZNemPaTT7IttjaAEAtwM0BsqgepEQ4gF1A801h8K82jqPbJcG0dzYvgy6XzzEwGHM5vBYX7bKDENQI9o6tC+GGetpX9ZSo6wGuUv904kbknBFs/CEQjabW/df0nT4jMK5G06wnFBgjKyaXH3hy/6tsy2481vOaCy9uJnzeYCgzIKqgcZAGVQvEkI8oG6gueaQzqtdvuwVUiRTXxXhxsJ6L30JbGSPAjof9ZOxquGl7WFVI9o5pn487KBPp/7Xw9hEn+q+md+37s9Gtk/B+YmbUqtFnX5Is+XK7Mq9rS5OXoxxny9e09DF0+q9oDfRCzuzQWdgjPO6824+fL4AVAk0BsqgepEQ4gF1A801h9vNK/tovr12WEEBakT93t8yfOv+QECZBVUDjYEyqF4khHhA3UBzzeF284pnC+hlxs5uAUb2XoAyC6oGGgNlUL1ICPGAuoHmmsNt5pXMwXrAc7e6Fbug42plzle3rgzfuj8QUGZB1UBjoAyqFwkhHlA30Fxz+Oa80mm3ZOzpy/QcrdtwMwZwGmSJp8vakW/dH8R8sw4A2AI0BsqgepEQ4gF1A801B+QVYKADUDXQGCiD6kVCiAfUDTTXHJBXgIEOQNVAY6AMqhcJIR5QN9Bcc0BeAQY6AFUDjYEyqF4khHhA3UBzzQF5BRjoAFQNNAbKoHqREOIBdQPNNQfk1RriL5k9/M/TMtABqBpoDJRB9SIhxAPqBpprDum82uXLXud04X916yFxFdFPw6m5Cl9oNnrszhlGFoDbABoDZVC9SAjxgLqB5ppDYV7p3Kz+RwbiHko2d/vUG721n5h9MFjz2g7YyDJq6mFkAbgNoDFQBtWLhBAPqBtorjkU59VHCnvtwq9lrRZjGnR43tiDcl/wutesaHl5KiYdRhaAaoDGQBlULxJCPKBuoLnmUJxX640sm76raEAts1+rH9GV+W8WnVHQ26f283N6NehKnOnliMIF20MXL68ritsflxpNaRz05Dh7nQGFs0+0mLxwPcIt6gzGtIjHNxgjOoto1Ndjex9n0E/Yxsf0h0+0qRf+V2xi7Tpe2Lx+ToxsNKFQ4+48o6jMRx8aAp8bAFUCjYEyqF4khHhA3UBzzaE4rzYZWYMOPWgN6NX4ObVNHBzPXuuYzie/0aDziA7/+Gcai6lN92iuZiM66J3S5TI7yjY9PrfVe0ETYxjls7fmWK3OIT0PL2lJX2keHhuD+4j60SfZ026jwx2S3tW9zpCmfJzcUAk142xkP8oac3D5Sli+R5bTwum9puV0SB1jkrujSxPDw6JYBwDcHtAYKIPqRUKIB9QNNNccivNqi5GNezldT6szgbaH1sMZyGQ9j0M9ig1onqLH+S4t3RHNnHu8ngbGPKsJdS9mGVMdXam9VLPrTKem1zufdByGtUbWS4uLJ3eeDwCUWVA10Bgog+pFQogH1A001xyK82rHHtl2QFN2fTkTqHymaXCQmMzVJY0OfvIMZ5YNRlaPZUib0PzvDPf8djVNt2xk116XBoMyC6oGGgNlUL1ICPGAuoHmmkNxXm0ystkxsoa1RlYNpe0ZveZhBRt7M29gZNkcd1s5I5tKE4zsVlBmQdVAY6AMqhcJIR5QN9BccyjOq/VGtnDWgg1GllYfKDzcp73uHyg82TSsgLlJj+wnivqPMkML1EC7cbRqdmFk14IyC6oGGgNlUL1ICPGAuoHmmkNhXm2dR7ZLg2gev/CUeozv1iUkPbhZs5lHP0SQvMhV1ONqTWjy0lX8stfwtZ3JYDWnaNCl1mFIczmcmt1jCudfzam8pmHPmGtOk5pZZ2Rb/THNp7/SaPpXlxbPyOp18cbrPhRQZkHVQGOgDKoXCSEeUDfQXHNI55X2QrLBK1r4y14hRbNkcIA1lck2hWZ2OaGg09ryktSSpkHHO5YxmGdntgdU1xkz++ZN0fF4+q1XMgWYXW9MbfCKZvHMCN5MBjI1V0jvoufU7vRpdDFNmV/Zd/gnCp/7aTFmNhyJ0Y3XPbBeWT4nAKoEGgNlUL1ICPGAuoHmmkM9ecU9ogdbhhWAuwRlFlQNNAbKoHqREOIBdQPNNYda8oofyXfdnK7gXoIyC6oGGgNlUL1ICPGAuoHmmkP1ecVzuv5IBw/wIwIPCZRZUDXQGCiD6kVCiAfUDTTXHKrKK30BTMbVnk68z8mC+wjKLKgaaAyUQfUiIcQD6gaaaw7IK8BAB6BqoDFQBtWLhBAPqBtorjkgrwADHYCqgcZAGVQvEkI8oG6gueaAvAIMdACqBhoDZVC9SAjxgLqB5poD8gow0AGoGmgMlEH1IiHEA+oGmmsOt5NX7kMK3te3bo34i2L+Z2vBbYMyC6oGGgNlUL1ICPGAuoHmmkM6r3b5stc5XUwXNU2lpZ+s5WPDyFYJX2MAqgQaA2VQvUgI8YC6geaaQ2Fe8QcM+HOu/mdY455RNpX71Bu9pXpspZprGNkqQZkFVQONgTKoXiSEeEDdQHPNoTivPlLYa6eNrGO1GNOg0zL7HRhj+dmtrRIY2TpAmQVVA42BMqheJIR4QN1Ac82hOK/WG1ljZekqGlDL7NfqR3Rl/l7OfqfzoEctb4zsajGh035X4uel1XtBk8VX2T/Z/hmFr55RZ69FneD/TdPojILePrWfn9OrAe/LZvlTYmSjCYUaZ+cZRRKfYzmjaNQ3cdnj7XX6dJoaAnFFs/HQ9ShzeoY0nl25377SYvqS+mLQ+fd96g1ff1cfceDzBqBKoDFQBtWLhBAPqBtorjkU59UmI2vQoQetAUX/eEejrjOAsZH9RFH/kTGTQ5our2k5HYrBbAdTur6eUtC2ZpIN4+H5n2ksplXXmaV1TOeT32jQeUSH4Xuau3G7rd4pXcbxtairn71dfaDwcN/9btYs39LIGOKk15g/k3tMbWem415lSZ/ZXs6HzfSElvSZpsGB2ff76gHm6wtAlUBjoAyqFwkhHlA30FxzKM6rLUY2NqNHFC7Yubrt1ciqsZQe22R7MbL8t27PRvjK6/ZchNQz6Yn3EwqGFrj4dDv7OdxH1I8+2d8Nq3lIh2y2uyOaXV8as/2D97u+RGb3sdsm+19PA2rDyAJwq0BjoAyqFwkhHlA30FxzKM6rHXtk4x7YjJFV+AWxi19luAAfJ2dks9s7I5tsx6w3sjZ9a8bQrti8tuwxPtp4OQ3ppU298KPbgZM7pYtzfaENRhaA2wQaA2VQvUgI8YC6geaaQ3FebTKy2TGyTNaYfqXF5IUxhPvUC84oejcu7pG9FSOrvatZ4+kdQ4zsBmNqDPdk2KNWq0fB+e/0LnqOHlkAbhloDJRB9SIhxAPqBpprDsV5td7IFs9akDGmbsxpPIZ13dCCWzGyaqzTQwu0R1bMdmoMrMfqbzR7/w+3/2Mazb7IagwtAOD2gcZAGVQvEkI8oG6gueZQmFc6dMA3sql5ZLs0iObJjAD6GF/HvIohNcZxMKbFKpktIO7B9R/7e0bWjnXNGtmCHldNH49/5UTEL3vpzAhfaRE9o07rmMK5/Ztf9mrxBx1OJ242ApOu8ITC2dIZZXdOyxmNeUaFrDF+4KDMgqqBxkAZVC8SQjygbqC55pDOK+39ZLNatPCXvUKK4mmrDNo7Gm9zZMzjR/uonv9u9Wj4ZkwnMrOB2f/shPr+9s7M2l7QZL01s0uaBp1kWzaz4Sg93lXNdmxA7fr09FoGNuKnxdNzrRavaejG8bIZfhO9EEO91xkYo+vF8YDhcwegSqAxUAbVi4QQD6gbaK45IK8AAx2AqoHGQBlULxJCPKBuoLnmgLwCDHQAqgYaA2VQvUgI8YC6geaaA/IKMNABqBpoDJRB9SIhxAPqBpprDsgrwEAHoGqgMVAG1YuEEA+oG2iuOSCvAAMdgKqBxkAZVC8SQjygbqC55oC8Agx0AKoGGgNlUL1ICPGAuoHmmgPyCjDQAagaaAyUQfUiIf+BBQsWLFiwYMGCBUtTlpSRBaBOoLnmgLwCDHQAqgYaA2VQvUgI8YC6geaaA/IKMNABqBpoDJRB9SIhxAPqBpprDsgrwEAHoGqgMVAG1YuEEA+oG2iuOSCvAAMdgKqBxkAZVC8SQjygbqC55oC8Agx0AKoGGgNlUL1ICPGAuoHmmgPyCjDQAagaaAyUQfUiIcQD6gaaaw7IK8BAB6BqoDFQBtWLhA9SPMsZRaM+dfaOKFxcu5UFLELq7XUomC7lz9ViShe8XzugabzbtdnsiPZS68C3gAqrOSCvAPPtOvhIYa9N7WBqatS74Cstpi+p32nJuex1+nQ6XdDK/Vofd30d7i+oa0AZVC8SpsVjC5kU9HhRM1jwW23m7hNFP/2y47HMtv1HmbTvgnd+MK2VwtcYNAPkFWDyOihqK/burUFbzUbU3XtMo9kXWi3GNDCGttWP6Mr9XhlXEf00vKNrcpvHruE88hoDYD2qFwmLxGMLfYu6o8vMHevK6HlArcLfqkPSU8pcLmkadMy5lTGyjKucYWQrBRVWc0BeAWadDmxbsVePKbwxX2g2enwH9bo97t2Y+9s8dj3ngboGlEH1ImGheOSRe5t64Ue3IuF6GlB7zW+VsHxLo95+yUoIRvY+gwqrOSCvALNWB9JW3N+eWItrD2qt11e0vDylXusurs1tHru+80BdA8qgepGwUDyljewVzcZDETvH1+oNaTzj+3NTCGa/03nQM+tOKAoH1DG/7+3tU2/4mhbapbta0PSUx7S6R1StHg0nC1qpidX1ZokLUzwO1v2WGvOkRvYJBeEoHhfV6r2gyeKrbCH7nwcmzckY2byR9dLvVYKrxYRO+904TUm8/vbPKHz1LElfvOi1c2NvZV1Zw91s+JxBM0BeAWatDnYysqZ9iM4oMHW53U7rZ60TXf13PaWg7db1QuLafDl7JfvJOtMuBOOZ2dvg1d/Pw3MZKrDXGdJ0mXlO6NKXHCuzyHH8utjVz9wmha59iCYUan3feUaRtiGMSceY63vZt0WdfkizpTlDZ/6SY3E7M89cB4WvT9JO7e11qX86ce0jj+0N3T5jehe3oV0aRHPX3vkkxjN9bL5q69ppxvymcfN1PgvoaDihz2vjun04fgB2RfUiYaF4ShnZrzQPj6ntzJyOP5JKZT6mvhYCNaemwFyODk3B36fD8IP5W4crHJgC8tlUDBMKeP/YOBb0kq4+UHi4bwriKV1yxRUbXhdHXFGaCiG8NH+ZymDyQgpk6zCk+co9asoVzMyxVpc06rrKJT6+G4MrlaapsKZDKfxSMfkVMZ/f+Z9pPOiaY/5Kk7E1takKjOM/OKLR5f19KFcFhZoD9xLkFWDW6mAHI6vDDziOZDttBx5RP/okawQT36HU0Wa/ufl327UbqzlFpi61dfzHlBGO69fWMYVzz2TGFPTIXkW2bRIjy2g7xG3bzGsfko6K3JC7VDuUtAXxMIvMtSm+Drb9bLUOXTug18WY4mBCV94+cRuq7VJ3RLO8k7Xk8mVDO23aUEmbd/342h/rmNgd8vg24HMEYFdULxIWiscJVwpP4eIZWSlUP3iVkZpEV0GpuYsrDEOqIGpBHlB0xaUyW+nkjaytENIVoFR6XDFJnGpk/Z5OTZcd8J/0iG4wskLW3LrKSysrd35JIXfbx+ejOAPsrefzOLjXY8uqgTUEmgHyCjBrdbCrySnaTsyk/74Fm8nnNJB63dbX/thbNYJ2ndbfGSNcSIGRLWiX0p00Be1Dah81vtqeGJzZXmdkhew61xb656ltTNxW5eIpat8yFB5nfTst5x6b6QxF51EBqGtAGVQvEhaKR4S7Y4+sEznHk17cNkVGtsDU2Ucof7KP5Xn/tUa2yIAa1BzLdkUFXSse3e+GRlbhR08Xv8aPvZJCvmZ7c3x7x64VL1ckRztUwg8Pvl6gGSCvALNWB7uanMLt/Kdbph1gA3f0s2sTXD1q9skt0pasaQcKqcLIqhEsYSaZ7LrC66Jxu2PntrmBkXV/56+nO199EirDI07owp+arDCNtw+nB4BdUb1IWCgeEW4ZI7uhMik0sumKZbV4TUNjCFu9gM6jKUWpSidrDDOFPMbfrkojq8MU9qkXnFH0biznlxTyojgcfk/0tfn3wU+ZXtvvA1RYzQF5BZi1OthocriuDmwdXLhd+uZ+NTulw2BiWgfG1qPrzdPDMLLay5w+z8yxc/Hc1MhuuVbxuGM2uHZog2xddB4VgLoGlEH1ImGheES4OxpZ93goFr2y+hvN3l9lCr8j9TjF3ZXH432ylU7WGKohzTxSSsVZVNBdxRP3At/QyGYfh7nzSwr5BiOr46H2HtNJ+IfvclgBgwqrOSCvALNWB5tMDteVB65eX7ed1tuHL2l88lPymD7bWxvzlRazD6aG/0Yjq50KNzay2g7pux4FFJ1zdp0bq5saWpBtq3Lx3MDIbmunfeLxyC7+dXl3y6CuAWVQvUhYJB57l7jrPLJqzvw3LfkNyBMKuVLSwp8bzK4vZjnjJ2+DfkneUo0Np/ud/55PaDSa0jIeZK+zBZjKLfIH++vdcvZlL7/S0W08Q6yVmz/kIbtOCrWpEAZjc67JW6BxRaTbFxpZg6u4dhvb9TBBhdUckFeAWaeD9LjVhPgpm1u/brukHjZ1YublJfveAz/qfklTqed5FoMLGoYz8y/dbxcjWzSUTdfZNkPTK+kQM6svfHnxa92t6dTH8f7YUjaBQ5NeNt/OALb6Y5pPf6WRae/y10HfEdGXofna8YtYj+K2Kt9r69Luj8/Nkjv23za209fTF3Qct42fjVE+yLR56fOoAtQ1oAyqFwnT4nGm0axLFr3rK/hNzVp2+ix/Kiw1sp1j6mtFkZoqS00m78vTco0pOuEKhCswnsrkizWpZr/s9FnJtCf8mz+ViCGePsX+Xjw9l/uNK66zM5vOeJ05749v8uvmH2kydMflyufNmE7YuHIFcXZCfX/7QjObqSS+Q/jagGaAvAJMXgdFbUV2sTfrtqfTW+8/nTOoYc13nJi2wf+sbGzCsvX3BjPrTFiyrRpCf5oq29a8i55T27QTo4uIwueZ+MNROh53DumpGH3TzT9qz6adbvLjZN11SE+L5U8zlr127eCMzlLXfU2vbObYYlw3tNNsZI+ClzSKpxkbGIPrmfNsXBXAxwVgV1QvElYunqKhBd81tle7neuZ+H5AhdUckFeAgQ5A1UBjoAyqFwkrFw+MbAZ+LGTuuCt6PNMEUGE1B+QVYKADUDXQGCiD6kXCysWTHVf0nSOP0fQFiO8UVFjNAXkFGOgAVA00BsqgepGwUvFkxyetewHqoaMvgGXHUH2noMJqDsgrwEAHoGqgMVAG1YuEEA+oG2iuOSCvAAMdgKqBxkAZVC8SQjygbqC55oC8Agx0AKoGGgNlUL1ICPGAuoHmmgPyCjDQAagaaAyUQfUiIcQD6gaaaw7IK8BAB+vgjzSE1D/4mcJXdr5zmV+cP27AM/YcePOxgo1AY6AMqhcJt4vnimbRiPqdfe+Tte7zfbW+vMUVRmQnbMZUXo0GFVZzQF4BprwOitqNZrNaTOli1KeO1+7JLDRdY1YnIQU/2a89ypcrZZYe99GFtn5xEmwCdQ0og+pFwm3iSb4sot+gviN0PlpOC4xso0GF1RyQV4AppwP9lPk9aDduDe9LZrGR5a80PvE+e+7g2Xri6Sb5E7Q/UjeYyJe6wHpQ14AyqF4k3EU81szegwoJH1d4EKDCag7IK8DcRAf3pt24NZyZVSMr7dFjGs2+2J8FNvE/05FnblezEXUxj/pWUNeAMqheJNxFPDCy4DZBhdUckFeAuYkOvg8je0ThIhlft1pENBxGtPBNK/fQ1joMr5mgrgFlUL1IWCie1YKmp307cH2vS0/7T6gVV0g8VvV3Og961IoLpxvw3uFJ//epF4woOHqRFNzljCIeWyTxmaXTp9Ppwt2x8liqMwp6+9R+fk6vBl2zzYH7hOtXWkxfunhb1Hn6lHr8lTDfyJq4x5wWiZuP/YpmSxMzH/M8MNt36Hl4TgOOozOk6fIfNAsH8aD84Cygo+GUUMfUByqs5oC8AkyxDvz62dW/w9exiVMj+yT4lU753QZX58qLUOZ3HnMaSjvynKJ32n6Yen7AY01tHLZtce9GyDEyH5VZU89PZhMv7lfSvth9Q5pdzWky1DajS4No7toiTtMkSatZWr0XNIk/YJMxsvKhmydJj+zyLZ0O/0RzE9lq8Zb+4vaTHlkY2a3w9QZgV1QvEubFw+N+Dkxl8IwiLoimcI6kEnBGNv5KlSnoqQL9KBkrtPpA4bEzsvzvw31TIZzSpRhMjc+aVVvZ2Upjr3VM55PfTGXEcf0nXU2HxnBqReMG0fN2amQl7o6rPE2lGvFbo6ayCsYUBR0bp1lah7/SZGx+M/H/cfy/qGv+r4PvebD+MYxsreQ1B+4ryCvAFOpAPj/O9S2P/3Ttxl7H1Ot2NKit2515NHX/avGahlz3c/378d+TdiQ2wF9oNnps/k4e18vLVC3z++itOYZ7eYo7M6RT4socs6ie/2/xuiRuHqt6LB0ynd5zO5OAa5v2WgOKrrjl+kRR/5GL+5qW0v7sUTvQ9iFjZL0xstd6bnrcOE6Mkd0Vvm4A7IrqRcKseOTuce8R9aNPusYN3PcfERU9YtHKJk0+Pq2cTGHXcUPuU7atfmTsqsMZ5tQ6qTjNfs7IStxxhcErnMmWdcbY8swKmWNL5do6pNElpkS5K1BhNQfkFWCKdGDr8aR+tcY1a2TTQwtse9Ci7ujStCxZY5jdxxlbv44XY8iGVONwM+hk6vm86TRIO6P7MUtnhN3wAO100TbHDWVbb2TdNWiva08wa0EZUNeAMqheJEyLRyuF9LiffIVUdGfKd+PGZHb6NLqYukdDGl9SuQlqOHV/Z2STCsMg69KVoFYs1shq3Obv3MLp/1J87OWEAn2E1T+hi3iIA6gLziPQDJBXgNmkA5mWSh7vc9272chqZ4St67cZ2QIzarBmWONY08asNbJ+O5MxsgoPrbv41Q1H2GxkxazKPLLDVBoFbq8wj+zOoK4BZVC9SJgWT/7RDrPdyDLJWFeO0z6e+aeLb0slU2Bk03fujiIjm6nkEtZVcIZ4XBVXvPpoDNQFKqzmgLwCTKEOjOGTsab8rsH57/Quem7aiVs0stkODyXVXtymkf1Ki8kL0y7sUy84o+jdeGuPLLg9UNeAMqheJEyLR4cR7KfmxtvNyCo6VpW3/y8XX+axT3bYQIGR1QqvdRjK4HkhZWQ1rfpiWMJq8Z7eL3VoQYGRVVZziuTlsswdOagUVFjNAXkFmLwOtP5NOj1sO7HZyKaHmm0xsjpmNTW0IBvHLRpZN+Y37jzZYWgBuD1Q14AyqF4kzIlHH73r26Wx2bO9l1LIU2NRTZE3BX54rIZz5QbJu4omftlL3/50Rtd/4Sr1qEjR4QrJYH1rkDkdZuHxtddusL4/C8LyksLhBc3iFwfSFdz19AUdxybdHSNTUYJqQYXVHJBXgMnrQA2kexk3nj0m6bTQp2rZl73izolcj6ua48RMxi976WwIrj1KOjiK6/n0+xK2bs+3M2pknRkXo2vSK7MmXNFsPJSndnGHS0Gc4PZAXQPKoHqRsEg88dul5re91iH9cvKU2vz4KJzS4qvrFeXfZDF3sx/f0PAooPN4iq0u9cPL5HF9aoosUzH0hjR244bsHXgSX8rM6qMr+c1UZr+8oD6/VBaE8fQr6elSuNLkqVn+7ioojdfvJXhBR8HLZDqXDsYw1Q1fd9AMkFeAKdKB305wR8Wb6IUYxaRO/UqLaZgMN+N24XRiDak+XZP1Zmn/TOEZG2Ndp72yPAZVp8/i9Vz/uykWYyOq+7h6Phu3aaPOwp8z7UxEb7L7TmZJe8MdOW/GdMLGldN9dmLanmR/PMW7ffi6ArArqhcJIR5QN9Bcc0BeAQY6AFUDjYEyqF4khHhA3UBzzQF5BRjoAFQNNAbKoHqREOIBdQPNNQfkFWCgA1A10Bgog+pFQogH1A001xyQV4CBDkDVQGOgDKoXCSEeUDfQXHNAXgEGOgBVA42BMqheJIR4QN1Ac80BeQUY6ABUDTQGyqB6kRDiAXUDzTUH5BVgoANQNdAYKIPqRUKIB9QNNNcckFeAgQ5A1UBjoAyqFwkhHlA30FxzQF4Bprk6cF8gw2dl7z2oa0AZVC8SQjygbqC55oC8AkxeBx8p7LVlfbLo164KfqvNSH6i6KdfYFobCOsEgF1RvUgI8YC6geaaA/IKMOt0sJqNqLvXou7okvijsQkruooG1Cr8rTokPeh9bSSoa0AZVC8SQjygbqC55oC8AsxaHSxC6u21qRd+dCsSrqcBtdf8VgnLtzTq7WMYQUNBXQPKoHqREOIBdQPNNQfkFWDW6qC0kb2i2XhIvZYdctDqDWk8uzLrV7Sc/U7nQc+sO6EoHFDH/L63t0+94WtauC7d1WJCp/2u7Gv3f0GTxdfExLr1vLSDCX3WOFPmlo/1ioJ4+y71w0taul/zrEszp2dKocT/nKJ3IfU7LbNNizqDsUvzkqZBxx0ns3T/n/Q//x/+EIyCoRm9X+nfpqGktR2M6V2cDpvmq8VrGup5dJ5RxNdCWc5ozGmTuM11DF7RbFlX33h5+BwA2BXVi4QQD6gbaK45IK8As1YHpYzsV5qHx9R25nO1GNOAjV9nSNP5mPrOKO61ejScLHhwAl2ODo0R26fD8IP5+xNF/Ud2++U1LadDMbvtYErWozoDqKZ1dUmjLhtLE6dnZFfzkA5bxtiN3hqb+dkYzQOzzSPqR5/sBik2pPnqXRJ/bLi/0Gz02Pz9mEazL2Z/Y2SHzyicq8HU4x1QMP3MiaFowMa8Y/5OrDQPkTjondLl7I/m+mauy+oDhYfGvLY61Ht+IebUnpMx2f3IXDWOgLcxv0uavtIiemaulTHYxtyvN+x3y1qNAVCA6kVCiAfUDTTXHJBXgFmrAzGyzmgVLp6RFWP5g2cY1fQ5E3k9paBt9umFtHBbxGa0O6LZtTVwsVlz2681skJ2nTPDHF/cy8vm1E+Xx7Y0Fxxz/ZAKa4rZmFsT7biKxMTH5yXHOEqO6a5xcp5uJobYLPOq9LWTscKtAUVXepLuOvrr7hmsFwB2RfUiIcQD6gaaaw7IK8Cs1UGZHtm1ptdtU2Rk1XimTNmCphe/xkMDShlZNXSpY2xgW5p3NrIrWl6eyrCA1mFI85SXdL20eo6cxoOfkvNda2S9XtzUtdPfs2nmRYcv3D84fQDsiupFQogH1A001xyQV4BZq4PSRjb9CD1FoZF1Y0zFKH6lxeSFMYM83vOMonfj8j2yNzKyG9K8q5FdTijQIQkF41T92R+ueVhB3DtruKmRTV2H+w/qGlAG1YuEEA+oG2iuOSCvALNWB2WMrDxCLxinufobzd4b21ZkZJ3xlMfubv94Oi+3fSkjG/fwHnvjVjewLc27GNl4HKwbF1uEjnvt/oHCE29YAVPayOrUZ/njrRbv6f09feELdQ0og+pFQogH1A001xyQV4BZp4Ny88jqGNEu9U8n7q3+K5qFJxTyWE81Y61DGl2ySdSXvZwhE0OnMwIkMwkkY0udqeRH9PMJjUZTWubGhq7il8Ra/DKVM3WrRURD3l7+8tmSZo0/NrLZ807GxdoX1hxsXI9feIZb9+PzT49jtdc4O4aWx+kWGFkd+6vGuNOn0ylbW8PyksLhRTw2+L6BugaUQfUiIcQD6gaaaw7IK8DkdeBMo1mfLDt82YvHt5723dRaZvGNlpqxzjH14ymlvN/NvpOhm06K3+B/M6YTNpHx9Fn6dj6b1Bc0+fjaxqfHitNntpu+dFNl8XrfpBawLs2aXl3f/pnCM39sapt6//pLMhtDdkn1HBvc8IPEsPIl4d5db5/eiMLUdF7GzL6JMumw8aanKjM3AP2XNPWn57pncDoB2BXVi4QQD6gbaK45IK8AU4sOUo/Hv0d42MNB8ewJ3wGoa0AZVC8SQjygbqC55oC8AkwtOvjejSyPx+0Wvwz2PYC6BpRB9SIhxAPqBpprDsgrwNSiAzefqj/H6/cDj6X9kQ5yY42/H1DXgDKoXiSEeEDdQHPNAXkFmMp14N7M5+PIkh0/+kDRF7m2jtP9DkBdA8qgepEQ4gF1A801B+QVYKADUDXQGCiD6kVCiAfUDTTXHJBXgIEOQNVAY6AMqhcJIR5QN9Bcc0BeAQY6AFUDjYEyqF4khHhA3UBzzQF5BZi1OpCxrZs+4fqQuKJZNKJ+Z7/wS2Y5ljMaB0d0uMu2AHUNKIXqRUKIB9QNNNcckFeAgQ78jxMUf5LXZ7UY06DziHrD19/2Apf/EQhe/A9EPDCgMVAG1YuEEA+oG2iuOSCvAAMdWKyZ3WJk5fOwj6gTTOwnbxchHfYCOo9mBZ/A3cRnmgbH7qtl7Glf01C+eOY+2fvAgMZAGVQvEkI8oG6gueaAvAIMdGDZbmRXdBUNqNUaUHSl/ab8SdzfaMSfi+30aXQx3a2X9up3CobODDt0uq52MKWHNjsZNAbKoHqREOIBdQPNNQfkFWAKdbCcUXQeUK+lY2TZsIUU9PaN0RrTu3BAHbMfz5E6iObe4/Armo2HZj99XD6gcHZl1q9MlL/TedCjVvsZha+emf1brmeTf3slccs+rR4FY+3h5OO+pH6nZX/b208/0l9eUsgm0vzW6gV0FvRpGI/pTael1RvSWNLiWC1oetqPz+Np/wm1NhnZ1SWNui1q9SMTcxbv/Dj957/TrOxXvGRM8iP7GVv9EpqkzZrbL/HwB7M07AtpnGYAdkX1IiHEA+oGmmsOyCvA5HXwhWajx7J+z73slUzubxZj1IaTBa2csUu+1sVfsDo2Ru6QRpfG6i0nFLAB5R7Mv5t/x8Zsnw7P/0zjQZdahyF9/BjSYVvjnFNk1seP2OWLYGp4+XH8QZwmTSfHMY+P/8wZWZuWdu8FTRZf3bhWk5aOfibWxdV5RpH5nZZvaSRGeoORFaO5fQyt3ASM2CAb0x2ENOX4t1LQ25u9FnK9b2Fs7h2AugaUQfUiIcQD6gaaaw7IK8AU6+Da+LYj85s3a4H7Qlfy6HtpzGDHbHNE4cKscaazG3+K9SstomfUic3ZRwp7bWts40fzzox6vZxqmnndP+bG5LZcL6XBPv7XNNnjt3qndJnt/RTT90O8X2LObVz2GEm8sZHcYFTTx94BNaK7fMlMxt526DD84K6dI74ZeEL9pwfJ2NyGgboGlEH1IiHEA+oGmmsOyCvAFOugvJG15nBTj6Uzsilj59aZeHOL9/h8tZjShQx14N80TStaTofx0ID+6Lek99OlNR8vp+8/3bk5A+7YNkZ2dyOr42Yf79gjy73HP1J3jUldiZk3aU/dADQLvvYA7IrqRUKIB9QNNNcckFeAKdZBvUZ27QtOOkWVG3f6LnqeMZPe2FSTtvgxvKR1nenU3tnHNJp9cet2NbJ+L24WNxdt97DEGFmT/suX1P9pvGa4AP9+6gx8izqDddvdb1DXgDKoXiSEeEDdQHPNAXkFmGId3HRowZ43ZjVLkZH9RFH/kTd2VflKi9l/0lwe9yeGc1OvaDwOlntyU2NrPVZ/o9n7f7hhBPupR/nbjKw9/4Lf9cW4bolZCxyc5p/6L/NDIxxyTt0fKZwv7fjjTJqbAuoaUAbVi4QQD6gbaK45IK8AU6yD9JhSRseuJkbWmdDYaOrLWPvUG711BpLHyZ7QKH5ZyRjNzJhR++jcmE5j6OxjeO5lvaBh+M6YNzbTbmYE+ZoW97xqmoyRHj4zJs89unfjSe14W/fiGQ85OJ04c3lFs/CEQk5rPPY0+5KZ7flMxvl6FM1aYMztzeaRNdEVmVhOx09/sEMI5AU0k/64B1ivd3amiPsP6hpQBtWLhBAPqBtorjkgrwCT14H2tLKp46VNj3uPKZ76ySzt4IzOUmNbXa9sakors+jXqjLTSaXNbHaKrcR8Jh8K4OmzXtCb6IWYaTut19wY2T4F5yduXzbDYfJIf11a7K+puPdah/TLyVNq8xCGcF2vatE8sjcj7j3WtHmLNcre2GG5VtpDrtttGsJx/+A0A7ArqhcJIR5QN9Bcc0BeAQY6KEH2y15gJ6AxUAbVi4QQD6gbaK45IK8AAx2URB75dxo5n+tdAY2BMqheJIR4QN1Ac80BeQUY6OAGyHjdIzps0OP9uwQaA2VQvUgI8YC6geaaA/IKMNABqBpoDJRB9SIhxAPqBpprDsgrwEAHoGqgMVAG1YuEEA+oG2iuOSCvAAMdgKqBxkAZVC8SQjygbqC55oC8Agx0AKoGGgNlUL1ICPGAuoHmmgPyCjAPSgfLSwr7hxRM/+rmwtX5Vnlu3EPqh5eYNusOQF0DyqB6kRDiAXUDzTUH5BVg7rcOPlJ4eETBeIcvZ8kcr489s8rm9SD5cICbNquJn3htOqhrQBlULxJCPKBuoLnmgLwCTE4H2a9w8eJ/iSv3+yPq9f6H97dbMp+itcbS/2JY9lOr2a9XmaX3R5rNQup3zDHiz94WsaLldEjdw5DmcYQZI2uQz+F2hzT1PwsLKofzEoBdUb1ICPGAuoHmmgPyCjDFOvhK8/CYWnv7a3owv9Bs9Nh9TtWxuqRRt0V7Wz/h6hnW1jGF869uvUPi+YH60Se3wrCcUGDM7PreVDatXeqOLr3f80bWxv2ERrMvbgWoA9Q1oAyqFwkhHlA30FxzQF4BZp0OrqcBtfc6FEyL+kGtGW0HU/Mv5SOFvXZBT2wW3veYOr0n1DHH3utke0g5noPMcVd0FQ2otdYkF5jWwnVFcYOqQV0DyqB6kRDiAXUDzTUH5BVg1umgWiP7ozGY712v7x61UkMC1pjNq4j6rVam11XhHuInO/bIdmFkawZ1DSiD6kVCiAfUDTTXHJBXgFmng+qNrDGYqzlFg65JQ4s6wcRYT2Zdr6mLvxfSwq1JyI6Rtenjc9vzzgFjZO8G1DWgDKoXCSEeUDfQXHNAXgFmnQ5qMbKMzCawb9KhL3+tM7KfKOo/Wh+/zFrQWf9SGGYtuDNQ14AyqF4khHhA3UBzzQF5BZh1OqjNyBqkp7TFL38d0ujy7Rojy0MFOpvjj+eRLdoX88jeFahrQBlULxJCPKBuoLnmgLwCzDodWCOrHxTIwmb0ODMmdbORXc1e0kDiyhtZHRpgX/56Qr1O0TjWHYwsuJegrgFlUL1ICPGAuoHmmgPyCjBrdbAIqWd+S02xpchj/G56iqyNRpaHBRy5aa+KjCyjU36lx7UmuPgLx8iC+wzqGlAG1YuEEA+oG2iuOSCvALNeB5/lrX8eu9o/ndDCdb2uFhM67Xep1TulS/+lqXXzyK4WNBn2vKmzimYYcMQvfxUY2Y2zFoD7DOoaUAbVi4QQD6gbaK45IK8As1EHxoROw4B6PH7VbGcXY2xHEc1iE2vHyya/Fy/Ss+t6eZP1RxQuMt238lLWv2SM7LZ5ZMF9hvMagF1RvUgI8YC6geaaA/IKMI3QwdYve4H7DOoaUAbVi4QQD6gbaK45IK8Ac991sFq8pmFvw7Ra4N6DugaUQfUiIcQD6gaaaw7IK8Dcbx18pPDwiILxDCa2waCuAWVQvUgI8YC6geaaA/IKMNABqBpoDJRB9SIhxAPqBpprDsgrwEAHoGqgMVAG1YuEEA+oG2iuOSCvAAMdgKqBxkAZVC8SQjygbqC55oC8Agx0AKoGGgNlUL1IyH9gwYIFCxYsWLBgwdKUJWVkAagTaK45IK8AAx2AqoHGQBlULxJCPKBuoLnmgLwCDHQAqgYaA2VQvUgI8YC6geaaA/IKMNABqBpoDJRB9SIhxAPqBpprDsgrwEAHoGqgMVAG1YuEEA+oG2iuOSCvAAMdgKqBxkAZVC8SQjygbqC55oC8Agx0AKoGGgNlUL1ICPGAuoHmmgPyCjDQwV1wRbNwQAfBlL5MA2qbPNjrhbQwv1xPh3TQD2m2XNlNHwDQGCiD6kVCiAfUDTTXHJBXgIEO6uYrzcMfqeuZ1Ws2s87Issm9HB1S+zCk+QPxstAYKIPqRcKbicfcKUZnFPT2qW3uFq/d2jwfKey1t2xTN5z2EfU7+9QLP7p1oE5QYTWH+5NX17QIj2ivHdD0/lQm3w33q8xW3a6saDmLaNTvxj2gtbOcUND9kcL5V7cia2QNqw8UHj6hYPrZrWg2aBduzmoxpTDoUes7qh9VLxIWimc5o2jUp475jX9v9YY0nr2n6Kdf5CJJgXK/3S+Tup0k7W0Y2TsCFVZzyOaVX/bTS5f6o6j+R51XEf00bFYd1ESyOijmE0X9R7TXGdK0yY+8r6cUtJ2u78jISjnrjmjmXcackaUvNBs9oe7o0ljv5rNWY1v8SEzj6wJ3s+7OU5etHmt1SaNuy24PI6t8pmlwYCqjAYWzK/M3352+kt7X1EVahNTb5SLfQ2xjDCN7V+Q1B+4rhXmlFac2qqsFTYY9apltW71TuqzNxHBD/riRdVDT2KXMruYhHba48X1E/eiTW9tQ1MzepZHNHDu/zhqfh6L/Yo3t6EceUl2g9WtrQNHVrnWpfUoBI6uYu5q+qYxyguD1+zCy4NvZpVEE94PivHKVZqpRdb1xtZkY06BdnlKvqK4Ct872Mmt7Bzs9s5htW/2I2HY0ljs2sqvZiLo79cg+nBu5Qo3t5EceWl1wE1MKIyt/xDjh7LV6NJwsvEcWpqHyu/JTRjbTJS6FLT+ONhnH8ZyidyH1O9wd3qLOYEyLtTceX2kxfem25fj3qTd8bbdfLWgaBkbAHQqiCYU8pom36TyjaJGMLZLtTvXRRJee9p9QC0b2zshpDtxbivOqyMjaRtUO2fkvWs5+p3Mp688ofPXMlL0WPZLyx4uWPRePrDui0JTZov06wf9Ff43Xc0WdNFx23+zCcZkax9VRsi5Oq30TXOoCU8cFZwEdYWjCVvgabkTajcc0uryk8HDfXNvj1PhOYdf6ejmjMee15J1X3wvr3s/Qdx+0nehS/3Ti7ef15Gnej2e0dL+m2xmjuadPrb58jWfTFbyyQ2lS5zVNtpFexE+0mLxwWs20dal2ySx+m5sdI+tpOT7v72GM7FY/UlQXmHyYcs4aTYyH8W92SIK5vfKHjvDi8th2cPE6rZ/W7G/YycssTVlwGm/1AjoL+jSUdG2jyJSyft24bUmjOVb/JU3jcqP7rEsP6zt05WZM77QONOVkEM3ddeVj6L6s7xEFRy+SNGSGeOx1+nQ6dXmya9m+RTh++b//RwK/LXnsCitfrBFFLvNSpIysuwC9n1z3vzkvvqOUONw2/jiOuHLSxs9UgLMvsl8OEbJJRzAxlY57zCBC/eT2tcdo9V7QxFwwe9yWN25IH024C7p8SyOpzGBk74q85sB9pTivioys1yP76jevodinw/M/03jQpdbhH+ndeJC5idT9jPn8+KZ4v95TeqoGxa/cc0+FvLjYyDLaELq0Sv3gmSx+HH4MI7uVzWV2ZS7zwL1Bb//dStXBjNb1Nn93ra9XizENNO9Nvf98FKTbFdnHtVmtQ2Okuf2xb/RzGmy7YfP5sO3M0GpOkdHV3t6BM4Gm/ZoOTQOtjbrun+jGmsaOa7eMKYj0Juu1uTFKOnHi83LDLFqdQ3oeXpo0aLuqTyz0Ork0sHHl84z1bbdvrx2q873MWnATP8Lo9XP5oTrS8dvqA1KP77lD7ikdhh9M7mzY/+rdDl7G/t2K84fje3ZjI2v1ZI41emu05Jn3eDy6dgroNuqVbHp8PxbfFKgn055/+fuRO3/+22j+2BlZ0f++0bfTY+yjWL9/3bFs3y6qFwn1jzTZXlAWkO/+DbFwJvSZL2q3wHnnxJXPoG2P+W0GJo8r7fZ6x6U9wfq3bJB6JGQvpv+4UysQGNm7olhz4D5SnFeuHMd3214vZ7ZizYzzypf3palwO+Y4aj6L9yuqO/L1SzYuQ6Y+kOPHhgfsysYyKw3gD0kdqzcPmUfju9TX+ncyNMEZBF8P2Xx3DXJqOINreG1D/tmaCu93bdhlXdH+hTdAXhrUBMg6015mz0v16l2DtPadQYvjdNr19e3KFc8jG69yfF/zyJbxI74mPE3GN1LZGwm/E83cCA+e2/zYun++Pkrnr83Pm70zkI27oAyofmKjuC49nvfZVl9K2VMjnCbvo8w6d7NmNb5D2b5lVC8Sbq6gtLuYxWMWv5vYXZTWkx494e7kuAB75C7ctsxfD3flX5xrWvR42y6e/u41bIZdjwmqYaPmwL2iOK9cOeY6IV6yjUu+rDP5srfGyGb2K1y/rWJmspWp9nxJek/oQh+NgY2sL7OuNzNlWrU3KN3wba+vDTlTWbBPNt9zOmDUePB+7wr06hY+ruyfaQ8K25HMvrKw1r7k07hzW8cm7U922AzHl9P99wNfz43s4EeymkjnFS/e9U897TXRG2N2NHC627r/tvzVXn7eh2d0+S1tvDeSjbu4TtSbMXvOO+gtV06y9aWWW5PmTp9GF1M3LKGgDDJ6MyfH3KFs3zKcTvm//0eMOfjwJ+/OlDECsm8le93E7qJYI8vdyQV3HrkLt2vh9tBj85im89/pXfTcbK8Xa9vF08osPXRh6zFBpeQ0B+4txXnlyvHGCqq48s2XvZqNLMNjveKb4qQhA+tZX2Z1OAdfy/yS6uXcWl8z2lPpes21Z3VDj2y6QVf8Y1kjm/49we6feQSaSpeLK6dJpeC8dmjrVovXNOzx49qAzqMpRazdtcd4+LBecpT0I3Eey99+fhThjJto65/GK/TN9m688db9t+evSaipatzYfpO2eCiLS2tSTrJeJBN3yjDaLYTUOe+Qnuw1KqovzZXWMeiSNnnCxtdGbwr96+Efc5eyfbuoXiTMiYcPvu93YTuyFyH++zV9lPFCptLKjtfJXbhdMt8n3/1vt9eLte3i6f77ybgP2WTTMUHV5DQH7i3FeeXK8cYKKl/WGWsa/LJ3m0ZWb1y3GFklHivpV+SgiHVlVvIz9cjToY1v6rfdGjs1eHxMXvyXbIRsvrthAGnT7D+O/Zs12/GwF+UrLWYfaKn7++1XYTuiY2oTVov39H65YWjB2rbO3QDEPdmuHOR0//1QqLHSfsTXRMFN6upvNHufqMTWRzwe/zc6OTpNnips3X9b/qaJx9hurDMVF3esDaeVTDmzad91qIMhV18WGVnFaFp8He//X07/mScsqacn99HImoOnKo+4V9R7SUIuol6UZLyGn/G6TVzB5O4stIJYNyBYL44bhB+/NaoX1H985I7qKqVYBPooMR7grI0XV5LrjguqpLDCAveSwrzScpx6nJxhXS9CyjSYyjJ+o5sXU6HO3xbvV2SMXMXc6o9pPv2VRtO/u/rE3bjGPTcuflOhfpy+oOP4ptbvkUEtsIlCHbgXPpKG0UfrbtMmxGM5d6ivpQf2h0IzoOTalbgXN3mz3RqH5MUVO56P06LDX7i37IKG4cz8Sx+p6os72og73XDarl3PsP+mNr+VPrww6dbz8hr6Av1bY6FtjjMe8nj8i0mLm1HhO9ZiocZ29CP5uuBvzpP4s1fwmOMTCr2ns3E+5byAepo1++fyN+tljEkcPkvS53xI+mbLR83qIY3evTFxey9dGeKXvXQGD+dj4puvrekxa1KejdGnKa6j0Fzr4bHezOnQCKfp+GUv+yJXbHTjPNihbN8yqhcJc+IxJ/OHP0zoc2qqh7SQbIF0hZyX3hlNpdJyf5uL+eZNZpvHPeqxO4+3+ZnCM2+ftXcyyd05X8Q30QvJjL3OIfU6ui8v5gKGIxFzvM7dCaTu8I1Qfjl5Sm0eqhDqGBBQJ5wPoBlk8ypX9v2KS9E7cd0mZUq9N8K5kQgnFAVdO171TUjPi/bLxqc9CPFNqVfBx2/Tmu14+qN3Y7NvMkbt2hjZo+BlUrfFE62DTfC1SpHNk1Svi5pY7/e9/0G9Hjea+vea+jrV0eAv9iWUz7m2R49rTIY3VdLm6bV4G9+gGFI3PeZYv7ygPr/4EoTx2MbVYkKnuemP/u56tdxxuR07O8vpP9seypPM+CaO9Tum6ISNgG/8vy/4uuTYwY8IRXWBydPU9Gb+TUiMGtb08ENh3f65+q3Iy7wzRrZPwflJMhXWxnz160XvHGL4xsubPo630enfdkjP497jjP7O6IxvpOJ1pk79+IaGRwGdx1Nscf3MM244UtPP+XmgPbsa13ovdptwvPJ//w8A6gKaaw7IK8DUpwPuHf3R3BylH+HbG5SnGALygEFdA8qgepEQ4gF1A801B+QVYOrRgXucWdh784niqZHAgwR1DSiD6kVCiAfUDTTXHJBXgKlHBzrOruix/zEdeWMGwcMDdQ0og+pFQogH1A001xyQV4CpTQc8LtGfK9QsPD1VmBvbCB4aqGtAGVQvEkI8oG6gueaAvAIMdACqBhoDZVC9SAjxgLqB5poD8gow0AGoGmgMlEH1IiHEA+oGmmsO9zuveEqakPoHQ5p+0Slo7NRcD/Fb9HcJyqyyXnMyDdIBpnO7KdDYLvBctgM6CKb0Raeicy9Hfm91nupFwlsVD3/6UeYgcwUbgAJQYTWHu8qr1WJKIc9ZmJqDNo1MEt71jIPMp6h1j52XsZ392iC4EfXrwM1FuyH/bwf7YYLijzrk2aw5Y3IvT6nX9ibqBztzL9qFe+1heM7bH6nrmVWZ19ubS/l7qvNULxLennj0KxHeHWplmGP99EvFFRyointRYYGdSOdV0UT3yZKbpPymxF/bMfGuNTI83+iT1Ndv0qbCIF+jeZKfkxSUhvMiRXYS9mxe5X4v+HBGiibU6TtoTs1G9tOmYCusk7vFn9j/HhpZ/jpY98fUTVLayBq+ozpP9SLh7Ypn07d7bw/51Frld+qgKu6+wgK7UphXajTjCtT/1GzBF3JuRP7b4SnEQGSOlTMVPJ3TE3yG+hYoLrP6VST3SWC3NsFOp7X+s5wJjajTd9KcO5eKPsv5kLkf7UI9HuYmiGnN6CpnZL+jOk/1IuHtiqcGEegnKGFkG8v9qLDALhTnlTOZuQrUfmLzdirRXYxspp7JrbM9yLs+NgbrWVdm7SeL1/W27nj9m1Kn76Q5A3/3H+1Tae5Hu3DPjWyqzi1a9/3UeaoXCfPisYOJ5Vu7/L3qs4COht7AYvmO8EeznWtoZJ1muorgiXxrV79r3eq9oIn7XrWQ+mavfoP4yu3rxccVgvxtFs4s/zvqbpEMy34T2aR7OHHzDsbzEprKNppQGH9j/RlFa9PkfcdYMNckSs4nNWG3VGTuuCIo//GrXivD8jI+Ns+LeBb0abjxUdvDha8BaAbFeVVkZPmx64HZPmNkN5VNE8qLM1KuuMyNKDh64QyAGtnnFL3TbUxdMRi776hzr/CTHXpkH8PI3gLrymwpI8vjD89tXfw8PKeB5On/QZ2OtiN2aQf8bf3f6Tw3Rpr14n9v3v8W/FdaTF96dbT/vXquv89kv/bzc3ol3+Q/MGn+kKyPNbIhnp00ZzbDE8Mbwdc7T5EfeUMf4zaWF21n/bbX5Mn8405t/2oxodP4t2Pqi75cnhZptjOkKXuDeDytS0enT6dTrdtYR6HT1pjejYfuiZXV7NXiNQ1Vxzt6kaKe/uIe2e+jzuNrJ//3/1DkYrWSweo8uP3YGNlrkz1X0cBcXM+cxeNitSCrkdUKJnnk2NIByDKGY9+YuVO6XF7bTxKaNNjHT9n4DFcR9VkAcWZle2o0XVwxfTZJmFDAYpPftZeIBZEYajlHv8GVNHVchWXSHD0zaTKNpoxzco/PWoc0uuQHZHZAdSv+nVdl05i9VjYd8TWQOJ/ByIJ7T3FeZYysV6Hbcq017aayyT+zMXiUPJbmcnicMbJckY/emnKmRlkf7WbHK+r2phzG8WOM7G2xrszubmS1bXB18eGvNBmbelbamv9I1+lrxkjLi1atrB4eUT/65OpgrZP1N5sum0Z73D1zvPPJb8aQPKLe/zyOTUjc8G+IZyfNSd2OMbI3ga9jlvV+RNtpL+8Y1s7BkWmr/7Zb2y91UtvdILuX9cRwsgfh/F6j2Y8zz8eYmOJONlfX+Z1wevPuvM+eMcW95xfWnIqmTdw6/GaTF8mOkfWOEV+D76jO4/OW//t/KFLoY9OWxlYIvpHNdsMXdcurmeQG6J+uYfPGGa3mFJk7ZJuRBftrj+daI6tGc+C+w+3iiH/XuzSvss3EaQuL7s8rXEXK6/7xTv6dGuelgtTzyKUxe61smtKN/PdLVnPg/lKcV14DrkunT6NoZpTus6VsSrlRY5IlW861TDnjYpBGoF1cV+kNJ2YtuB3WlVmbJ7sY2eTv2HzG5PM6v851cng9UqvF2BjSHyQuawiSeHPpco1+bryuW69p3BbPZs1h1oJvoUhjcv3X+JFYE17bzW35QZzH29p+5038tj/XmVasWWuIM+ucKY01mtFWEpfnf8p4kasvUp+21/oIzFqQoL0mfBfQP6GLuKucrzkX6rJGVntlWEyfnKn1f/cp2D9nEosqPYa78v9kH0eZc0p+3yZm/d38nVtMOv7tLCNGRs25izOXxuy1MhWc63mW3urRbzT1HyV8Z/C1Bc2gOK9cGRS9a69VlwbRPK4r0qwrm7qvWcdG+GLqHgUz64ysX/+4oQk8p2eqLuBtMY/sbbKuzGaNXhpbt+Yb8uz2OxhZbdC9OrYInrbtQh4Fc13rHSdnKhxr1q+NZ4PmpB3APLI3plBjG/yI5IW0q2oouV0+8szltrbfr8eUrAcp0uwaHatGVbNrjey69OjvrLnsoulJ5pHNyw/zyKaJx4XwBdTHLHyh7qeRXbnxJjz29DyaUsRxxL/vKJ5UJZpg77yyFV0mzlwaeVVRo+vGfYkw3SOI75BCzYF7SXFeZRoAfazmPQJUNpdNJhm/KBW2jj8rKOf5MgXqYl2Z3ZwnXE8ee2OmC+piIZ/XpY3sakGToalbeRzl+e/0LnqeNti7Gtlt8YDKWNsurPEjguqCe0Gvzb8PfvJ6V7e0/f6+sffbxchmOrJiMpq9qZFNlQOwDtWLhGvFw7jH/pqp1tSVNbJ+9/21M7Wbp2spZ2Szj5xcGuLft4knM47PY7V4T+/nYxn/mn4k5Z+TOWhBJbupgrePxDZUyg+cjZoD94rivHJl0NOvPlZLD5/ZVjZ9dDyYlpm8uYGRvTvWllnXWOce2TMyBKu7uYdMyOf12nq+4GbJHCg3ZM1qxTvOTkZ2h3hAZWxtFzJ+xOKGL5k8Own/4A0rYLa1/UWa2sXIqk7SQwvUB8RlobSR3eJF8HQphepFwqx4rqcv6Dg2me7Rnxo291KTfWnJNDzx3JG8cMYvnRHNvuzlGVd9VOCPe2GBDl/SdJkxunp3LPFrZrsKjtM0n9BodEYj/lve/Ptibt7cW62a5qK7J305SxtYHfPqv3XIswwML8zvOs4vedvaGlHvJZVMgdBeKHtduOF9R9Phs6SwuGtQWPl/B2Q1B+4vhXmlZTjVk6FGlM1sQKGUI1dW15VNU4kPj3U8V+Yxod4cxkZGK/nbmt4LlGF9mU2GlsQzuRj0TfD0jc2Wnqy4Tp/SUvM/rsdVH+mbpdUiouHoDc3EILjhLfFb34nRKH6ylqy3dbEajfXxgOoo0thGP6Joe57Lp21tv68p9zKYdjKZdXYs6+dizTrPkMzI5Oo/zxSntcUUpEeN7E5ehP8AiupFwqx4WDhHwUsaxdNR+GN+9I19zmQ2qxOKgm567Eo83RVvw/v7U1JYUtNdyNgXY2J1zKg/xRYf+93YZLQ/rtRvMFlES89Q81QpY4pOWCwc78icx393x+HFCCgcyV1SvM71Km1MkznvWTx9hln4sdPYf7HFFIj4bUfeN7SPpOJxf+Yub9in4PwkmUboOx6/x9cQNIN0XmlD78qBLH4PqTfmlZe2uXl7va5sGv1/ntDwKKDzeAobdwOslXscz88UnvnHRa9s3fB1X0u2zpeF6+zIq+O0p0t/941Bpk7/+Dqd/3HvmNkuNTVWYp79zgOO4030QkwEtyFno6cUz1pgFjWztrc1Wc9twXxDPBj7Wi18zbNs9iNKkcEt0Fth22805XXI8dcJT/o/mP/zzfiMJms1a4hvdJJ99cuGeW2NKMzG9SbK1HP2pn2zFwEKXx/5v/8HAHUBzTUH5BVgoANQNTfXmH1a0/5On3B+r6heJEQFBeoGmmsOyCvAQAegam6uMR7a16Pv9eXp7xXVi4SooEDdQHPNAXkFGOgAVM1NNSYvmh744/XB94DqRUJUUKBuoLnmgLwCDHQAqqaUxvRlQIwh/W5RvUiICgrUDTTXHJBXgIEOQNVAY6AMqhcJIR5QN9Bcc0BeAQY6AFUDjYEyqF4khHhA3UBzzQF5BRjoAFQNNAbKoHqREOIBdQPNNQfkFWCgA1A10Bgog+pFwp3FI59by0wIfO9Y0XIW2cmT3YcOhLtIO38fWiZ69z+nBxhUWM0BeQUY6ABUzf3QmPvoS+pzyXVjv3SX+5xyzBXNohH1O/v37sMwq8WULtj31HD9VC8SFovnE0U//XKHGXlD/C8C+Ua2dvyvisDIZrkfFRbYBeQVYKADUDV5jRV9SbBguVPTWT/JV8Pu2xcO3aema8oTPo783//DR74R3FRxqJm9UyPLqJmFkc1SpDlwP0FeAQY6AFWT1xi3of9CvdFb8y/9229T+QlsSP3uT96nab8PrJm9j5/qdmb2zo3s8i2N+FvTMLLfCIzsOtAoNgfkFWCgA1A1eY2ZNnQ49ExqUZv6hWaj4LtrY2FkE71ImBKPmlizThcZp8HjPc8D6rW8cabLSwp5LKrZptUL6Czo01B+c3dJHZ6seJ96wYiCoxc0/ZJ97O8/NvAzhPd/RYGmo9WjYDxzd2RFfKXF9KU7Xos6T5+adOoxDKXSzuj4E46P09al/umEFlKWOG2/03nQo1b7GYWvnlGHjxlMJH2rxYROXbx7nWPqyzn4hc7EPR7a9MmxhzSe8deh+Zhncs7t5+f0asBxHJj0/r34Wja8zPK5g2aAvAIMdACqZrvGtnUObWi7/WGHZmFf8yV+RG8W8Qt+++4bsXS7vdcZUCjt9hqM5xhzHBI3t9uvaLbkRGg7/wP1Rn+KPQh7nOGEj854XsAfI7ta0PSU37nhOLv0tP/ExL+Lb1rnWf4/NJuG7jhjehefn7lm4SVdLV7TUOPqPKMo/uCE77d4e3N+w9fOHzH3pUc2lxC+43nsEq1m0K5rHYY0lxP4SvPwmTWD8sWNR3QYfrAZs/pA4bEzX1cR9X2Taba4igapDJHPzbVdxq7mFMWmrug7yiaTpkOTMV0aRHOOjS5Hh1ZAcoySaZd/H1OrdUijS2swbXzOrKYKwz4dnv+ZxiZ9EtfVhIJOmzqDsclUk67LUycMLXQ27nbvBU2MKFaLMQ1YDJ0hvYmeJwWqdUznk9/Mb+Ya/vE3+td117LB5DUH7ivIK8BAB6Bqtmtsk5Hd0nbzJlk/4bxKbMTir4WZdjj2P5l4l9zOm21ag+LhDNxGH3ZcnMb0RWoc/y+ai9ex7XzL+YC489C0++Hc+AIe1um2SYzsZ3PeB4mhjDscd/BNb4y5LfIs/03XmUWNtKSd02LS//xCzLfEa3xMqx+ZK2oQD6fX1KUr9SL9vTWyjPaeaoKtoFq9U7qUOw0PMXvGpcfjWjwKHvunu8idydSLZtCM9dfFOOGlfsuZ5RJpL4pPM3fvMY1mX8wKd31SQnaGObXuE0X9R2Y/V+gk7h+oH31yv6vJfmTXycwKmfPcdC0bTF5z4L6CvAIMdACqZrvGNhjZndpuQ2xEn1D/6UFicmMy/scZt+7o0nYmGWMr5nSNkRW/4v+m5titKxoSYD2OdwznBdTI2t+dTxCyHYDbfFORZzFkjpN4Je96ZTybNbZJWuz5NNbIak8oO/ou9Ue/ed86Vpdufuv0aXQxTbqdtxpZd2yJN7N4+8RIRqRFkT9GibTnMpZRw6n7F10fty6Vxkyhc3Hnz82lv/DYG65lg+HzAc0AeQUY6ABUzXaNbTCyO7XdFu1lLO5VTbfv1hBmPMZa1Gv47bsuNs2FY1td51tsRFPnonGmz7mcbyryLIbcNct6JV6V92yMTLMlQzb5OP71XXOsCuDzk//7fyQUJaTgBNkQ6tgLuWj+4/9knIdczM6Qptz7uaORTYtxPbk7GWarkWWK0653MenjZ/cvuD5619Ud0SxOSJGR9dOQobAgMmuuZYPJaw7cV5BXgIEOQNVs19h6I7tb2834w/5abiig+0lIt+83MrIbTFyhkXWeJU57yguoGfd6SQ3lfFORpzPcxMiuFjQZGt/EY3DPf6d3MizSv75rjlUBqhcJ8+IpSkiRIBLi8Z4Z1x53w+sFV8O31si6x/E5s2bimX3IPAIw6J1MPN7VsJORTUilPXtnJDghxXdvRdfHpduNc7FkCp17RJF7lLH6G83em6OtNbJK5lo2GDSKzQF5BRjoAFTNdo1t6JHdqe127X33R9NOL+3YVx43qu+gCJn2vchjrEUf+eff6Vkt3tN742mKjKw1y97QgZQX0DjT6Sznm27LyGpaElNt03GfjSxn/nxCo9HUXAi9K9CLbQQ1fJaYNjfuRERkTnx4rJmuj/F1v7ThW/lvxrlMsd3+xvD1X7pH/tx7ekHDcBZnYoI+etc359TscXxmkR7SEmk3GW8HdidvEVqj679w5cx4KqP0PI3gsy9zSVo4469cwfFnQbiiWXhCoRFF4R3lxmvZXPKaA/cV5BVgoANQNVs1VjTmNWaHtltekjLtb9x+6nss+rK4ITOmNeUx4ndV2Gec0KjoBXRNY6dPp1ObDpklaXghT2ut8WOf4N7R0Re3PBOqXiA25fG43uzLXOwt7BPp602+qdCzFBynaCiGGlnxUmp03fWKZ2fwPEnu+lWH6kXCvHgSM2hN2d/dXZAzh2I43xkz2Kfg/CSZ9qof2ikm2HwdBXQun2fl7e10DvaymIvrd+ubfaRrOjX+0xw/Nb2Db/wK0K5u2daI7ZcX1OcXpILQZGjJtAvGXPpTbXAXuk7/pZmq8aWEYdI9eRHvx1NrnfR/MP8PKFRBp6bQMIsT+1cnbo03NrMbr2Vz4XMEzQB5BRjoAFTNJo2pAeRtdMk/vdzQdmsHHa+XdltNmcZnvMHZWbp9157fNe32ekviTcMp/kLNpZ6HWafThBb+7o7Di3uynOr0ax3SLydPqc3nF27xTV+LPUv+OCMKU17JmNk3UW7fycckHewP30QvxAzLlGTvxsXXryL4GPJ//w8A6gKaaw7IK8BAB6BqvgeNWQOpQwLAt6B6kRAVFKgbaK45IK8AAx2AqvkeNAYje3uoXiREBQXqBpprDsgrwEAHoGoevsb0ZanMTEvgRqheJEQFBeoGmmsOyCvAQAegah62xrJjcovG+IIyqF4kfNjiAfcRaK45IK8AAx2AqoHGQBlULxJCPKBuoLnmgLwCDHQAqgYaA2VQvUgI8YC6geaaA/IKMNABqBporAw8B/2ADoIpfdGptNxUXdfTIR2kphR9mKheJIR4QN1Ac80BeQUY6ABUDTS2K/zxhx+p65lVmQ0h/prpFV2ODqm909fImovqRUKIB9QNNNcckFeAgQ5A1TRJY6vFlC74Q0WZr2XdHPcy2C7x8Ze+5DO77uukhrSRNcgXxp7kPpX7kFC9SIgKCtQNNNcckFeAgQ5A1TRHY9mvhLnVNSGmVT4Z61YYckZWPjf75EFP86V6kRAVFKgbaK45IK8AAx2AqmmWxpyZvSsjmzKtRetsD+9DnuJL9SIhKihQN9Bcc0BeAQY6AFXTLI3dnZFdzUbU3alH9jGMLABVAc01B+QVYKADUDVFGuOxqGHQo1b7OUXvQup3Wma7FnUGY1rERm5Fy9krCnr7Esdeq0fBeEZL96v5kcYcB//G+8YvSV3RLDqT/drPz+nVoGt+P3DjSvm3kTse79el/unEO6ZvZLMfO9BP0Prrjyhc/F1mGujw35zGs4COhmw0Of2/07mcp2eMl5cU9jlNe9TqBXQW9Gk4NWeVHSO7CKnnjh0bV4yRBaBaoLnmgLwCDHQAqiansdUljbpqJPepN3xtjKTtadzbe0yj2Re72Tykw3aPhpMFrVZzinxDKoZu3xjBU7pcXtNyOhQj2epH9HfuxZS42Vge0/nkNxp0HtFhOKOP4TG1Woc0urwyR7CzAPCnZTvBxBnkbI/sV1pEzyTuVC8on8PBkcQjPanmOGpAOd3HbGT984zjs+fZimce4JkKnlkjK/8+prack9ctG4NZCwCoHGiuOSCvAAMdgKop1lj+Eb48Ro97PZ3hM8aULScjhtHE1eqP6WM0MAY0Mb3GPYrRjbd3vZn+/mqg0+usIU4MdNHQgk8U9R8ZUzyg6Mo6SE7LgYtH0h2b4yzZ+JY0DTrOgBebVZ1HNj68A/PIAlAD0FxzQF4BBjoAVVOssW1G1v1u9s0tvZf0v6X3lh/rZ+2ewxnZVC9q0TpnmPf2OhRIr2iRkV25Ht9H1I8+mb95nyP3bwMPCdChEf0TupguvBkFsvFpXHwuXeqPfqPpIpluCyR6kVD/AKAuoLnmgLwCDHQAqqZYY7sZ2eKXmtR8ljOy2qObjlPHu24ysgYdJsAvY13zsIKf4t5ZYTmj6DygXosN6qahCow3dtakJxm/CxjVi4SooEDdQHPNAXkFGOgAVE2xxrYZWfc4vzOkaepR+ldazP6T5jK0YJ8Oww9e76dHUe/rVUR9YzRTQwvUFMfDBtYYWTd+lYcznIR/iIcV5IjH8qrJXhefZbUY04B7czPTbn3PqF4kRAUF6gaaaw7IK8BAB6BqCjWmPZyxwVsZn8nmtBVP9i8ve7X4cf1L9/idezIvaBjOaKWP8/2xqWwih2ZbY3yLe1+dGW25F8jMGmsk+UUwZ4g1Xd542BhnhPfiIQaW6+kLOo4N9WeaBgfJ/rn4ljQdPktmJnDnkTbX3zeqFwlRQYG6geaaA/IKMNABqJqcxq6nFLTZELql/TOFZ0XTXH2lxfTl2qmyVosJnbpprOz4VGt4bc+uxpU1s1c0Gw/dEACz+FN6ZdOVG7qQMakONrJHwUsaaVo6AwpnxpYWxmfiGPYpOD9Jphz7Dl7gKgNfK/m//wcAdQHNNQfkFWCgA1A1D0djtte4jd7TSlG9SIgKCtQNNNcckFeAgQ5A1TwcjfG43R5ezKoY1YuEqKBA3UBzzQF5BRjoAFTNQ9GYjNk9SH9CFtw+qhcJUUGBuoHmmgPyCjDQAaiaRmtMX9byxuCCalG9SIgKCtQNNNcckFeAgQ5A1UBjoAyqFwkhHlA30FxzQF4BBjoAVQONgTKoXiSEeEDdQHPNAXkFGOgAVA00BsqgepGQ/8CCBQsWLFiwYMGCpSlLysgCUCfQXHNAXgEGOgBVA42BMqheJIR4QN1Ac80BeQUY6ABUDTQGyqB6kRDiAXUDzTUH5BVgoANQNdAYKIPqRUKIB9QNNNcckFeAgQ5A1UBjoAyqFwkhHlA30FxzQF4BBjoAVQONgTKoXiSEeEDdQHPNAXkFGOgAVA00BsqgepEQ4gF1A801B+QVYKADUDXQGCiD6kVCiAfUDTTXHJBXgIEOQNVAY6AMqhcJH5J4VospXYz61GkHNL12K2/MFc2iMwp6+9QOpnST6G43PUV8pcX0Nxr1uzdO441Yziji89o7onBR/qiosJpDc/LqjsrCdwLKLKgaaAyUQfUiYVo8HynstWUdL63DkOYr91OW1QcKD/fjbfd6IS3cT3eDl/ZbMI7X04Da7txu1jDeND2fKPrpl922X4TU+6Y03oQlTYOOPS8Y2QdPOq+ujeSOXN6bpXVM4fyr+y3LV5qHx9TSbW+olZ25k7Lw/ZDWAQC3DzQGyqB6kTAvnhVdRQPXAB1QMP3s1vusaDkdUke2eUT96JNbf9c483hbPaCucbx5w1g+PavZiLpl0v/NabwJamZhZB86hXl1FVG/xWW/RZ1gYtRQwHJCQacl+7f6EV251ZVyJ2Xh+wBlFlQNNAbKoHqRsEg83Bu53+nQD+a3wl5Z6Y39gTqdR2b/jjG7hU3ZHdBwI7t8S6Pefrn0w8iCCinMq+spBfum/P9gjGphr6ztjW27OqQ2bcLIVgbKLKgaaAyUQfUiYZF42Mg+Cn6jV302qvleWek17DyncHRoflcjW/DI2TUssi4eenBFs3Bge3NbPQrOAjoaasOzouXslYxLtfF0qR9e0pIbzrYfj/+Is0298KPsXWwceazriPqud0jiPJ3QIjbnG9KTahgzj1X98xkPqSc9VMb494Y0nmn/U1F6MufIxxzPaKkmVuM3iz0uj/176aV/n3rD10n6d2m8VwuanvKYVhe3OeZwsjAp4Z+mFAY9arWfU/QudMdpUWcw9q4Rbzeh037X7t85pr6kFUb2oVOYV1weHz2n8St+clPQK7u6pFH3XygIf0lpMxmuo2XWlQ9Zp1q6Qf0gvxmKysJyRmPWt2xvyk7wimbL7J25su7YXIfwePkfqDf6E4VaDrxyxKTKiFlavRc0WTiTv7yM92v1AjoL+jTkepPLZhiY+sPUo9E0SWtnQOHsEy0mL1zdkimT6+KrCD4OAFUCjYEyqF4kLBKPNbJT+sqGlSvK1KPBTxSZCvQwfE9zMXZ+jyz/xubXMzj6GNIZPzHBXi/Oah7SsWuo+N+HLdPYjN6axumzMcYHJi43dCETj9naDYHYZGTdOL3WIY0u+Qyu6NKYb7/x3ZSedMPIjagxer2fTAOjV8P1PLkGa7UY04CNYGdIU2ks80ZWzrHtGsDVnKIBN0Z6s1BgfOW8Nb16TbxrvtXI6nVyx9BHvnyMr2w4sgb5C81Gj83fj2k0+2KjkH3ariE11+Hy1DWuMLIPncK8EiPr6ac1oOgqtnOitzY/yTFaT2uzqMym64wb1w9MtizIk6OO07W5IYyeGZNaYLwdxcee0N/joVaeOdUbz3h7dx5S9q/joVc2LbZMJU+3uN54ZoznZ5Pk5OZY47bnaf7uHNJzMeo63ljPdV18MLKguUBjoAyqFwmLxKNG9jpuZBJTYyt7brhMw5AzsgWPnLU31RlQ6ZWJjaWPO1Z3RDPXJlpj+IOtvDPxMLaHZ4ORlZ6hVtqIxy+p2XNanx5D3DBO6DObt+4zirSHhZH4XfoENYHa4GSNqWuAvPTI9TTHsOvWGN9W0ljbcy5jZNXMq9lweRQfI3/M9HV155QyKwU3LCVAhdUcCvNKjey1GtMWdUeXxqYa/DJRoM18mU3XGevL45b6gckcL6mrdIci452wqS7Ip9vFr+fu6pW4bLv6yqbFnmOrd0qXud5gfdLj16OuTHrnmj7+pviqAWUWVA00BsqgepGwSDxcaVoju4p7FmwFzY3JD67RKqqAtxvZ5CWQFnX6J3QxdY/mtJHxjGqKmxjZQpOnZtOle116GLd/60mPnvCjv/g8He53vobpRdOUNYnu76J95LzyplKRqbzO+REkb1/GyCo8ROFPdK6PLnc2su73VL4U5HMJ+HxBMyjMq9jImn9r+RFzeG2NrRqwAm3my2xGSzetH5jU8TJDgVLLGt1uqAvy6Ta4p0TpG+UFTS9+jYc/2LQk9agMhxj9RtP4hniDkV1bJjfFVw18LgBUCTQGyqB6kbBIPFxpWiNr8HowT8I/eD0cNzSyDM9DGpsy96ivAiOrvZ1pk1eQ7qL08PqUkTX/z/aAyO8FBjcm2yDZv9ebznwDxg3jZGjMJ4/ZO/+d3kXPzTmXM7KrxWsamoaVx9KdR1OKOI8yaVrbaGq+eL1DhflcAlRYzaEwr3wjGz/2blH35IxO/CcUNzGysuoG9QNTZGT9srQLa+qCfLoNrk6yxzM3ijKelcfhnlH0buz9xvDQpN+TG8l4ONFNjCyzLr5qQJkFVQONgTKoXiQsEg9XmrGRTd39e48QCytg7e3cYmSVeIwob/9X++jQG6OWoqAhy1fumQagqMek8FG5I5UeE0HcML6mjzK+zsTlz+KQGr/qsfobzd7zEbMNkns8Go+hVUwjOPtg4shur49uk6Ed9pzLGNnsI1lnHOJjbGs03f6pfIGR/V4ozKuUkTXEPZmmnPs3PAXatDeXW4ysUqZ+YFLHy4wN91gt3tP7bY/kM3VBvq7Rc/HH8Hv1Y8rkponH0ktddlMjm5COrxpQZkHVQGOgDKoXCfPicQ2A3yBpr2zK/Klp9V62iBuPfToMP9BKexPNMaSRMxXtx+kLOubfZHv3woZ7LBkPY/B6PleLiIajqWnu0oZKexklXq3g1ezG6dTxof5b+lzpP7LpM39fr03PKtOjm/Q8JcZV1/kzIfCbzycUsvHMpceskjGvJo7+S/c4kHtWLmgYzsy/XAPG288nNBq9MXFxI9elQTSnVfwGdnLNNY1ps+7j4uzw+N4v5ljurW9Nk6YxZ561UU5uZOKXUbThlGvvvRS2I3nNgftKYV6JafPzXcuBXxes0abeXMoNofZiuvrBmMazcHjD+qHgeFpvdfp0qsME+G3/4YX3dCFhU11gjaR3bH3ZS29KxUSbci0vRCYzmdi0GLM+fJYYcGf87W8F9WiuTKqR1TK5Kb5qQJkFVQONgTKoXiRMi8eZHrPOLtpLwObmJzrI9DYk25lFewP8aaR4Chl5xJaM4+LG4ih4KZ+SjLfxZgFITzXlG0RTfcdvy7MRDO1jdtNIjS6mtPiaTZP28CSNiqznR/Q83RVHaViXHm244vh6ZzQVU+n+1kYmO7WVNpq5a6Tp2XSO5jft+Y1NY2LYed2b6IU01pzOs9HTTBqLemR8s8AzE4wpOuGG01zDH3tJunlp/0zhmXeOcQ9Q2nDwFGMn/R/M/wMKvXGEu8JxgGaQzivtPVR9eD2ObFAPMr3+3nZ+ebQzh/A6o/1wQlHQjcekfr1h/ZAvr7YspKfE8m8g82yqm9RIdp4+9eogLy7/pp1vnN+M6YTNqJzj/5eiYZ+C85NkejtTf82WV5nrZMrb2Vm63jD1zJs36XNrBxG9KYyvbEncHT4uAFUCjYEyqF4khHhA3UBzzQF5ZbFGtvjR/vcAdACqBhoDZVC9SAjxgLqB5poD8soCIwsdgGqBxkAZVC8SQjygbqC55oC8YrLjxr8/oANQNdAYKIPqRUKIB9QNNNcckFcbxgV/R0AHoGqgMVAG1YuEEA+oG2iuOSCvAAMdgKqBxkAZVC8SQjygbqC55oC8Agx0AKoGGgNlUL1ICPGAuoHmmgPyCjDQAagaaAyUQfUi4fcjHjtHbv3j2+7quPcXVFjNAXkFGOgAVA00BsqgepHwYYqH3zIe0jD+5GNd3NVxmwUqrOaAvAIMdACqBhoDZVC9SPggxSOfeOx63y6vibs6bsNAhdUckFeAgQ5A1UBjoAyqFwkfnnj0E5j6ed26uKvjNg9UWM0BeQUY6ABUDTQGyqB6kbBQPMsZjQP33fDcd7xX5uco+R55wTfHp2FAvZYxdNGEwvi75c8okm34e+khBb19agdjehcO3Pf+uzSI5t5k41c0Gw9T3/cfx99cNxSm8R/ed9zd0g5oem3iis7cMad0fT1Nf8/cfZc9+V67fsGHz/WV7CfbtXoUjGeUt6n+9+PdUnRct+1Mz5njOwvoaOh+W17G16vVC+gs6NNw+lfve+zue/WLkHp6HJd2IXVN9qkXvKr0++s3hdMNmgHyCjDQAagaaAyUQfUiYU48qw8UHu4bI3VKl8trWk6HYrpa/chYMPPzPKTDljFJo7fG0Bmjd3lqzWZnSNPlP2k2eixx8tLqvaCJMa+r2Yi67qs41/JvZ8KMkRtOFrSSR/It2uuOaCa+6yvNw2Nq6/6LMQ065nc5htlgYxp1AvOkZ9Qe3x4zNpTLtzRig9oaUHSlZo/3fUqH4Qcx1HKubU3jnKIBm8wDE+9nu3mK3Y4r61rHFM6t8edjHIuR/SLXrnUY0jy+Bs/ceNtPFPUfmXickWWuIurzdVcjK9ekQ73ha1qszM1C9MxcE2Pwg0mB8b5b+HqAZoC8Agx0AKoGGgNlUL1ImBaPforxMY1mX9wqa+CsSbRmK23+rOlMPt+YN3SkPaBqulyPYtJLuXS9js6oibH9gfrRJ/mV9Lh7j8y6v21JY8HxmdwxC86VDePguTs3ZyydgWfUmPrrEnY7rvT6tg5pdJmNwV4Da8712iqZ68Nkrqk1yF6+6M1BKq/uB6iwmgPyCjDQAagaaAyUQfUiYVo8ahg9w5TCTiVlH5u7VQY1eNas3YKR9R+dpxZ+5D/bksZdjaxBejWTXkvuHT0aqEl155pLg1n8x/kxOx53OaGAe5dlOMQJXUwX0vtrjh73LPMwi/7ot2S4xlYjq8f20hgv667T3cHpAs0AeQUY6ABUDTQGyqB6kTAtni1GVnv5MkY2bdZuy8hmDGHMNrNdwsjSZ3PcA9drycMi+mYfHTZQdv7XEsddzig653HEbDT9x/88Jvd3Oo/Hueowhh2NbDZf7imosJoD8gow0AGoGmgMlEH1ImFaPPq4fT8eJ5rGjdXMPK62PbL82J+HAtyCkc30lMas/kaz9//YksYyRlbTbuI6/41Ojk7dGF3GnauOy435SovZh3S6hHLHFeJxt3lTHo8LlmtWYN5T11TzLT9+d7V4T+/v2QtfqLCaA/IKMNABqBpoDJRB9SJhTjz66Nsfx8mGa/hSDF38spe8VOR+4/Gp8UtKaro8Q6cvJrmXudJDERh9mUnHq+q42y71Tyf2OMRv+59QyL9vTKMxmmIo2VjPaDr61abbHTM3vlV7meMxvgn2XHkIgM7KwD2mFzQMZxsM9ObjXk9f0HFswP0e4SuaDp/FL4HpOdr9MjcYqwVNhtpr68ysewFur9OnUx2uwLMgDC88c34/QIXVHJBXgIEOQNVAY6AMqhcJi8SzWkzodN30WmLmvCmpUtM8ac+qM1hsZsOR9Egm69JLOzijs9RYVNfryNN4nfbdmFGz+AbNsCmNcW+mmxXhazytllu0Z1hQ0+y/9KXwVGEvqc9xyb6+sc6zy3E/GiN7FLxMpi/rDIw5Z4trrt2wT8H5iTsen5M37ZnOsqD7vBtT0E6Ppd2cb/cHTh9oBsgrwEAHoGqgMVAG1YuEEA+oG2iuOSCvAAMdgKqBxkAZVC8SQjygbqC55oC8Agx0AKoGGgNlUL1ICPGAuoHmmgPyCjDQAagaaAyUQfUiIcQD6gaaaw7IK8BAB6BqoDFQBtWLhBAPqBtorjkgrwADHYCqgcZAGVQvEkI8oG6gueaAvAIMdACqBhoDZVC9SAjxgLqB5poD8gow0AGoGmgMlEH1IiHEA+oGmmsOyCvAQAegaqAxUAbVi4TbxXNFs2hE/c4+9cKPbt1dfNufP8QQ2Q8JpD5oAJoGKqzmgLwCDHQAqgYaA2VQvUi4TTzX8dep2p6RvQOupxS0OR1mgZFtNKiwmgPyCjDQAagaaAyUQfUi4S7isWb2jo0so2YWRrbRoMJqDsgrwEAHoGqgMVAG1YuEu4gHRhbcJqiwmgPyCjDQAagaaAyUQfUiYaF4VguanvapY37b2+vS0/4TasVGlseq/k7nQY9a8RhZXhdSv9My2+9TLxhRcPQiGT+7nFE00vjM0unT6XRh9mJ4DO4ZBb19aj8/p1eDrtnmgILpZ/PbV1pMX7p4W9R5+pR6rYyRNXGPOS0SNx/7Fc2WJmY+5nlgtu/Q8/CcBhxHZ0jT5T9oFg5sWlo9Cs4COhpOqbahvkA0AJoB8gow0AGoGmgMlEH1ImFePJ9pGhwY0/eMosVXYwjf0siYzHiM7OqSRl02lsYIqpGVdY/oMPxgzenqA4XHzsjyvw/3qdU7pUsxmBqfNavJGFw2lsd0PvnNmE6O6z/pajo0hrNLg2hu4r2iy9GhNaxqZCXuDvWGr2mxMqY3ema2N4Y3GFMUdGycZmkd/kqTsfnNxP/H8f+irvl/ODfnxlHMQzqGka2VvObAfQV5BRjoAFQNNAbKoHqRMCue1WxE3b1H1I8+6Rq6igZejyzzkcJeOzGy8sh/n3qjt7S0G8Tk47Pm8ZB7VrsjmrHzXYTUM+lo9SNjVx3OMKfWXUXU93pkJe7WgKIr27cbm2xZZ4wtz6yQObYY59YhjS7jWEHNoMJqDsgrwEAHoGqgMVAG1YuEafG4abX2jihcJH2U+TGyGSOrvbgmLh42MLqY0kK8pcbXoWDqWVw1nLq/M7LtwOsZlXWZcbmpMbIat+11TS+c/i/Fx15OKNChCv0TuoiHOIC64DwCzQB5BRjoAFQNNAbKoHqRMC2eLzQbPTbrHtNo9sWt28XIMslYV47Tjkf9p4svYyaz+xcYWduT26Lu6DIxmkVGNpUGnzUmmonHz7Lp5aEIk1xPMqgOVFjNAXkFGOgAVA00BsqgepEwLR4dRrCfjHc17GZkFR2rytv/l4sv/Xg/N2ygqEfWDSNoHYY0TxLiGVlNq74YlrBavKf3Sx1aUGBkldWcInm5LN0DDaoFFVZzQF4BBjoAVQONgTKoXiTMiUcfvbd6NJwYuxibPdt7KT2kqbGoxmUagzk8VsO5oqW8pOXMa/yy1wua8MtjanT9F66k9zVjZOPhCvuZl7k4HWbh8bXXNu7ULAjLSwqHFzRbae9y2sheT1/QcWzS3TH8cbagclBhNQfkFWCgA1A10Bgog+pFwiLxrBavaahDBFqH9MvJU2rzVFXhlBZfXa8o/ybLEYUf39DwKKDzeIqtLvXDy+RxfWqKrD1jaoc0ntmXrVKzFpglZWZXC5oMvam1fnlBfX6pLAhpKqaYN5nQKX+2Vrbhca8vzW9/NwY1mbXAN7NsZI+Cl/ZTt/xbZ0ChSwuoB77uoBkgrwADHYCqgcZAGVQvEkI8oG6gueaAvAIMdACqBhoDZVC9SAjxgLqB5poD8gow0AGoGmgMlEH1IiHEA+oGmmsOyCvAQAegaqAxUAbVi4QQD6gbaK45IK8AAx2AqoHGQBlULxJCPKBuoLnmgLwCDHQAqgYaA2VQvUgI8YC6geaaA/IKMNABqBpoDJRB9SIhxAPqBpprDsgrwEAHoGqgMVAG1YuE/AcWLFiwYMGCBQsWLE1ZUkYWgDqB5poD8gow0AGoGmgMlEH1IiHEA+oGmmsOyCvAQAegaqAxUAbVi4QQD6gbaK45IK8AAx2AqoHGQBlULxJCPKBuoLnmgLwCDHQAqgYaA2VQvUgI8YC6geaaA/IKMNABqBpoDJRB9SIhxAPqBpprDsgrwEAHoGqgMVAG1YuEEA+oG2iuOSCvAAMdgKqBxkAZVC8SQjygbqC55oC8Agx0AKoGGgNlUL1I+DDF85UW099o1O9SO5jStVu7leWMolGfOntHFC7cXouQensdCqZL+3cdFKXjAYEKqznUk1cfKey1y5XVHFc0i0bU7+xTL/zo1t1GvGVYmaIbSb2z1wtp4dY+BFBmQdVAY6AMqhcJ14snMYO8jV261B9FNJv/TqMLbSzuIWI+bZp3b8SWNA067jzv0kDel3RUB58baAab8mq1mNKF3HBp/dCiTn9E0ey9uRF79Y1G7hNFP/1C0x3lfz0NqC1paHtGtiRXEf00/AbTa/bvt9y1gJEFoBTQGCiD6kXCQvGs5hQN2MDuUy8Iabr46tYvaHpqG676ejluiDOz5dKpJvKuDeR9SUc1oMJqDsV5ZW5yo2dSD7R6AYXTBa10/fQl9Tst2msHO5vQIlazEXVLxmHN7E2N7BeajR5/e712PaWgDSMLQFmgMVAG1YuEefFc0eXokFpsYkdvjaXK8pXm4THtw8hWCIwsuB/k82pFy8tT6rXYxJ7S5dJaWJ/VPKTD/W8wssu3NOrtlzbDNzeyyTnByBaDMguqBhoDZVC9SJgVjzRC/HisNaDoKt9ICcsJDYPfjeVVrmg2HkpDwPG1ekMaz+yv/PgxDHrUaj+n6F1oe2v4EeRgTIs4eh5b9ooCbrzM/nutHgXjmbFzvP53Opf9n1H4inuBzL7BxPzm9f7wPmy8h6+TOHc0sqvFhE51+ETnmPqSBmcgeazqeWDOyx8ja841HNjHqZzOs4CO4seR3hg5SRM/an3perQ3ncuWdAjrrvGGeJeXFLo4uefsLOjTsM6xvmvg9IBmkMur1QcKD1mbj6gffXIrs3ym6fBFUn94T3JE36bcDCfai8tjW8+k7EtZVROr25plbRlOxdulp/0n5gZcjWwmXtmhqOxO6LMzsf4x40UM6bWpTo7cOhe/Vzc8D89pwPVQZ0jTzxNrZJ8EFMZpS9dNqbJullbvBU2kjuA6LXRpHtM7Tas5t0E0d9fLYI495vIuv3EdE9IsvqFYV098GxwXAFUCjYEyqF4kTIsnqbBb/chUibtge2jbrjJeLcZJpX71jkbdrNG0j/D29h7TaPZFYhDz3HaNWzys4YCCN8bccqPg9j88/zONzW+tw5Dm/+DxaGoETcMZHJhtPMO5i5E1hjzotJ2pNoYwbtDYQC5dOvnvJF555Nk6pnBuh1tw2o+dkbU3AdqT7cXnN3BF53K1KR0c84ZrvDbelzT+18c2fmnjOI5nMLKgFLm80vHnm250U6zoKhoY02XK8/SzK3NGu663VcqTaNcvq/Ylrc09sq7Md55RxCYwNsDWaBbFu6ns5uoLHe8a96zqeXD879wTExt/6/BXmozNDSTH/eG1LY+dAYVsII3ZngzZdJqyGX4wsXyiqP/Ilt3lNS2nQzGrfNyvXppjs7+6tHVod0QzvtzuRsL2hif72/p6Qz1R0HNeBk4TAFUCjYEyqF4kTIsnedEobwD9XgldjNGamwak+4PXO6NGVXts8o1S+hGg3d43ztoI2XVu/0zDaU1j0itk4yxjZF06U/G6RiY2kHrOSbxynNYhjS6zNr8oPtuwtPZa1B1dmkas6Fx2SIc0Zjtc41QcNi/XPf69S9KaA/eZbF7ZcmbKfpHJVJMbL1zG/8OWgVibro7x98+V1e1G1tYRfq+wbzTd0IJMvOvLriGbhoIhAul6S+uGTM900dAC34xeOyOq9Z3bPj5u7lr4w4y+unNMOgFMRSg3/hLf1nri5qDMgqqBxkAZVC8SpsWjFV+mIvbRHhVtmHKNly5a4W8zsu73ojgkDZsbNXlzWh7x8T5ljKyLN3We2bGpeSMbn7880juhi/hFl+J0qim36SjaZod03OAac8OuvTV2tonfkpf27hhOO2gG2bxKejq1jGTRpyNZ88SPzf9kh8Dw/r5Wc2W1uCwlaLlMpyFdrxiy8a4tu4bstjsbWa9uYArHyLobU/98eFjExa/xcKr4uLlr4dcF+pRozbXfWk/cHI4HgCqBxkAZVC8SZsUTN1TeI7g0mUZGKs9MZZ4i3ygVGdmk4s6yplHTR3Y81u38d3oXPTdxljCy2Ud2wg5GlonHx3Ej4YY3aHzZdKbSUXAuu6TjBtfY4o2f5TzVx7t3DCqs5pDLK9Vr/Kg8S77MrBavaWgMG4/TPo+mFLG2fa3myuo6PSt6w+31TBq2GlmmqOzy+uy2lRlZY+gnL8zx96kXnFH0blyiR3YXI7upnrg5KLOgaqAxUAbVi4T5hkpf5jCVfOqFLCXTyMhYMq9BUFZ/o9l7fniWb5TSDYI/Zsw/mKnwZx9MnEWNmj5GTBoyG6dXiRc1YinccVOGfUcjq8TjeXn7v7r4/Mf7ZpPUI9Cic9khHTe4xlni8XKpBvZuQIXVHPJ5pcNljFnT8akpsmXG6Tu+UXPa9rWaK6vb9KzlP22mdzKySqrsml+z26phvw0j6+KSx/+uLNuhRga3fXzcXJr9ukCHFqy5idhaT9wclFlQNdAYKIPqRcJC8XhvDqfnieQePjfzQNzIaMPWpf7pxBlffjv4hEI2mbmeSm2Eksrcjnc1FXDqDf8LGoaz5GWHVKOmjYh7mzd+izd5nKk9y/7Y2zTJo3d9azg2e2ad7e35nBtjdj19QcdxI+IeozrzGr/spW8o6/g1feGq8Fx2ScdVyWvMmAZw+Cwxx+6x6vrrUR+FmgP3kuK80in6jD75iUg4TW5445ky1OA5Uyqm94sp1252Eu+GL19W3T68zXxCo9E0bcyYeIhT9iVRLjO2brnOxLup7KqBbPXHNJ/+SqPp/y91g6m9yjZ+NrMzVzdkjKyWxezLXnqjKsfRToJkhgFNo16LxMi6GwG9aY/P2xvry+c+NHXn8svmeuIbQJkFVQONgTKoXiRcLx5TAUZh5stevPB4y/P0+LLUNDhm6fTplH/X3gld3/6ZwjM2oLpOezeyU2m5ivhrdv/EqPkNCxvAN9ELaQC4ATkbPSX7lR+3rO2F1Md8djuequak/4Mz7zOaSE+IxmPTyo3hUfAyuS7aYAlswL1pxPb48eErOzVO7lr4pnNTOtx13vkaa7xsZPsUnJ8kU56lpum5OzidoBmszyvW+u8Upr7sxQvrzBinCzW3vrb5Jm9M0QkbQKtHOyTI21/Kqtkn/uCCvbkrImUujbH75cSUe2esP0649zQd78dNZTc2wnojas4vnj3ES6spd6OLiMLnft2QNrPxlIPyG++rN+jyo5vFwPzGJvzNmE7Y+Jo678feD16cbGbP6IwNfbzO9h6np+/Kx19YT9hfbwzHBUCVQGOgDKoXCSEeUDfQXHNAXgEGOgBVA42BMqheJIR4QN1Ac80BeQUY6ABUDTQGyqB6kRDiAXUDzTUH5BVgoANQNdAYKIPqRUKIB9QNNNcckFeAgQ5A1UBjoAyqFwkhHlA30FxzQF4BBjoAVQONgTKoXiSEeEDdQHPNAXkFGOgAVA00BsqgepEQ4gF1A801B+QVYKADUDXQGCiD6kXC6sXD801Gdu7GtfO5loQ/MynzV7qv8twY92GF1JyuOyCTmmcmQr8L7ks6SoIKqznUnVfxHKxly2Qpbljuv2NQZkHVQGOgDKoXCSsXjz9h/60YWf1kI8f5rUa2DvhLZkMafrPZvK147h5UWM1he17pl/oOzA3VZ7euDJ6u9atYXLZhMu8VKLOgaqAxUAbVi4S1iEfN7G31yMZmtgFGVhrn7rf3mt5WPPcAVFjNYWterT5QeOi+sHeTzx/ndO0+Twsje69AmQVVA42BMqheJKxFPN+tkdVv0n/r4//biud+gAqrOWzLq9VsRN3OE+rxZ5BbA4quynwMtUjXMLL3EZRZUDXQGCiD6kXCvHi+0mL60n2fnx/f67fH9beQgt4+tYMxvQsH7pveXRpEc0qaMD+OFnWePrXfLF9rZDcd05L6vnjnmPryjXX99riOq3tO0btXkj79Pvrsap582zyVTvut+HN/PB5/pzwMTFpNwxpNKIyP94wi/ZY5j889d9to47u8jLdt9QI6C/o0nM5dI83HdYukT4/5jMJX/D15k85gQsvsN9L5O+wT/ka6NvZ+PCa9nwvSwcTjh922/rfWdzm/GuBjgmawOa8+UdT/gbqjf6eP4bHR6D4dhh+8esCxc/ngcqhGlstKmNQhg7FXH3DZ1XJu9jNlJRjPzO0t/7RN4wXlnllb/gDD1wSAKoHGQBlULxLmxHMVUb/lzBV9pmlwYLaxZkl6X7iS50Ureh3X1h3RzLolWk6HpkFQ0+gZsXVGdsMxheWEgk7bNWYm/stT01BxOtjI/qdt+CRdaoC/0lwaVrNP7zmFsyuTLPcIVHuNcuPxvtBs9NjFww3uC5qYhs+ec8s01pfmXPxtNH12XeswpLmcPx/7mRvL6l4q0W398cLc6J//mcaDrtn3j/Ru7I0zlPM1aYsb2kw8hekwuHNs9U7pcmkSs3xLI2nsOd6/7nB+9cDHB81gY15xuW0fUzg3BlHKsNFWXA8oJcqH4Iwsl+XRW68+eEyj2RfZYjUP6bCt9c+cIlOGdtZ4rtxLjCb5m8ofQJkFVQONgTKoXiTMikcaidYj6kef5O/raUBtv6GRN+X3qB1MTTPEZB7zu4YiNV5OG7k1RnbzMZ1pSz225J6gR8kxix5HSjp9g1Y0HCG7X0HDmhsWkd3GxhubxxQbGurU+TjjHa9zad2UroJ1tsFOriNjr60ajF3Or3pQYTWH9XnlDGpczrVMJobTcsPy4ZVlWx+orrPHVd0b4yrrdtF49hjbyh9AmQVVA42BMqheJFwnHn5cfyGPrk0D4DcK24ys/N6mXvhRfhV2NEvFx3SNTmrfzDELGr+t6RSy++3SCGa30R5oTnOX+qPfaBo/pt+toU7gIRZ/so89Ob5N6cqtK9rGoD1QElfBNjCyYANr80p6LZ94pjUpB+mXvr69fFgjq3WK+13iyyyi4V00vq4Mrit/gK8vAFUCjYEyqF4kzIlntbBjSnnc2fnv9C56XqpHtvBR9TaztOmYuaELzH0ysoxprHXcnTmmfczJUxHt1lAzq8VrGvZ4WEBA59GUIk7rpnTl1ulwA38bxj/eLudXPaiwmkNxXumjeNZ6wZJ62sB8W/koMrJJuc6yi8bzx9hc/gDnKwBVAo2BMqheJEyLRxuo5PFg6aEFbhhBMibOsNEsbTume2TZcmPxhPtmZBNWizENeHydbL9bQx2fY2zWXVo3pSu3Tq9jemhBeqjHLudXPaiwmkNhXommfkjrTNCbqYwGPW5SPtJG1pWVzpCmqaEKX2kx+2BKzi4azx5jW/kDKLOgaqAxUAbVi4Rp8Wgj4F7UWs5oLL0oScOk49ESg5gdG6cvZyQvXi0ifjvfNCS85F4G2XZM75GlvryhjaHEaY57+Rfba+v1BOXTqUbWG8Onvb3xfgW9mrmXWLKNtYl3+Cwx2e5FkbRx5G1nNB39StOrd/aYqUbSNazyZvWX5I3sOF0F8Sz/mTcN8cte9jpJ487XPr4J2OX8qgcVVnPI55V7eXOdyXM3kHudgX3J8pvLh96gJU957LhvnpXkpRumwD2+FzQMZ+ZfO2g8V+63lT+AMguqBhoDZVC9SJgVjz5i4/VsiN5EL8QQcsN0NnpKbf63W9rBGZ1xAxCvc72dOlRA1hlD+8sL6rfN/4PQGx+XsOmYtjE0hmzywo2d5W2GdNL/wfw/oPBNSM+5t0WOxcsRnYU/Z9IZ0RsxsbrONHJvIttLE6/7H9TrsSH3tglHtlHWpTeiMBUP9xK9Mw11n4Lzk2SqIJ72y/UWxaabZ3l4nUlr3Fj758c3AGOKTrgxTuJKxTOZ0SSXDjcmOb4RsL/xtRqrocheg9z51dMry8cCzSCdV1kN+U83DGpi4+Vby8fPFJ6x0fXjY52b8pKarq9L/dOJuWneQeOPe9TL1Bf///bO58VtpN33/W9o7W3vspuVV97kLM4mm1lo4U0vejEQOAYvBrI4ELgCwwuBgQZBEwg0NILA8HKDQQy8BIIv5m5CMIbh3BCMD0PghMYMoQnmufWU6pFKP/xDHZe65Xw/oKJb1k/Xt6q+Lj2qipZ/7yx/Pzr8XQHgEmgM1EH0olOIBzQNNNcekFeAgQ6Aa6AxUAfRi04hHtA00Fx7QF4BBjoAroHGQB1ELzqFeEDTQHPtAXkFGOgAuAYaA3UQvegU4gFNA821B+QVYKAD4BpoDNRB9KJTiAc0DTTXHpBXgIEOgGugMVAH0YtOIR7QNNBce0BeAQY6AK6BxkAdRC86hXhA00Bz7QF5BRjoALgGGgN1EL3oFOIBTQPNtQfkFWCgA+AaaAzUQfSi03riMTPxtH7qxhuaxyENuqfZRAJmdp/Nc7gb9KDv1qxBoDaosNpDo3mFsvVgQZkFroHGQB1ELzo9iHhuYvp1tMMAPiCSudt5Fh9rRqxKeHrMEY3QsB4UVFjtIZ9XMqWsPTNWcbGmgN4Kylab4LwFwCXQGKiD6EWn3y+eZG7znT2ZD4zEzO4wsnpO9h56iA4MKqz2UJlXulx45Scz6wXFw/5+5QVlq1WgzALXQGOgDqIXnX6feNa0ml3qOcqPz8je0Czsk4dHnQcHFVZ7qM6rJAzn7iFGKFttA2UWuAYaA3UQvei0LJ4bmkdD6qr1J55PwVVAZzpsQJnW+R90Hfjk6QYsM7F8jGSRhkkdYzxKP/P8EY3nN8nhK8lvf9IdUpRuz+eNKRz0zDk86g5e0nR5az5e0jQK1L7q3PGEItmu+4xi2Ybh7S4HyX2d9Ojp4GfVkIqR5ZjZKwr8U2PIpaE118ML3/OXOcXX5lxpA3yI69v0nR8nfP+gHVTn1R5GNlfeEl2PJksOKKhRthSrOY25ztHbnpI/ekvLtf6ApkHXHOOMoqW6EB1ja47pR7TUB1AUjxG8oflKHwTsCX+nALgEGgN1EL3otCie9TyknndO0SIxWetFROdsquRxIjcGdgNmGo+sR/aWFtE5dfwXNFFGbb0c07Cr9uuOaFrZeCTbe16fwpkyr6sJBby9N6T4Zq3P3/dU4xO+V02XZZ718f7WYQ36mtTiyTn5HpSh7IUztQfzRTV6jzPzuHpPoTKtEiObbJ8cI7sPiQeUhjUJoUjOlTW2h7i+jd+5/u/44O8CtIPqvCoaWaP7vphHjn8dKuP4WJWTL1mZTrffr2wVy21al6Tb/RfFg0fqb2NkmZuYBlz+xMiuP1LU7xoDfEvL+Jky1+rHZjBR5RXsC8oscA00BuogetFpUTz6kbuYyhIVPTFFI6sN7080iD/rj7NG6pG1zkI3PLbpNI2NNrLGCBpTm2CMb2oEi42i4tuUgk7WmCXG0T6/NLRWaEHJkFccd1MD/J3Xt/07Pz5QYbWH6rwy9YD6LLekvaDy41TKhek93WhkN6wz5cQbxJSUjGJ5k15Zy8hWlX27fMoP8lyZBbuo1gEAhwMaA3UQvei0JB7pPeFei8EFvZ7y40BhDyNrP97LLdXxqInJ3BSrWv0IM9lHzrnLKMrnVmOnKMXI3snIHuL6FFu/8+OjpDnwYKnOq7Lu9ZOJtEdWUD9Kp/9MwpHUcWobWWM6MyNb3GaXkZXtuf4pLvn6AGyHvzMAXAKNgTqIXnRaKZ6VxKtxhW8/htvXyNoN1Ha2GlnpPSkYxfw5dxlF6RHODwt0ECN7kOszbPzOjw9UWO2hOq+qf8DZrJdvaeSfkucHdB1PKb5Lj2zas2ueVugwgdMaPbLmmFuuE+wHyixwDTQG6iB60elW8ejhdPjlJGko9jCyJlSgZMTWf9H8z4pH5yamzetHtCh1Q35OYuAKjwET8yuhAruMooQRnFI/+pj2dB6mR/YQ11eg9J0fH6iw2kN1Xu0ysqZc9EKa62Jxx9AChRhivg5e8i+Oyo/UTUa2EKtrsV7+SX/iha+9QZkFroHGQB1ELzotiufb9AWdp4bPvGwhRq0qvswYQG8wpsX0FYXTv0yMaI8GlxPzhjG/lX9BUeVA6eYc/DaxfmGK4TjZC3WsL9nLVPK2sjF6mfGVxsxqAOWFD2lI0xfIzJvTqVnkxjGJZf1mwgHKjzHZkM5pGr6yXt7K4m0PcX1bv/MjBBVWe6jMq51xpsbo6pe0vtJq/kaPCJJtv1/ZSnpgf9oQdsQUfqSulzQZyegExsxKL253QJcSsrOaUTR6bUw22AeUWeAaaAzUQfSi06J42FSdBS+z4aRkKCzp6eB1ejG9IKkptM1cYegduxGpYuv2PLyVaQj15+o86fA58mjR7MdmMQq1sU7XmV7PXM+O16ffLp5Sh4e6iqb0acK9s1X7mLektQGe0yR3LunN/f7r+7TpOz9S+B5BO8jnlRhQS79qyZ5iCOqH6OSFCZPhemFM8QWbVI4Bj3TZ2Kts5X5w2os6pvzoTUcgUeu53HwYq3pK/YgOf0+HwFsvJ3S5aXg8sBf83QHgEmgM1EH0olOIBzQNNNce7jev+OnEL6WwgMS8Pj3a0JuHCMoscA00BuogetEpxAOaBpprD/eXV2taTUfUNU9H8nymePj8aENvHiIos8A10Biog+hFpxAPaBporj3cX15JbLkda6/QcbDndGa9uAncgzILXAONgTqIXnQK8YCmgebaw73mFcfO6+mds/hYHs4r2hZvD5yAMgtcA42BOohedArxgKaB5toD8gow0AFwDTQG6iB60SnEA5oGmmsPyCvAQAfANdAYqIPoRacQD2gaaK49IK8AAx0A10BjoA6iF51CPKBpoLn2gLwCDHQAXAONgTqIXnQK8YCmgebag7u8Smb/Kk+msCerOcUhT6KyYypnPfNgNqveejml17xfbnpdM9HDxil3AcoscA00BuogetEpxAOaBpprD/m8qp7ZS2bC+34+U/zrb3uYSbXd4JE5/w4jm8NMncv77TStPP3tiEYyrfQPDn9nALgEGgN1EL3oFOIBTQPNtYfKvFrPKOx56rMnFM6/mpXfz3oeUm/vXlGZ/rmOkWWMmd11Hn2PvbQn90cHZRa4BhoDdRC96BTiAU0DzbWH6rza0wzWQU87e1rjmC6N7A3Nwj55VkjCjw7KLHANNAbqIHrRKcQDmgaaaw/VeVU0g2tazf+g68Anr/OMojfPqHviUTf43zSNryhQBrXz/JreDHvqeI+VOfxIc1nPMbJiYtW5ZEliZ29pOX1Jgy73/vL6U/JHb80sX2Jkf6YgCtNtPP8FTZa3vEESR3vNEyrYhnTbtfM6MbHZtZx0npD/RO2TrhPzbI7F6w4WXvEw4XsEwCXQGKiD6EWnEA9oGmiuPVTnVcEMfptS0BGTd0r963/RWJtWWacW75yuJ7/TsPuI/P84V0Y3WZ+97FXRU3oT08BjQzxRtvWLMq6P1T5iSsXI9mgQzdR/yvROXuhZwLx+RIu1THHL59liZNMwCbVdem6JBbb2Wy8o1veU76XlcIjH/iXNVsc91xh/PwC4BBoDdRC96BTiAU0DzbWH6ryqMJ2yzhtSfGOZOj1qgDKXg5huzCqNWb/NyK4XEfW9RzSIP+v/v00D6pSMrB1aIOZVYncrDOm2a99mZBltrO174fOdpdd3zKDMAtdAY6AOohedQjygaaC59lCdV/uYQUPJsBr2MLKCHjJLhwjYvatVRpZHGhhasa0HNrLSKyxmnXtzH/+aN+5HCsoscA00BuogetEpxAOaBpprD9V51ZCRXS9pMvLJ83wKrv+gD/HzHT2yro2sOgOPrHDiUS+c0TcOKyj2NB8pKLPANdAYqIPoRacQD2gaaK49VOdVE0ZWTGk2xNfeoQVpeMPhjSytP1LUP6WT3j8ouvgxwgoYlFngGmgM1EH0olOIBzQNNNceKvOqahxZWVcwskkPZtnIyvos3tSYSTahiwmF4TuaazPZo2G8oPVqTmMeWeBEYmYlHrb4stcp9aOPygYzsk0WZ5tepx3LW1onRpb3m9M0fEXT9GUuMdj8Apt1jCMHZRa4BhoDdRC96BTiAU0DzbWHfF6JwUtGHEiXJz756agFajFmNulBzdaLmS2uT4auUkY05mG7siG01su3NDLDcvG6d/ELbX5PukOK5sr+rpc0jSR2ltcP6HK6NCZWemzNZycd8q+urNEVeDmj6NO78rrlN3XoMQ15SC/Pp9FEjmlYTShQn5VeYDti+LsBwCXQGKiD6EWnEA9oGmiuPSCvquApch//MGEFDHQAXAONgTqIXnQK8YCmgebaA/KqAh6Gqzeywg2OH+gAuAYaA3UQvegU4gFNA821B+RVkVtaRL/Q43CWDzc4cqAD4BpoDNRB9KJTiAc0DTTXHpBXCfJymn657HJipsn9cYAOgGugMVAH0YtOIR7QNNBce0BeAQY6AK6BxkAdRC86hXhA00Bz7QF5BRjoALgGGgN1EL3oFOIBTQPNtQfkFWCgA+AaaAzUQfSiU4gHNA001x7uJa94fNjXFzTo9qyZtcwYtoUJF9xzQ/M4VNdySn70yaxzxGpO8TWPi1sxo9g9gzILXAONgTqIXnQK8YCmgebaQz6vNkyIkFus2b7uhH2O+zd02eQNHcdG1p7AAUYW/HhAY6AOohedQjygaaC59lCZVxumo6X1guJh/wAmTMzswzB0iZl1bWSZh3XfNiizwDXQGKiD6EWnEA9oGmiuPVTn1SeK/I7Dx/wwsjCy4EcDGgN1EL3oFOIBTQPNtYfqvNrHyK5pNX9DgX+qj3Hi+RSM55TZsxuaj0fke/wo/YQ8f0Tj+Y35rGjo+Fh/0HXgkyfn5DjayMSTxhOKBr3kPN1nFC9v9VE0qzmNeT/+7OSU/NHb3WPA8rEvB9TV+/To6eBntb8xslYc6/PomoZdj04eqUVvqxY/omV6/bxODPAtLaeR/j46wZg+RMP0+MN4YSZXKN63+Z5zx7kf+BoAcAk0BuogetEpxAOaBpprD9V5VTSyymjOLsnvs4lLWC8i6nd8Gk2WtNYhB2w0HyuD9kV9yrNjnVPHf0ETZTrXy3FiCLsy7WvB0Ekog7qW5JxfaR4+Sf5XiyfH0ZMWeNRLZ936QtPgcWpu0/Po/Tb1eub3odV7CrUZZyP5wYpjVeftv6LJ+Bl1vXOKPvyTBmzKtZFl1nQTD1MDnE2ooBZl6pPvxdxXL6S5vuCikVVmP/qV/EFE83ueDpevGwCXQGOgDqIXnUI8oGmgufZQnVd2T6G1pCYuMZreIFZWLEGMnF6nDdxPNIg/m0/FmD4y64qGjima54ptvk0p6FjXYf7PrsOcxxtSfFNtDJPrlOvQa3KGNDuvvY2ieG69qhCSsIzIV99BJ5iqozDygtcZRUteY9/TgmbhGfWG4wcxi1i1DgA4HNAYqIPoRacQD2gaaK49VOdVObRA98CmPbIbjC4vbPSMoSt/XjSL32lkTY9nZmSrjmsjn4uxTMgb0g3HOKiRPaWf/X/PwigeAJw/ALgEGgN1EL3oFOIBTQPNtYfqvCob2TzJ55lhK6AN3SYzyVSZxTsYWRPC4Hl9CmfKyq4/UtQ/3dIjKz3D+SHE7s3Ickxv+N6KK74/UGaBa6AxUAfRi04hHtA00Fx7qM6rXUb2M8WDR1bMq3BLy/lHWt3ENPA86gaTvElb/0XzP7nv9FBGVh1y+ZZG8sKZWvIvlRWRMIJT6kcfTZxt0ZBuMLIS73oQI6uOPZmZuOL8tdwXKLPANdAYqIPoRacQD2gaaK49VOaVmLZtsaYcasBmdfCSpnoUAR554DWNorn6y/SUnvRocDkxMaD8YtMFRbontBgzqyidU7axDKU2yMqwystTugf2p8xI7sNqQgG/EJa+kCUvqrER5hfJ/i/NiufVGPPOL34t+MUy20AnZlbihDMja/ZJe4AL9yQ9yOlLcvcHyixwDTQG6iB60SnEA5oGmmsP+bySHsOkd1OW6hACHm7qJQ3SUQJs06rIDXGllu6ALqfKOKa9lHJ8ZQKvrpKe1nTdv5HvswGU/5Xxi8J83C33jOZMqL1sf2SfM6Fen367eEodHj4siil6bl+bbWbNyA16ODE28BF9iJ9TR91X+HpKnybcOyv78Xd2RVfcw5yuK94Tm99/Jb3QZt3GUI0G4PMD4BJoDNRB9KJTiAc0DTTXHtqdVzyU1i/l3kw9pNbT3AtdYDsos8A10Biog+hFpxAPaBporj20N6/WtJqOqGvFrGZ8pnj4fGNYBCiDMgtcA42BOohedArxgKaB5tpDe/NK4k3LIQ2T0TmdPYAXqNoEyixwDTQG6iB60SnEA5oGmmsPrc6rdBpbiTvlUQsCinQsLqgDyixwDTQG6iB60SnEA5oGmmsPyCvAQAfANdAYqIPoRacQD2gaaK49IK8AAx0A10BjoA6iF51CPKBpoLn2gLwCDHQAXAONgTqIXnTK/2DBggULFixYsGDB0pYlZ2QBaBJorj0grwADHQDXQGOgDqIXnUI8oGmgufaAvAIMdABcA42BOohedArxgKaB5toD8gow0AFwDTQG6iB60SnEA5oGmmsPyCvAQAfANdAYqIPoRacQD2gaaK49IK8AAx0A10BjoA6iF51CPKBpoLn2gLwCDHQAXAONgTqIXnQK8YCmgebaA/IKMNABcA00BuogetEpxAOaBpprD8grwEAHwDXQGKiD6EWnhxPPN1pGZ+p4XQqmK7PuGPhEkd+hTjBVd9gQy4j81n2Pa1rNYwoHPTrxI1qatVWgwmoPbvLqlpbT37VW0nK1XtL09QUNur0jqz+OA5RZ4BpoDNRB9KLTvHgS08brsqVDfvTJfA7ABr5NKegYzcDIHg35vJIfq3b9UFyeUDj/arbfgP6hlmyfGFn7uMf2Q/g44LwBwCXQGKiD6EWnVeJZz0PqcaPSC2m+NisB2IWYWRjZo6Eyr9YzCnsenXQCmtqPKdYLiof9/YyoMbPZk45jfaJzHKDMAtdAY6AOohedVoqn1MgAsAcwskdHdV6ZJzdFI1sHGNlWgTILXAONgTqIXnRaKZ5SI8MxbREF/qlaN6YP0ZC66vOTkx4N4wXpTttijFvpUbP9+FDCFW5oHl8lx31+TW+GPfO5tYgpSh9H7hnqsJpTfB2Q7/UpVOcYdD19PM9/QZPlrdlIwduFA3M/aukO6HK6TO7Jvr70u+BY0Mgc75T8IKTg7EXWoG87Hn9HEV+TaqzjCUUcT6q3eUaxXFN63dKg7/Hda9S1jkdqv+S8pfusYL2c0KVcQ26ffc/J270034VH3adPk/PDyB4N1Xm1h5FlrV9a5cDzaTSRcqWAkW0VKLPANdAYqIPoRaeV4ik0MmmoAS/SIMnjRR1+sKabeEie3sZqiG5iGuSMjWyXmNFv04A66XHP6XryOw27j8j/X/+g/2BzlGsov9I87JMfvqfdzdxnigePkuOy2Ry9paW6xtXsUhstrx/RglvU9UeK+qfKwF3SbKVWrN5TqMzbycljdQ9fcvedNrj6vh9RP/pozKk6xrkxsluP99/q+p+Ya8pMY3IOj3rhTB2P71G2Sb7H3d+9vghaTUfKNBijqR/xZgY1Mws25jvqjmi6+mb2T7a9vcs5lZGeqfzRGoCRPRqq86poZE3ZUuUqX86TckSrCQXF8gwj2ypQZoFroDFQB9GLTivFU2pkFKV1K5oGXbX/GUVLXiONl9UQVTxqTsyr1atqjusNYmWFBDnWIxrEn80qZaQe/0rxjXZRe1C8PkaMYvJCSmISrXMo1ouI+my+xbAV71vfkzLHFYZ69/EqGuvSd1Sxzc7v3vzvDdPvp+pacojplu/dXEd6jl3nNMY2l2+lHy7VoMJqD9V5VfVSqJ3vt7SIzslL9Wi0AyPbWqp1AMDhgMZAHUQvOq0UT6mRUew0U+yF2KTezcjmzsWYXhwxSmzMHufM7i7K16eOYhnk/65uOKXnURrd0vV9Ucd9rL83DhsIX09pqb3jhoY4dzxXRtYYdMvIlvfZgA4JeaXDCPie0u13nVN/XgjzqMjvKlBhtYfqvCqHFugfbGmPrMChJ/+k68BPeuphZFsLyixwDTQG6iB60WmleKpM0C5joziokc31nn5Rf59t7l2spMrI2tf42Ry/2HAWGunK68tiZ/n7Sx7P/73H8VwZWWMkPOkpNj1i23pk2WRMXpDP+wRXFH8Y6+tIz7HjnEmPr4REGGBkj47qvCob2SLr5VsaqfLh+QFdx1OKWTswsq0FZRa4BhoDdRC96LRSPFXmbQ8zVTKy0ht5JyMr5kyZpYsruqgVVsBUGVm75/JbOXyBKT4y33J92gzGz6ir7+f/7XE8d0aWe1YnI9PzxYvnUzCeqy03oMMALCNqriM9x65zmjCCNN6YgZE9OqrzapeRNfHXaTy10Q6MbGtBmQWugcZAHUQvOq0ST9LbpgxJ2hBl67KGR16oygZALxlZ2cY7p2hxm/bS8Dll9IHycW2yl7ZysZh7IcZLeinlZS+PusEkMXjpy1nW2/psTM316k3M9aXnV2ZtdC7mTV54MuZ15/Gkl9n6jiSuNP2uZZvMEO/+7k0P7A4DmUMbCfVdDMe0XGcjHtihHNvPKSEW8jKdmHrO27x2ilRpDjxMKvNKfqDaoSw5jNHVo3F8pdX8TfL0ohTDbZfrsu7BwwFlFrgGGgN1EL3oNC8e0wCpddnSoSf+E2VQs3Wd4IquctslvXRlIyvmkbdRpmkQ0Yf4OXVMbOmnCW9vH7doZgtGMUV6b8SImdU5xMj26OngZ9NT2aPB5SS//WpOY4nhU4vnj2g8T5rW5H6y69M9jWxkzwK6TofYUseMZokxZjYeT65Hjqe+pyjUvVLZ8UOKctvs+93/nTeR1pKOoFDE7sHlkQnejemCzYm6n1/8n3LH2JTf+V5gZWh/e0EDfhEuiGi6ZegvPgZoB/m8knKXaYOXcrmVsBWji9GY4gs2qVYdYB+jQve52Gtw73C+AOASaAzUQfSi00OKp2xkDwD3WHY29fxwL+Ege7yeo/Ao/Khhw/8PZSBNT3MKD4l1Tv0HZgpQYbUH5BVgoAPgGmgM1EH0otNDiicxslmowffDowz8Sr2SQUvgGNqzMytGM8cPZGT1CA/nFffJ399zGj6wR7WosNoD8gow0AFwDTQG6iB60enhxJPEuOVe/vledMxpv8IY39Jy+oqC4DXNqx6ba4oxncdLEm/Ij21fWo/0k8e7/Y1G//5AhdUekFeAgQ6Aa6AxUAfRi06/TzwyLivHtRWN1F2Rlz7UMXPTxdahGOt74HCHBwcb+2RK2fSeedSCSMa4fVjw9YF2gLwCDHQAXAONgTqIXnQK8YCmgebaA/IKMNABcA00BuogetEpxAOaBpprD8grwEAHwDXQGKiD6EWnEA9oGmiuPSCvAAMdANdAY6AOohedQjygaaC59oC8Agx0AFwDjYE6iF502l7x3NA8DmnQPXU8eDq/SPU7hYNexcDv4C6gwmoPd8urNa3mf9A1TwyycRpbxkywsHWbHayXNH19oeqBXste6DzAvTcIyixwDTQG6iB60WlbxZPNuuV4FiAzJzx/TzCyhwEVVnuoziv5EckzwZkRMsYzWsQjGrGZ/DaloGNGz3Bq1OyZxh74yCQ3Mf06am/9gTILXAONgTqIXnTaZvEkZraB6SyNmYWRPQyosNpDOa9k2mhrauZ0WmbbTJoh8Jz3OIqZfchGNhlSsM31B8oscA00BuogetFpm8UDI9tOUGG1h3JemYlGSgaV1z+BkS2hjP/sknyv3fUHyixwDTQG6iB60WlePFZsm39BcTSkrvr85OSU/NFbM7g+P1a80oPvd55f05thT33+WDUiX8xn1iNH7rW5nOQH5U97b/hznkQhsmbnUvuPR7rS5/09f0Tj+Y35TMHxcJcDc009ejr4WR0nMbLlUAN7UgSepvbWitt7RtGbZ+o46vx6+luOg31pXbd9vwoY2YOS1xx4yJTzSmbMK5QRVXfcSGiBpmBkrRCdcnk023D5jgJV/pUpjScUDbhuUdt3n1G8caKVKiO7ozwX6pmT7pAiu57J1VFq3+CNqaM2133r5YQu5XrV4vkvaLL8mppYWZ9c50353jXb68/1ckqR3uc5xR8is52qw4bjfB3rAL4eAFwCjYE6iF50mhPPTUwDqXQ9n0YTnlXrhmZhX1Xqp9SPPtJtahh5m3O6nvxOw+4j9dmcPkXn5Hl9CmfcKMh+YhYVesrZU1XJX9Js9c08olSV/iBWW9/SQu3f0Q3Araq0x+q4qqLujmiqG5EvNA0eZ43a6j2FeiYrMa4yy5jdQyuNrmo4P73L4vb4Xq7/RWPVEOkpdf+H71uu05zHbhhhZA9KTnPgQVOVV+tFRP3UBA4ojOdJ+c5RMLKrmTKmZ1k4wnpGYc8YNr2NNaOfWhIjqOoBM/1yL5ypEl5FhZHV9dim8pzUM2k9tZpQwPWMN6T4Rp1B11FdY3yVIY6zH7xfNtZ9/4fGXM/ouiqr19L6olh/lO6dVxauq1h/2vukxly+M/fTcPN5AXAJNAbqIHrRaUk88qKGH9HSrEor3l5Ic25NTMWcGFCD2Sa/LjGuSUX7tzGaVqW7XlDMZpL30fv/RIP4c/JZOlXtI70uadCSvxPKxrUcarBSjVhXHYN7gLi1MI2rNFqGpGHOjp0cB0bWFaiw2sOmvCr2QJank7aM7Bf+0fmEhvGiYEYLZrfKlFbVRznK+2wtz8bkZsbYmFVTJ+h6xq4fpO6TdZV1n/mBLuvMNW80sprCve+sP7nOLH5fcm92necGlFngGmgM1EH0otOSeCobDtOzWajMcxVzZWUtZpQbkc/mbzGVBcz+ulHMLVxJ/5f6mBur/L7FSnxvI2s1BDb86O71NT/a5PPCyLqipDnwYNmeV/wIP9KP2pOy2rPMqilr3r+T//PphrLjxsgKVeU5+UG8yfjJsXj74mLqkG11gR4K7FX6faTbVO5TuPed9SffG4wsOF6gMVAH0YtOS+KpbDiMIdxS6SYNRLEithuZfYxsuTFKqH6EdjAjqxqgycgnj4cRuv6DPsTP1XGsa9nWeIHaoMJqD+W8UmVqNMo90dCGdvIiMYzy1KZgZE/SR+Y2jozslvK8l5Et1g82lXWB3D/H015R/GFcu0d2d/0JIwuOG2gM1EH0otOSeKoajuJjr6qK2cTX5h6NiQHVPbnfTChAEmtrN4OaXFybxfovmv/5P5X7FivxciO1j5GVEIXMJCfHhZF1BSqs9lDOKy5TT6wQH6FYtrL/J59MvLt3TtHCfmmruM8hjOyO8iz1FMfGlyoh2VdeXs1YL/+kPzlWf2PdZ4UrmGtOt9nDyKbXtbH+5COX6y8YWXAsQGOgDqIXnZbEIw1H6aWDrHKv7j2QlxXkJTGu/LkB45chjPlMX6ywemc4Tnb0kqarr8n+uTd1b2geXVDEDVK6rzm+ia/l6+c3d3UjkmukrF4ivY0ys4v3Sbyb1RBkDaF5LJq+sZzF2Mn95hsZcFdQYbWHcl6ZH4fc2zmWl7yyHsm0rEtsqSlr6Qti6cub1japUSs+SleYMp319BaRfaS87irP8vLXKfnh++z64wsKuX6TuFQ75pdfVBu91uevrPu0UVU/wvXoAdmICMUf/t5gTIvpK3Oe4r3vUX8WvlO1whjvbS/DHQaUWeAaaAzUQfSi05J4xMh2z2kgsW9WpZ70ALAxTJa8mS0Ma5Nr7BLyL4moyn+gTKwMrZMbXksthRdI1su3NJJrUmb4t4un1OFzRNPU+Camm/fnAdsnFAc9dY4Lev0uoud8X3Jsy8zax+W3pd/FL3RjxcPyXIXqHLIPLxt7hsC+8PcI2kE5r5SR/UdI0y9zikOrrNplXeoQ+Yx/RE6vtJlL/ldG9V1c2ObfyPd5hBFrmyi09lFLqezJExfZJumZ3Fae9TBbO+uZ6jpqY90noQy8no3ouzFdsOHUddCMVumPbjPawG3F96OfGG2pP4vfaec/Kbpiwy7r3PbK8jkAcAk0BuogetFpSTxSYcKwAUegwmoPyCvAQAfANdAYqIPoRacl8cDIAsegwmoPyCvAQAfANdAYqIPoRacl8eyMSQPg+0CF1R6QV4CBDoBroDFQB9GLTnPiMS8l8Dq95F6KAuAwoMJqD8grwEAHwDXQGKiD6EWnEA9oGmiuPSCvAAMdANdAY6AOohedQjygaaC59oC8Agx0AFwDjYE6iF50CvGApoHm2gPyCjDQAXANNAbqIHrRaWvEw2M/vr6gQbeXDZbO6LheawD1g2MGWEe88MFAhdUejjavnNcbxwXKLHANNAbqIHrRaTvEI7P18Etojhufm5h+HdmTPIBDgwqrPWzOqzWt5n/QtZ41S14Q7dEgjGm+GNNweOhZ8D5T/Otv+DF5T6DMAtdAY6AOohedtkc8xTnVXZBMd5mfrQwcGlRY7aE6r3hK12fU1bNehRTzbFkMPzWJgmRmqgOPQ62nhsVTkXsDZRa4BhoDdRC96LQ94nFtZNe0ml3qRhhG1i2osNpDOa9UOZmO9PSuXj+iRWmsafP5IY3s6j2FPOUsjOy9gTILXAONgTqIXnRaKZ7VnMbpI0PudYlovkpnIlcfxxRWzEWefCy9MspwxtPsOHqe88+0nLwwc4mr/YZjWurD3tA8vqLA/4n88J8UybF53vKJzIFeYWTVdcbX5lypueXre6OOlcy1ns53Lp/m5lFP5mKfLL+mJlbWJ+e5yR6f5hpRvt6QBl2eT92c43Ji7oXPMaVI7/Oc4g+R2c6+X8Vqlt6n5wd0FQxo5DJk4gHB9wzaQTmvPlM8eKTWP6JB/NmsK7D+SNGvr8yEKnXqi0lW9rvPKOZtxMTqfYtLh/zokzrIJ4r8jll3RtGSCyqfV8reKflBSMHZi6QMb6w3vuM6jxy+VwBcAo2BOohedFoSDzdC/VNlri5ptvqW9b4Mkpi39SKivqcahvC9Moeq8hcD2B3RdHVrxbKKSbw1+6j/u316rk3lLS2ic2VwuTH8i27iYRpnJ/ukDZh3TtGCG4qikU3CAJJzZQ1S/vq+0DR4rD6XRtc0wvpas3tLe2DNhBDp/+sZhT1jVlMja67d61M442/khmZhX12/aviCCa3sfbgBHb1V5lWu9QmF869qn+T/rEeLj/kMRhY8OEp5JTP/eUOKb+RX2Wa21xd/W2XYqi84jECVp144U3swxqimZXBt6gwxsowYbGNkdTl8RP3oY3IMrtfO2cjuU2/c9TqPF75vAFwCjYE6iF50mhePNBBiuHjVguJhzxhZ0wjkGjExpVKhV4UAmIbImvb22zSgjtUQFf9n8g1F1XGL60xjZp1nvRzTsPtTYmTFpBtTrk5KQWeLkdUUGlFjVNNjMOa4mVEtNrzF+1spg901PxaOvQksgwqrPZTySmb/yz2h2MQd6wtTLrM4213liUnKVGpk9THEmBbZ8KP4u6/zeEGZBa6BxkAdRC86zYtHeivk8VyRcoPCJIZTDGCV4dzdEFUZWen9SUxj1XEL66Q3dFfDoofyepWGH9QyspXbyPcm17brftdpb3Dypvfv2SPMHwBUWO2hlFdiZPfqkb1jfXEII5s+jVHH6Q4ofD3NwnpK5zzUdR4vKLPANdAYqIPoRad58ewwsmIUCxV+3txVGc7dDVGlkTUNxebjFtbtNLK3Jkb3lPzgiuIPY+v4ij2MbL5xE3Y3jOX745g8e/iix2rfL+az4wYVVnso5ZWUMfupzSbuWl8cxMgyEntvYmx1mAC72Q31xndf5/GCMgtcA42BOohedJoXj4QWnGaxZTnMo/tCb0xi7iQOtaLCv6OR3X3c4jq5PomrLaB7eK2YtpxRVuxhZPO9xELx0eQ+DW9GEv6wzYAfF6iw2kM5r+SRuyoDlaMWKDgcafRSmca/7lZf7GFkk2PsMrKCDBcm22+qN773Oo8XlFngGmgM1EH0otOSeFYTCthUpS8zKdKGaZ29FKFfYjKfcQxt2qhJr640AIqKHo/E2GWmMvmfX6QwcaPyslfai1Jx3NK67JG9HX+6XsY0Cqe00kZVRg+4ofl4pF/oSE2pMbLeYEyL6SsKuYdUrj1t5ExDbo2okBhR+8WS4v3KDwS5X9Xojp5lZtt853lzfLygwmoPlXllynzyZv8FvZ7KyCL8lOENBf1f0rpj//rCMojyQlka626MLJfBxYRCLsvyg1IfR560qH3U9Woz++kdjc7lHFIvSD1RrksOc53HC8oscA00BuogetFplXjyQ1QVhqGRxiodEocf078xw3NJr4g0KB3yr66SXgtZp8zdu3eJaZV13AP61Rjb7tOnpkGyz1tx3OhDxTrubVGN2vRl9dBY6yVNRuZRPhvRd2O6YMMpQ3SlDbRp0G5Nj0t6DuntyUywXq+OFYzn6ioV0ksj+3T+k6Ir7smRdebaRwMKrnnKXT4/36s9xNlxw98DaAeb84rLWWTVA7xwXRAV4r3r1BfKJEah/jGZrtO9ndKjyj9Qzagmqgwmo4Xwdlx+JxQHvcxYq3I4OgvoOhxkseh6xJSquoTrjUNc5/HC9wiAS6AxUAfRi04fini2PXoHxwUqrPaAvAIMdABcA42BOohedPpQxAMj++OACqs9IK8AAx0A10BjoA6iF50+DPEUY0jBMYMKqz0grwADHQDXQGOgDqIXnd6/eORt4CzeLD9qADg27l9zYF+QV4CBDoBroDFQB9GLTiEe0DTQXHtAXgEGOgCugcZAHUQvOoV4QNNAc+0BeQUY6AC4BhoDdRC96BTiAU0DzbUH5BVgoAPgGmgM1EH0olP+BwsWLFiwYMGCBQuWtixERP8fxXlGiVSErzEAAAAASUVORK5CYII=" /></p><p>&nbsp;(1)Adverse reactions reported in post marketing experience.</p><p>(2)See Description of selected adverse reactions.</p><p>(3)Reported in open-label studies.</p><p><u>Description of selected adverse reactions</u></p><p>The use of Lacosamide SPC is associated with dose-related increase in the PR interval. Adverse reactions associated with PR interval prolongation (e.g. atrioventricular block, syncope, bradycardia) may occur.</p><p>In adjunctive clinical trials in epilepsy patients, the incidence rate of reported first-degree AV Block is uncommon, 0.7 %, 0 %, 0.5 % and 0 % for Lacosamide SPC 200 mg, 400 mg, 600 mg or placebo, respectively. No second- or higher degree AV Block was seen in these studies. However, cases with second- and third-degree AV Block associated with Lacosamide SPC treatment have been reported in post-marketing experience. In the monotherapy clinical trial comparing Lacosamide SPC to carbamazepine CR, the extent of increase in PR interval was comparable between Lacosamide SPC and carbamazepine.</p><p>The incidence rate for syncope reported in pooled adjunctive therapy clinical trials is uncommon and did not differ between Lacosamide SPC (n=944) treated epilepsy patients (0.1 %) and placebo (n=364) treated epilepsy patients (0.3 %). In the monotherapy clinical trial comparing Lacosamide</p><p>SPC to carbamazepine CR, syncope was reported in 7/444 (1.6 %) Lacosamide SPC patients and in 1/442 (0.2 %) carbamazepine CR patients.</p><p>Atrial fibrillation or flutter were not reported in short term clinical trials; however, both have been reported in open-label epilepsy trials and in post-marketing experience.</p><p>Laboratory abnormalities</p><p>Abnormalities in liver function tests have been observed in placebo-controlled trials with Lacosamide SPC in adult patients with partial-onset seizures who were taking 1 to 3 concomitant antiepileptic medicinal products. Elevations of ALT to &ge; 3x ULN occurred in 0.7 % (7/935) of Lacosamide SPC patients and 0 % (0/356) of placebo patients.</p><p>Multiorgan hypersensitivity reactions</p><p>Multiorgan hypersensitivity reactions (also known as Drug Reaction with Eosinophilia and Systemic Symptoms, DRESS) have been reported in patients treated with some antiepileptic medicinal products. These reactions are variable in expression, but typically present with fever and rash and can be associated with involvement of different organ systems. If multiorgan hypersensitivity reaction is suspected, Lacosamide SPC should be discontinued.</p><p><u>Paediatric population</u></p><p>The safety profile of Lacosamide SPC in placebo-controlled (see study details in section 5.1) and in open- label studies (n=408) in adjunctive therapy in children from 4 years of age was consistent with the safety profile observed in adults although the frequency of some adverse reactions (somnolence, vomiting and convulsion) was increased and additional adverse reactions (nasopharyngitis, pyrexia, pharyngitis, decreased appetite, lethargy and abnormal behaviour) have been reported in paediatric</p><p>&nbsp;</p><p>patients: nasopharyngitis (15.7 %), vomiting (14.7 %), somnolence (14.0 %), dizziness (13.5 %), pyrexia (13.0 %), convulsion (7.8 %), decreased appetite (5.9 %), pharyngitis (4.7 %), lethargy (2.7 %) and abnormal behaviour (1.7 %).</p><p>A total of 67.8 % of patients randomised to Lacosamide SPC and 58.1 % of patients randomised to placebo reported at least 1 adverse reaction.</p><p>Behavioural, cognition and emotional functioning were measured by the questionnaires Achenbach CBCL and BRIEF that were applied at baseline and throughout the studies and where mainly stable during the course of the trials.</p><p><u>Elderly population</u></p><p>In the monotherapy study comparing Lacosamide SPC to carbamazepine CR, the types of adverse reactions related to Lacosamide SPC in elderly patients (&ge; 65 years of age) appear to be similar to that observed in patients less than 65 years of age. However, a higher incidence (&ge; 5 % difference) of fall, diarrhoea and tremor has been reported in elderly patients compared to younger adult patients. The most frequent cardiac-related adverse reaction reported in elderly compared to the younger adult population was first-degree AV block. This was reported with Lacosamide SPC in 4.8 % (3/62) in elderly patients versus 1.6 % (6/382) in younger adult patients. The discontinuation rate due to adverse events observed with Lacosamide SPC was 21.0 % (13/62) in elderly patients versus 9.2 % (35/382) in younger adult patients. These differences between elderly and younger adult patients were similar to those observed in the active comparator group.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via submitting completed forms to: npc.drug@sfda.gov.sa.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms</p><p>Symptoms observed after an accidental or intentional overdose of Lacosamide SPC are primarily associated with CNS and gastrointestinal system.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The types of adverse reactions experienced by patients exposed to doses above 400 mg up to 800 mg were not clinically different from those of patients administered recommended doses of Lacosamide SPC.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reactions reported after an intake of more than 800 mg are dizziness, nausea, vomiting, seizures (generalised tonicclonic seizures, status epilepticus). Cardiac conduction disorders, shock and coma have also been observed. Fatalities have been reported in patients following an intake of acute single overdose of several grams of Lacosamide SPC.</p><p>&nbsp;</p><p><u>Management</u></p><p>There is no specific antidote for overdose with Lacosamide SPC. Treatment of Lacosamide SPC overdose should include general supportive measures and may include haemodialysis if necessary (see section 5.2).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antiepileptics, other antiepileptics, ATC code: N03AX18</p><p><u><strong>Mechanism of action</strong></u></p><p>The active substance, Lacosamide SPC (R-2-acetamido-N-benzyl-3-methoxypropionamide) is a functionalised amino acid.</p><p>The precise mechanism by which Lacosamide SPC exerts its antiepileptic effect in humans remains to be fully elucidated. In vitro electrophysiological studies have shown that Lacosamide SPC selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes.</p><p><u><strong>Pharmacodynamic effects</strong></u></p><p>Lacosamide SPC protected against seizures in a broad range of animal models of partial and primary generalised seizures and delayed kindling development.</p><p>In non-clinical experiments Lacosamide SPC in combination with levetiracetam, carbamazepine, phenytoin, valproate, lamotrigine, topiramate or gabapentin showed synergistic or additive anticonvulsant effects.</p><p><u><strong>Clinical efficacy and safety</strong></u></p><p><u>Adult population</u></p><p>Monotherapy</p><p>Efficacy of Lacosamide SPC as monotherapy was established in a double-blind, parallel group, non inferiority comparison to carbamazepine CR in 886 patients 16 years of age or older with newly or recently diagnosed epilepsy. The patients had to present with unprovoked partial-onset seizures with or without secondary generalisation. The patients were randomised to carbamazepine CR or Lacosamide SPC, provided as tablets, in a 1:1&nbsp; ratio.&nbsp; The&nbsp; dose&nbsp; was&nbsp; based&nbsp; on&nbsp; dose-response&nbsp; and ranged from 400 to 1,200 mg/day for carbamazepine CR and from 200 to 600 mg/day for</p><p>Lacosamide SPC. The duration of the treatment was up to 121 weeks depending on the response.</p><p>The estimated 6-month seizure freedom rates were 89.8 % for Lacosamide SPC-treated patients and 91.1% for carbamazepine CR treated patients using the Kaplan-Meier survival analysis method. The adjusted absolute difference between treatments was -1.3 % (95 % CI: -5.5, 2.8). The Kaplan-Meier estimates of 12-month seizure freedom rates were 77.8 % for Lacosamide SPC-treated patients and 82.7% for carbamazepine CR treated patients.</p><p>The 6-month seizure freedom rates in elderly patients of 65 and above (62 patients in Lacosamide SPC, 57 patients in carbamazepine CR) were similar between both treatment groups. The rates were also similar to those observed in the overall population. In the elderly population, the maintenance Lacosamide SPC dose was 200 mg/day in 55 patients (88.7 %), 400 mg/day in 6 patients (9.7 %) and the dose was escalated to over 400 mg/day in 1 patient (1.6 %).</p><p>Conversion to monotherapy</p><p>The efficacy and safety of Lacosamide SPC in conversion to monotherapy has been assessed in a historical-controlled, multicentre, double-blind, randomised trial. In this study, 425 patients aged 16</p><p>to 70 years with uncontrolled partial-onset seizures taking stable doses of 1 or 2 marketed antiepileptic medicinal products were randomised to be converted to Lacosamide SPC monotherapy (either 400 mg/day or 300 mg/day in a 3:1 ratio). In treated patients who completed titration and started withdrawing antiepileptic medicinal products (284 and 99 respectively), monotherapy was maintained in 71.5 % and 70.7 % of patients respectively for 57-105 days (median 71 days), over the targeted observation period of 70 days.</p><p>Adjunctive therapy</p><p>The efficacy of Lacosamide SPC as adjunctive therapy at recommended doses (200 mg/day, 400 mg/day) was established in 3 multicenter, randomised, placebo-controlled clinical trials with a 12week maintenance period. Lacosamide SPC 600 mg/day was also shown to be effective in controlled adjunctive therapy trials, although the efficacy was similar to 400 mg/day and patients were less likely to tolerate this dose because of CNS- and gastrointestinal-related adverse&nbsp; reactions. Thus,&nbsp; the 600 mg/day dose is not recommended. The maximum recommended dose is 400 mg/day. These trials, involving 1,308 patients with a history of an average of 23 years of partial-onset seizures,</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>were designed to evaluate the efficacy and safety of Lacosamide SPC when administered concomitantly with 1-3 antiepileptic medicinal products in patients with uncontrolled partial-onset seizures with or without secondary generalisation. Overall the proportion of subjects with a 50 % reduction in seizure frequency was 23 %, 34 %, and 40 % for placebo, Lacosamide SPC 200 mg/day and Lacosamide SPC 400 mg/day.</p><p>The pharmacokinetics and safety of a single loading dose of intravenous Lacosamide SPC were determined in a multicenter, open-label study designed to assess the safety and tolerability of rapid initiation of Lacosamide SPC using a single intravenous loading dose (including 200 mg) followed by twice daily oral dosing (equivalent to the intravenous dose) as adjunctive therapy in adult subjects 16 to 60 years of age with partial-onset seizures.</p><p><u><strong>Paediatric population</strong></u></p><p>Partial-onset seizures have a similar clinical expression in children from 4 years of age and in adults. The efficacy of Lacosamide SPC in children aged 4 years and older has been extrapolated from data of adolescents and adults with partialonset seizures, for whom a similar response was expected provided the paediatric dose adaptations are established (see section 4.2) and safety has been demonstrated (see section 4.8).</p><p>The efficacy supported by the extrapolation principle stated above was confirmed by a double blind, randomised, placebo-controlled study. The study consisted of an 8-week baseline period followed by a 6-week titration period. Eligible patients on a stable dose regimen of 1 to &le; 3 antiepileptic medicinal products, who still experienced at least 2 partialonset seizures during the 4 weeks prior to screening with seizure-free phase no longer than 21 days in the 8-week period prior to entry into the baseline period, were randomised to receive either placebo (n=172) or Lacosamide SPC (n=171). Dosing was initiated at a dose of 2 mg/kg/day in subjects weighing less than 50 kg or 100 mg/day in subjects weighing 50 kg or more in 2 divided doses. During the titration period, Lacosamide SPC doses were adjusted in 1or 2 mg/kg/day increments in subjects weighing less than 50 kg or 50 or 100 mg/day in subjects weighing 50 kg or more at weekly intervals to achieve the target maintenance period dose range.</p><p>Subjects must have achieved the minimum target dose for their body weight category for the final 3 days of the titration period to be eligible for entry into the 10-week maintenance period. Subjects were to remain on stable Lacosamide SPC dose throughout the maintenance period or were withdrawn and entered in the blinded taper period.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Statistically significant (p=0.0003) and clinically relevant reduction in partial-onset seizure frequency per 28 days from baseline to the maintenance period was observed between the Lacosamide SPC and the placebo group. The percent reduction over placebo based on analysis of covariance was 31.72 % (95 % CI: 16.342, 44.277).</p><p>Overall, the proportion of subjects with at least a 50 % reduction in partial-onset seizure frequency per 28 days from baseline to the maintenance period was 52.9 % in the Lacosamide SPC group compared with 33.3 % in the placebo group.</p><p>The quality of life assessed by the Pediatric Quality of Life Inventory indicated that subjects in both Lacosamide SPC and placebo groups had a similar and stable health-related quality of life during the entire treatment period.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Absorption</strong></u></p><p>Lacosamide SPC is rapidly and completely absorbed after oral administration. The oral bioavailability of Lacosamide SPC tablets is approximately 100 %. Following oral administration, the plasma concentration of unchanged Lacosamide SPC increases rapidly and reaches C<sub>max</sub> about 0.5 to 4 hours post-dose. Lacosamide SPC tablets and oral syrup are bioequivalent. Food does not affect the rate and extent of absorption.</p><p><u><strong>Distribution</strong></u></p><p>The volume of distribution is approximately 0.6 L/kg. Lacosamide SPC is less than 15 % bound to plasma proteins.</p><p><u><strong>Biotransformation</strong></u></p><p>95 % of the dose is excreted in the urine as Lacosamide SPC and metabolites. The metabolism of Lacosamide SPC has not been completely characterised.</p><p>The major compounds excreted in urine are unchanged Lacosamide SPC (approximately 40 % of the dose) and its Odesmethyl metabolite less than 30 %.</p><p>A polar fraction proposed to be serine derivatives accounted for approximately 20 % in urine, but was detected only in small amounts (0-2 %) in human plasma of some subjects. Small amounts (0.5-2 %) of additional metabolites were found in the urine.</p><p>In vitro data show that CYP2C9, CYP2C19 and CYP3A4 are capable of catalysing the formation of the O-desmethyl metabolite but the main contributing isoenzyme has not been confirmed in vivo.</p><p>No clinically relevant difference in Lacosamide SPC exposure was observed comparing its pharmacokinetics in extensive metabolisers (EMs, with a functional CYP2C19) and poor metabolisers (PMs, lacking a functional CYP2C19). Furthermore an interaction trial with omeprazole (CYP2C19-inhibitor) demonstrated no clinically relevant changes in Lacosamide SPC plasma concentrations indicating that the importance of this pathway is minor. The plasma concentration of O-desmethyl-Lacosamide SPC is approximately 15 % of the concentration of Lacosamide SPC in plasma. This major metabolite has no known pharmacological activity.</p><p><u><strong>Elimination</strong></u></p><p>Lacosamide SPC is primarily eliminated from the systemic circulation by renal excretion and biotransformation. After oral and intravenous administration of radiolabeled Lacosamide SPC, approximately 95 % of radioactivity administered was recovered in the urine and less than 0.5 % in the faeces. The elimination half-life of Lacosamide SPC is approximately 13 hours. The pharmacokinetics is dose-proportional and constant over time, with low intra- and inter-subject variability. Following twice daily dosing, steady state plasma concentrations are achieved after a 3 day period. The plasma concentration increases with an accumulation factor of approximately 2. A single loading dose of 200 mg approximates steady-state concentrations comparable to 100 mg twice daily oral administration.</p><p><u>Pharmacokinetics in special patient groups</u></p><p>Gender</p><p>Clinical trials indicate that gender does not have a clinically significant influence on the plasma concentrations of Lacosamide SPC.</p><p>Renal impairment</p><p>The AUC of Lacosamide SPC was increased by approximately 30 % in mildly and moderately and 60 % in severely renal impaired patients and patients with end-stage renal disease requiring haemodialysis compared to healthy subjects, whereas C<sub>max </sub>was unaffected.</p><p>Lacosamide SPC is effectively removed from plasma by haemodialysis. Following a 4-hour haemodialysis treatment, AUC of Lacosamide SPC is reduced by approximately 50 %. Therefore, dosage supplementation following haemodialysis is recommended (see section 4.2). The exposure of the O- desmethyl metabolite was several-fold increased in patients with moderate and severe renal impairment. In absence of haemodialysis in patients with end-stage renal disease, the levels were increased and continuously rising during the 24-hour sampling. It is unknown whether the increased</p><p>metabolite exposure in end-stage renal disease subjects could give rise to adverse effects but no pharmacological activity of the metabolite has been identified.</p><p>Hepatic impairment</p><p>Subjects with moderate hepatic impairment (Child-Pugh B) showed higher plasma concentrations of Lacosamide SPC (approximately 50 % higher AUC<sub>norm</sub>). The higher exposure was partly due to a reduced renal function in the studied subjects. The decrease in non-renal clearance in the patients of the study was estimated to give a 20 % increase in the AUC of Lacosamide SPC. The pharmacokinetics of Lacosamide SPC has not been evaluated in severe hepatic impairment (see section 4.2).</p><p>Elderly (over 65 years of age)</p><p>In a study in elderly men and women including 4 patients &gt; 75 years of age, AUC was about 30 and 50 % increased compared to young men, respectively. This is partly related to lower body weight. The body weight normalized difference is 26 and 23 %, respectively. An increased variability in exposure was also observed. The renal clearance of Lacosamide SPC was only slightly reduced in elderly subjects in this study.</p><p>A general dose reduction is not considered to be necessary unless indicated due to reduced renal function (see section 4.2).</p><p>Paediatric population</p><p>The paediatric pharmacokinetic profile of Lacosamide SPC was determined in a population pharmacokinetic analysis using sparse plasma concentration data obtained in one placebo-controlled randomised study and three open-label studies in 414 children with epilepsy aged 6 months to 17 years. The administered Lacosamide SPC doses ranged from 2 to 17.8 mg/kg/day in twice daily intake, with a maximum of 600 mg/day for children weighing 50 kg or more.</p><p>The typical plasma clearance was estimated to be 1.04 L/h, 1.32 L/h and 1.86 L/h for children weighing 20 kg, 30 kg and 50 kg respectively. In comparison, plasma clearance was estimated at</p><p>1.92 L/h in adults (70 kg body weight).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the toxicity studies, the plasma concentrations of Lacosamide SPC obtained were similar or only marginally higher than those observed in patients, which leaves low or non-existing margins to human exposure.</p><p>A safety pharmacology study with intravenous administration of Lacosamide SPC in anesthetised dogs</p><p>showed transient increases in PR interval and QRS complex duration and decreases in blood pressure most likely due to a cardiodepressant action. These transient changes started in the same concentration range as after maximum recommended clinical dosing. In anesthetised dogs and Cynomolgus monkeys, at intravenous doses of 15-60 mg/kg, slowing of atrial and ventricular conductivity, atrioventricular block and atrioventricular dissociation were seen.</p><p>In the repeated dose toxicity studies, mild reversible liver changes were observed in rats starting at about 3 times the clinical exposure. These changes included an increased organ weight, hypertrophy of hepatocytes, increases in serum concentrations of liver enzymes and increases in total cholesterol and triglycerides. Apart from the hypertrophy of hepatocytes, no other histopathologic changes were observed.</p><p>In reproductive and developmental toxicity studies in rodents and rabbits, no teratogenic effects but an increase in numbers of stillborn pups and pup deaths in the peripartum period, and slightly reduced live litter sizes and pup body weights were observed at maternal toxic doses in rats corresponding to systemic exposure levels similar to the expected clinical exposure. Since higher exposure levels could not be tested in animals due to maternal toxicity, data are insufficient to fully characterise the embryofetotoxic and teratogenic potential of Lacosamide SPC.</p><p>Studies in rats revealed that Lacosamide SPC and/or its metabolites readily crossed the placental barrier. In juvenile rats and dogs, the types of toxicity do not differ qualitatively from those observed in adult animals. In juvenile rats, a reduced body weight was observed at systemic exposure levels similar to the expected clinical exposure. In juvenile dogs, transient and doserelated CNS clinical signs started to be observed at systemic exposure levels below the expected clinical exposure.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong><u>Tablet core:</u></p><p>Microcrystalline Cellulose PH 101, Low substituted Hydroxy propyl cellulose, Hydroxypropyl cellulose, Crospovidone, Colloidal silicon dioxide, Magnesium Stearate, Purified water.</p><p><u>Tablet coat:</u></p><p>Lacosamide SPC Tablets 50 mg: Opadry II Purple 85G500001 Lacosamide SPC Tablets 100 mg: Opadry II yellow 85G52072 Lacosamide SPC Tablets 150 mg:</p><p>Opadry II Tan 85G27190</p><p>Lacosamide SPC Tablets 200 mg: Opadry II Blue 85G20458</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 Years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C. Protect from light and moisture.</p><p>Keep out of the sight and reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10&#39;s Blister Pack</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sudair Pharma Company (SPC)
King Fahad road, Building 911- The First Round
Riyadh, Saudi Arabia
Tel: +966-11-920001432
Fax: +966-11-4668195
Email: info@sudairpharma.com
 Mailing: P.O. Box 19047 Riyadh, Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January 2020 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>